



US009447445B2

(12) **United States Patent**
Hsieh et al.

(10) **Patent No.:** US 9,447,445 B2
(b4) **Date of Patent:** *Sep. 20, 2016

(54) **SYNTHON FORMATION**(71) Applicant: **New England Biolabs, Inc.**, Ipswich, MA (US)(72) Inventors: **Pei-Chung Hsieh**, Topsfield, MA (US); **Luo Sun**, Hamilton, MA (US); **Thomas C. Evans, Jr.**, Topsfield, MA (US); **Theodore B. Davis**, Boxford, MA (US); **Andrew Gardner**, Manchester, MA (US)(73) Assignee: **New England Biolabs, Inc.**, Ipswich, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/837,820**(22) Filed: **Aug. 27, 2015**(65) **Prior Publication Data**

US 2016/0060671 A1 Mar. 3, 2016

Related U.S. Application Data

(60) Provisional application No. 62/193,168, filed on Jul. 16, 2015, provisional application No. 62/189,599, filed on Jul. 7, 2015, provisional application No. 62/042,527, filed on Aug. 27, 2014.

(51) **Int. Cl.**

C12P 19/34	(2006.01)
C12N 15/10	(2006.01)
C12N 9/12	(2006.01)
C12N 15/64	(2006.01)
C12N 15/66	(2006.01)

(52) **U.S. Cl.**

CPC	C12P 19/34 (2013.01); C12N 9/1252 (2013.01); C12N 15/1027 (2013.01); C12N 15/1031 (2013.01); C12N 15/64 (2013.01); C12N 15/66 (2013.01); C07K 2319/00 (2013.01)
-----------	--

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,580,759 A	12/1996	Yang et al.
5,811,238 A	9/1998	Stemmer et al.
6,117,679 A	9/2000	Stemmer
6,150,111 A	11/2000	Tseng
6,261,797 B1	7/2001	Sorge et al.
6,361,974 B1	3/2002	Short et al.
6,372,429 B1	4/2002	Sharon
6,582,914 B1	6/2003	Caldwell et al.
6,635,449 B2	10/2003	Short
7,575,860 B2	8/2009	Evans et al.
7,723,077 B2	5/2010	Young et al.

7,776,532 B2	8/2010	Gibson et al.
8,435,736 B2	5/2013	Gibson et al.
8,476,045 B2 *	7/2013	Wang
		C07K 14/195 435/194
8,623,628 B2	1/2014	Ost et al.
8,921,043 B2	12/2014	Gardner
8,968,999 B2	3/2015	Gibson et al.
2003/0194786 A1	10/2003	Sharon
2005/0112631 A1	5/2005	Piepenburg et al.
2006/0057683 A1	3/2006	Hyman
2006/0281109 A1	12/2006	Barr Ost et al.
2007/0141591 A1 *	6/2007	Borns
		C12N 9/1252 435/6.18
2008/0076123 A1	3/2008	Buzby
2009/0048885 A1	2/2009	Bishop et al.
2010/0184187 A1	7/2010	Young et al.
2011/0053272 A1	3/2011	Benders et al.
2011/0053273 A1	3/2011	Benders et al.
2012/0053087 A1	3/2012	Gibson et al.
2013/0260422 A1	10/2013	Ong et al.
2013/0295645 A1	11/2013	Gibson et al.
2014/0296082 A1	10/2014	Gardner

FOREIGN PATENT DOCUMENTS

EP	1664287	9/2004
EP	1929012 A2	6/2008
EP	2239327 A2	10/2010
GB	248527	5/2012
WO	9838296 A1	9/1998
WO	9838297 A1	9/1998
WO	9838298 A1	9/1998
WO	9838299 A1	9/1998
WO	9947649	9/1999
WO	0118213	3/2001
WO	0123411	4/2001
WO	0166775 A2	9/2001
WO	2007021944	2/2007
WO	2007032837 A2	3/2007

(Continued)

OTHER PUBLICATIONS

WP_013748330.1 (NCBI Reference Sequence, *Pyrococcus* sp. NA2 DNA polymerase, GI:503513858, priority to May 27, 2013), 2 pages.*

WP_011011764.1 (NCBI Reference Sequence, Pyrococcus DNA-binding protein, priority to Jul. 18, 2013), 1 page.*

Gibson D. (2011) "Enzymatic Assembly of Overlapping DNA Fragments" in Methods in Enzymology, vol. 498, pp. 349-361, and supplementary material.*

(Continued)

Primary Examiner — Nancy J. Leith

Assistant Examiner — Neil P Hammell

(74) Attorney, Agent, or Firm — New England Biolabs, Inc; Harriet M. Strimpel

(57)

ABSTRACT

This disclosure provides, among other things, a composition comprising: a 5' exonuclease; a strand-displacing polymerase; and optionally a single strand DNA binding protein and/or a ligase. A method for polynucleotide assembly to form a synthon, as well as a kit for performing the same, are also described.

(56)

References Cited**FOREIGN PATENT DOCUMENTS**

WO	2008074346	6/2008
WO	WO 2009/131919	4/2009
WO	2009103027 A2	8/2009
WO	2010062776	6/2010
WO	2010080910	7/2010

OTHER PUBLICATIONS

- Doherty et al. (1996) Nucleic Acids Research, 24(13):2488-2497.*
 Wang et al. "A novel strategy to engineer DNA polymerases for enhanced processivity and improved performance in vitro", Nucleic Acids Research, 2004, vol. 32, No. 3, pp. 1197-1207.
- Zimmerman, S. et al., Macromolecular crowding accelerates the cohesion of DNA fragments with complementary termini, Nucl. Acids res., vol. 13, pp. 2241-2249 (1985).
- Lai and Masker, "Repair of double-strand breaks by incorporation of a molecule of homologous DNA", Mol. Microbiol., 36(2):437-46 (2000).
- Gibson et al., "Complete chemical synthesis, assembly, and cloning of a Mycoplasma genitalium genome", Science, 319(5867):1215-1220 (2008).
- Gibson et al., "Enzymatic assembly of DNA molecules up to several hundred kilobases", Nat. Methods., 6(5):343-345 (2009).
- Tseng, DNA cloning without restriction enzyme and ligase, Biotechniques, 27:1240-1244 (1999).
- Kaluz, et al., 1992, Nucleic Acids Research 20:4369-4370.
- Dekker, et al., Joining of long double-stranded RNA molecules through controlled overhangs, Nucleic Acids Research, 32:E140 (2004).
- Garforth, et al., Mutagenesis of conserved lysine residues in bacteriophage T5 5'-3' exonuclease suggests separate mechanisms of endo- and exonucleolytic cleavage, PNAS, USA, 96:38-43 (1999).
- Gibson, Enzymatic assembly of overlapping DNA fragments, Methods Enzymol., 498:349-361 (2011).
- Hsiao, Exonuclease III induced ligase-free directional subcloning of PCR products, Nucleic Acids Research, 21:5528-5529 (1993).
- Jessberger, et al., A Mammalian Protein Complex That Repairs Double-strand Breaks and Deletions by Recombination, The Journal of Biological Chemistry, 268: 15070-15079 (1993).
- Joannes, et al., DNA filter retention assay for exonuclease activities. Application to the analysis of processivity of phage T5 induced 5'-exonuclease, Biochemistry, 24, 8043-8049 (1985).
- Li, et al., Ligation independent cloning irrespective of restriction site compatibility, Nucleic Acids Research, 25:4165-4166 (1997).
- Pickering, et al., Variation in the Steady State Kinetic Parameters of Wild Type and Mutant T5 5*-3*-Exonuclease With pH, The Journal of Biological Chemistry, 274, 25, 17711-17717 (1999).
- Pickering, et al., A single cleavage assay for T5 5'-3' exonuclease: determination of the catalytic parameters for wild-type and mutant proteins, Nucleic Acids Research, 1999, 27, 730-735 (1999).
- Sasaki, et al., Regulation of DNA nucleases by molecular crowding, Nucleic Acids Research, 35, 4086-4093 (2007).
- Zimmerman, Macromolecular Crowding: Biochemical, Biophysical, and Physiological Consequences, Ann. Rev. Biophys. Biomol. Struct. 22:27-65 (1993).
- Yang, et al., Construction of recombinant DNA by exonuclease recession, Nucleic Acids Research, 21, 1889-1893 (1993).
- Yu, et al., Recombineering with overlapping single-stranded DNA oligonucleotides: Testing a recombination intermediate, PNAS, 100, 7207-7212 (2003).
- Zhou, et al., An improved ligase-free method for directional subcloning of PCR amplified DNA, Nucleic Acids Research, 23: 1089-1090 (1995).
- Declaration of Daniel G. Gibson, Ph.D. dated Nov. 13, 2014.
- Ignatov, et al., A strong strand displacement activity of thermostable DNA polymerase markedly improves the results of DNA amplification, BioTechniques, 57:81-87, 2014.
- Argos, A sequence motif in many polymerases, Nucleic Acids Research, 16: 9909-9916, 1988.
- Ito, et al, Compilation and alignment of DNA polymerase sequences Nucleic Acids Research, 19: 4045-4057, 1991.
- Braithwaite, Compilation, alignment, and phylogenetic relationships of DNA polymerases, Nucleic Acids Research, 21:787-802, 1993.
- Steiz, DNA polymerases: structural diversity and common mechanisms, J. Biol. Chem., 274: 17395-8, 1999.
- Loh and Loeb, et al., Mutability of DNA polymerase I: Implications for the creation of mutant DNA polymerases, DNA Repair 4, 1390-1398, 2005.
- Matsukawa, et al., A useful strategy to construct DNA polymerases with different properties by using genetic resources from environmental DNA, Genes Genet. Syst. 84 3-13, 2009.
- Baar, et al., Molecular breeding of polymerases for resistance to environmental inhibitors, Nucleic Acids Research, 1-12, 2011.
- Hashimoto, et al., Crystal structure of DNA polymerase from hyperthermophilic archaeon Pyrococcus kodakaraensis KOD1, J. Mol. Biol., 306: 469-477, 2001.
- Biles, et al., Low-fidelity Pyrococcus furiosus DNA polymerase mutants useful in error-prone PCR, Nucleic Acids Research, vol. 32, p. e176, 2004.
- Kim, et al., Crystal structure of Pfu, the high fidelity DNA polymerase from Pyrococcus furiosus, Int. J. of Bio. Macromolecules, 42: 356-361, 2008.
- Elshawadfy, et al., DNA polymerase hybrids derived from the family-B enzymes of Pyrococcus furiosus and Thermococcus kodakarensis: improving performance in the polymerase chain reaction, Frontiers in Microbiology, 5, 224, 2014.
- Gaidamaviciute, et al., Site-directed chemical modification of archael Thermococcus litoralis Sh1B DNA polymerase: Acquired ability to read through template-strand uracils, Biochim Biophys Acta., 1804(6), 1385-1393, 2010.
- Hansen, et al., Engineered split in Pfu DNA polymerase fingers domain improves incorporation of nucleotide gamma-phosphate derivative, Nucleic Acids Research, 39(5), 1801-1810, 2011.
- Wynne, et al., Structures of an apo and a binary complex of an evolved archeal B family DNA polymerase capable of synthesising highly cy-dye labelled DNA, PLoS One, 8(8), e70892, 2013.
- Arezi, et al., Efficient and high fidelity incorporation of dye-terminators by a novel archael DNA polymerase mutant, Journal of Molecular Biology, 322(4), 719-729, 2002.
- Brennan, et al., The winged-helix DNA-binding motif: another helix-turn-helix takeoff, Cell., 74 :773-6, 1993.
- Martinez-Hackert, Structural relationships in the OmpR family of winged-helix transcription factors, Journal of Molecular Biology, 269:301-12, 1997.
- Gajivala, et al., Winged helix proteins, Current Opinion in Structural Biology, 10: 110-116, 2000.
- Huffman, et al., Prokaryotic transcription regulators: more than just the helix-turn-helix motif, Current Opinion in Structural Biology, 12(1):98-106, 2002.
- Kenney, Structure/function relationships in OmpR and other winged-helix transcription factors, Curr. Opin. Microbiol., 5:135-41, 2002.
- Lintner, The structure of the CRISPR-associated protein Csa3 provides insight into the regulation of the CRISPR/ Cas system, Journal of Molecular Biology, .405: 939-55, 2011.
- Kelman, et al., Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps, Nucleic Acids Research, 23: 3613-20, 1995.
- Wang, et al., Crystal structures of an NH2-terminal fragment of T4 DNA polymerase and its complexes with single-stranded DNA and with divalent metal ions, Biochemistry, 35: 8110-8119, 1996.
- Lee, et al., Journal of Bacteriology, 14, 3666-3667, 2011.
- Ignatov, et al., Biotechniques, 57, 2, 81-87, 2014.
- Harris, et al., Biotechniques, 54, 2, 93-97, 2013.
- Communication dated Dec. 21, 2015 from the International Searching Authority for International application No. PCT/US2015/047161.




FIG. 1A

FIG. 1B




FIG. 1C




FIG. 1D





FIG. 1E






FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A




FIG. 3B




FIG. 4




FIG. 5




FIG. 6




FIG. 7

Sequence of Single-stranded oligo:
ATCTTGAAAGGACCAACACCGGGAAAGAACCTCTTCCAAAGAGTTTAGAGCTAGAAATAGCAAAGTT (SEQ ID NO:28)
Double-stranded vector used: GeneArt® CRISPR Nuclease Vector with GFP Reporter Kit Catalog number: A211174

FIG. 8A




FIG. 8B





FIG. 8C


Sequence of single stranded oligo containing degenerate bases:

FIG. 9A



三
正

Sanger-sequencing result from assembly pool. Partial designed ss-oligo sequence is displayed.



१८८




FIG. 10

1

SYNTON FORMATION

CROSS-REFERENCE

This application claims the benefit of U.S. provisional application Ser. No. 62/042,527, filed Aug. 27, 2014, 62/189,599, filed Jul. 7, 2015 and 62/193,168, filed on Jul. 16, 2015, which applications are incorporated by reference herein.

BACKGROUND

Synthetic Biology relies on the ability to build novel DNAs from component parts. Double strand (ds) DNA molecules have been assembled by creating staggered ends at the both ends of a first DNA duplex. This has been achieved using restriction endonucleases or by using exonuclease digestion or by T4 DNA polymerase followed by hybridization and optional ligation of a second DNA duplex to the first duplex. Techniques that utilize exonucleases and ligases in a reaction mixture also specify the use of non-strand displacing polymerases.

SUMMARY

This disclosure provides, among other things, a composition comprising: i. a 5' exonuclease; ii. a strand-displacing polymerase; iii. a single strand (ss) DNA binding protein; and, iv. a non-naturally occurring buffering agent, wherein the composition does not comprise a crowding agent and/or a non-strand-displacing polymerase. The composition can be employed to assemble polynucleotides into a synthon. Embodiments of the composition optionally contain a ligase depending on whether assembly is performed for purposes of cloning in a bacterial cell that would contain its own ligase or whether assembly is performed for purposes which do not include a cloning step in bacteria.

Previously described assembly methods required a non-strand displacing polymerases and evolved to additionally require a crowding agent (see for example U.S. Pat. No. 8,968,999). Contrary to the prior teachings, present embodiments demonstrate that a strand displacing polymerase has advantages over a non-strand displacing polymerase when used with a 5'-3' exonuclease. This combination has a preference for including a ss binding protein over a crowding agent which is the reverse over prior art teachings which assert that use of crowding agents are four fold more effective than alternatives including the use of a single stand binding protein. Present embodiments provide compositions, methods and kits that provide increased efficiency of assembly and cloning of functional genes and synthons from oligonucleotides and polynucleotides including ds and/or ss nucleic acid molecules in a single step method and/or in a single reaction vessel. These embodiments do not rely on crowding agents nor do they require non-strand displacing polymerases for filling in gaps that are present after two molecules anneal. For example, when a 5'-3' exonuclease that acts upon ds DNA generates a 3' ss DNA overhang that can anneal effectively with a 3' ss DNA overhang from another molecule, the strand-displacing polymerase can fill-in gaps left after the molecules anneal. A combination of activities of the strand-displacing DNA polymerase and the 5'-3' exonuclease results in a duplex synthon containing a nick at or near the site of joining. This nick can be sealed in vitro by a ligase or in vivo by an endogenous cellular ligase. Additionally, the inclusion of a ss DNA binding protein in the reaction mixture enables efficient assembly of relatively

low concentrations of nucleic acid fragments, thereby providing a cost saving without loss of efficiency or loss of accuracy of joining.

In some embodiments of the compositions, the strand-displacing polymerase is a Family B polymerase. A strand-displacing polymerase should preferably have strand-displacing activity that is greater than that observed with Phusion® polymerase (Thermo Fisher, Waltham, Mass.) (which is generally described as non-strand displacing) 5 under the same reaction conditions (for example, using an assay such as described in FIG. 1A-1E. In the present compositions, methods and kits the strand displacing polymerase is utilized primarily for its strand displacing activity. In some embodiments, the strand-displacing polymerase 10 may be non-naturally occurring, for example, the strand-displacing polymerase may be a mutant. Examples of mutants include polymerases having one or more amino acid substitutions, non-naturally occurring polymerases may alternatively or in addition be fusion proteins with a moiety 15 having an unrelated amino acid sequence where the fusion polymerase is not encountered in nature. Preferably the strand displacing polymerase is stable at 50° C. or above and may thus be referred to as a thermostable strand displacing polymerase. In some cases, the strand-displacing polymerase 20 is a fusion polymerase having an unrelated or heterologous DNA binding domain. In some embodiments, the polymerase moiety may have an amino acid sequence that is at least 90% or 95%, or 98% or 99% identical to SEQ ID NO:102. In another embodiment, the polymerase may have an amino acid sequence that is at least 90% or 95% or 98% or 99% or 100% identical to SEQ ID NO:1 preferably 25 at least 90%. In another embodiment, the polymerase may have an amino acid sequence that is at least 90% or 95% or 98% or 99% or 100% identical to any of SEQ ID NO:33-55 preferably at least 90%. In some embodiments, the DNA binding domain moiety may have an amino acid sequence that is at least 90% or 95%, or 98% or 99% identical to SEQ ID NO:2. In another embodiment, the polymerase may have 30 an amino acid sequence that is at least 90% or 95% or 98% or 99% or 100% identical to any of SEQ ID NOs:1, 3, 56-96 or 102, preferably at least 90%. In other embodiments, any of the polymerase domain moieties described herein may be combined with any of the DNA binding domains described 35 herein provided that that the Polymerase moiety and the DNA binding domain are heterologous. For example, in other embodiments, the fusion protein may have an amino acid sequence that has at least 90% or 95% or 99% or 100% identity with SEQ ID NO:1 and SEQ ID NO:2, preferably at least 90%. In other embodiments, the fusion protein may have at least 90% or 95% or 98% or 99% or 100% sequence 40 identity to SEQ ID NO:3 preferably at least 90%. The strand-displacing polymerase may or may not have a 3'-5' exonuclease activity. Where strand displacing polymerases have 3'-5' exonuclease activity, polynucleotide joining may be optimized by balancing 3'-5' exonuclease activity, 5'-3' polymerization activity and strand displacement activity using the conditions that include those exemplified herein. The efficacy and accuracy of the assembly can be confirmed using the assay described herein (see for example, FIGS. 3A 45 and 3B). In some embodiments, the polymerase is not Phusion, 9° N, Pfu or Vent, or a polymerase that has an amino acid sequence that is at least 90% identical to Phusion or wild type 9° N, Pfu or Vent. In some embodiments, the polymerase is thermostable, i.e., active at a temperature of at 50 least 40° C. or at least 50° C. degrees. In contrast to strand-displacing polymerases, some polymerases such as Taq DNA polymerase, degrade an encountered downstream

strand via a 5'->3' exonuclease activity. This activity is utilized for nick translation protocols. Hence Taq DNA polymerase is not included in the definition of strand displacing polymerases.

An assay to determine efficiency and accuracy of synthon formation is described in the examples and shown in FIG. 3A-B. The designed assembled fragments encode the lacI and lacZ proteins, which yield a blue colony if DNA fragments are assembled correctly. Thus, the number of "blue" colonies from an overnight plate denotes both efficiency and accuracy of assembly. In the absence of a blue color, efficient assembly may occur but errors at the joining/extension region prevents expression. When synthons are assembled and then cloned into a host cell, efficiency and accuracy of synthon formation translates into a confidence that each clone will contain the accurately assembled synthon. With this confidence, only one or a few duplicate clones need to be sequenced to confirm the presence of a synthon. This reduces the cost and inconvenience of sequencing clones that might contain errors. In one embodiment, at least 80% or alternatively at least 90% of clones will contain accurately assembled synthons.

In some embodiments, methods utilizing the compositions described herein are capable of yields that are substantially in excess of minimum requirements. For example, as many as 5,000 or 10,000 colonies can be produced in a single transformation event. If the purpose of assembly is to create a single example of a synthon rather than a library of synthons, then lower starting amounts of nucleic acid fragments and reagents can be used even below the ranges provided herein. Examples of concentration ranges suitable for use in an assembly mixture include the following: 0.02 nM-100 nM for DNA fragment or for example 0.2 nM-10 nM DNA may be added to the reagent mixture in a reaction vessel. In one embodiment, vector DNA is included at a ratio of 1:1 with the DNA fragments although higher or lower ratios can be used. A higher concentration of ss DNA may be preferred when compared with the concentration selected for ds DNA. The reagent mixture in the reaction vessel may further include 0.0004 U/μl-0.064 U/μl of the 5'-3' exonuclease (for example 0.0004 U/μl-0.01 U/μl); 0.5 U/μl-32 U/μl of an optional ligase (for example 1 U/μl-10 U/μl); 0.0025 U/μl-0.25 U/μl of the strand displacing polymerase (for example 0.005 U/μl-0.1 U/μl); and 0.001 μg/μl-0.1 μg/μl for the ss binding protein (for example 0.01 μg/μl-0.5 μg/μl) (units correspond with those specified by the manufacturer (New England Biolabs, Ipswich, Mass.)).

The amount of 5'-3' exonuclease can be further optimized according to the length of overlap of nucleic acid fragments and size of each fragment. For example, amounts of 5'-3' exonuclease may be increased within the range for nucleic acid fragments greater than 80 nucleotides in length. The absolute concentration of the strand displacing polymerase within the specified range is not critical.

A ss DNA binding protein for use in the composition may be *E. coli* recA, T7 gene 2.5 product, RedB (from phage lambda) or RecT (from Rac prophage), ET SSB (extreme thermostable single-stranded DNA binding protein) or a ss binding protein with 90% sequence identity to SEQ ID NO:100 although many other ss DNA binding proteins are known and could be used in the composition. The inclusion of a ss binding protein improves the efficiency of assembly particularly for nucleic acid fragments with longer overlap sequences (e.g. at least 20 nucleotides) than would be otherwise occur in the absence of ss binding protein as measured by colony number.

The optional ligase may be an NAD⁺ dependent ligase such as Taq ligase or an ATP dependent ligase such as T4 ligase. However, for PCR, it is convenient to use an NAD⁺ dependent ligase since ATP can inhibit Taq polymerase used in subsequent amplification of the synthon. Examples of a suitable ligase include a protein with at least 90% sequence identity to SEQ ID. No. 101.

The 5'-3' exonuclease used here may be an enzyme that has a 5'-3' exonuclease activity as well as a ss endonuclease activity (see, for example, Garforth, et al., PNAS, 96, 38-43 (1999)). Examples of a 5'-3' exonuclease with exonuclease and ss endonuclease activity include T5 exonuclease, as well as homologs and variants thereof. In one example, the 5'-3' exonuclease has at least 90% amino acid sequence identity SEQ ID NO: 98. There is no requirement to denature the 5'-3' exonuclease prior to joining the polynucleotides with the strand displacing polymerase. Hence the use of a thermostable 5'-3' exonuclease is described in the examples.

In some embodiments, the composition may further comprise dNTPs (i.e., a mixture of dGTP, dATP, dGTP and dTTP) and, in some embodiments, where T5 5'-3' exonuclease is used, the composition may further comprise potassium salt such as KCl (e.g., at a concentration in the range of 7 mM-150 mM).

In general, a method for producing a synthon is provided. In some embodiments, the method may include incubating an embodiment of the composition described herein that comprises a strand displacing polymerase as described herein and a 5'-3'exonuclease and optionally a ligase (if the reaction is in vitro or in vivo in a cell or organism that does not contain a ligase) and may also contain a ss binding protein, with a set of polynucleotides and/or oligonucleotides in which at least one or some of the members of the set have a sequence that overlaps with one or some other members of the set, under suitable reaction conditions. In some embodiments, the polynucleotides or oligonucleotides may be ds DNA, e.g., overlapping PCR products or overlapping restriction fragments. In other embodiments, the polynucleotides may be ss DNA or RNA. In some embodiments, the set of polynucleotides may comprise ss DNA or RNA. In some embodiments, the set of polynucleotides may comprise ds polynucleotides. In some embodiments, the set of polynucleotides may comprise at least one ds polynucleotide and at least one ss polynucleotide. In some embodiments, the set of polynucleotides may comprise a sub-population of polynucleotides that have identical sequences apart from a sub-sequence that varies between members of the sub-population. In other embodiments, the set of polynucleotides may comprise ss or ds polynucleotides or polynucleotides that have overlapping regions at their ends for purposes of joining but different internal sequences that form the synthon. Thus, in one embodiment of the method of the invention, the polynucleotides in the set of polynucleotides are ds; such as wherein the ds polynucleotides are overlapping PCR products or overlapping restriction fragments or assembled from ss polynucleotides. In an alternative embodiment of the method of the invention, the synthon is assembled from polynucleotides in the set of polynucleotides that are ss. In a further alternative embodiment of the method of the invention, the synthon is assembled from a set of polynucleotides that comprises a mixture of at least one ds polynucleotide and at least one ss oligonucleotide. In embodiments of the method of the invention, the synthon is assembled from a set of polynucleotides that comprise a sub-population of polynucleotides that are identical to one another except for a sub-sequence that varies between the members of the sub-population.

5

Embodiments of the method may be used to produce a variety of synthons, including coding sequences, vectors, guide molecules for gene engineering and expression cassettes.

Prior to assembly, the initial ds polynucleotides may be in the range of 100 bases-30 kb in length, although polynucleotides outside of this range may be used in certain cases. For example, in some embodiments, individual fragment sizes can be as much as 20 kb-30 kb or longer or as short as 30 bases-500 bases. Moreover, in some embodiments, fragments of different sizes can be joined in the assembly reaction. In one example, long polynucleotides (e.g., fragments of 5 kb-20 kb in length) are joined to short polynucleotides (e.g., fragments of 100 bases-500 bases in length). Newly assembled synthons may be sequenced, either directly using single molecule sequencing methods or after cloning or amplification.

In one embodiment, the members of the set may contain overlapping sequences having a length less than 2 kb for example, in the range of 15-200 nucleotides for example, 20-100 nucleotides.

In one embodiment, a composition is provided where the composition has a 5'-3' exonuclease; a strand-displacing polymerase; and a buffer containing a potassium salt such as KCl in a concentration range of 7 mM-150 mM, for example, 20 mM-50 mM. A sodium salt (e.g., sodium chloride) in the range of 10 mM-100 mM such as 20 mM may also be used in addition to potassium salt. A ss binding protein may be included in the composition. In some embodiments, the composition does not contain a crowding agent such as polyethylene glycol (PEG), Ficoll, or dextran. In some embodiments, the composition does not contain a non-strand displacing polymerase. In another embodiment, polynucleotide and/or oligonucleotide fragments are included in the composition for forming a synthon.

In another embodiment of the method, a set of oligonucleotides may be joined using a composition that comprises a crowding agent such as polyethylene glycol (PEG), Ficoll, or dextran in addition to or instead of the ss binding protein and at least 7 mM potassium salt such as KCl together with a strand displacing polymerase and a 5'-3' exonuclease in the absence of a non-strand displacing polymerase. In one embodiment the potassium salt is at a concentration of less than 150 mM for example, 20 mM-50 mM.

Also provided is a kit for polynucleotide assembly, comprising: i. a 5'-3' exonuclease; ii. an optional ligase; iii. a strand-displacing polymerase; and iv. a ss DNA binding protein. In certain embodiments, the kit may further comprise dNTPs and/or a buffering agent, for example. The components of the kit may be in separate containers (e.g. one or more different reaction tubes), or, the components of the kit may be in a single container. The components may be lyophilized or in solution or in part lyophilized and in part in solution. The components may be immobilized in part or in whole on a solid surface such as a bead or surface of a reaction chamber or may be in solution. The components may be added to target polynucleotides that may be in part or in whole, immobilized or in solution. In some embodiments, the kit may contain one or more mixtures of the components of the kit. In some embodiments, the kit does not contain a non-strand-displacing polymerase, or a crowding agent.

In one embodiment, a polymerase having at least 80%, 85%, 90% or 95% sequence identity with SEQ ID NO:1 is provided for the assembly mixture. In another embodiment, a polymerase having a binding domain having at least 80%, 85%, 90%, or 95% sequence identity with SEQ ID NO:2 is

6

provided for the assembly mixture. In another embodiment, a polymerase having at least 80%, 85%, 90% or 95% sequence identity with SEQ ID NO:3 is provided for the assembly mixture. These compositions may be used in reaction conditions in which the polymerase is strand displacing. The compositions may be used in reaction conditions in which any 3' exonuclease activity associated with the polymerase activity is active.

The assembly reaction may occur using ss or ds nucleic acids. Any number of fragments e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more fragments can be assembled. Chemically synthesized ss polynucleotides can be assembled into ds overlapping fragments and hybridized and ligated to the ends of linearized vectors to form synthons suitable for cloning. Alternatively, duplex fragments can be assembled into synthons and inserted into vectors for cloning or PCR or isothermal amplification (see for example, FIG. 2A-2C). ss nucleic acid fragments can also be directly inserted into vectors (see for example, FIG. 7) by hybridizing the nucleic acid fragment to the 3' ss end of a linearized ds vector. The ss nucleic acids may be assembled through overlapping complementary ends at the same time, before, or after the a ss nucleic acid fragment has hybridized to the 3' ss end of the linearized vector. Assembled fragments may be amplified by PCR or isothermal methods before insertion into vectors for cloning. The nucleic acid fragments may contain randomized nucleotide sequences or degenerate code enabling libraries to be formed that contain representative variants at each nucleotide position of the variable region. The random sequence may be positioned between a defined sequence at each end. In one embodiment, the random sequence positioned between defined sequences may be for hybridizing to a second nucleic acid fragment (such as a second ss genomic polynucleotide) or to a linearized vector end. In one example, the random sequence hybridizes to a target genomic sequence for guiding a Cas9 protein to a target nucleic acid for gene editing (see for example, FIG. 9A-9C). Thus, in accordance with this aspect of the invention, the method may be used to hybridize at least one member of a set of polynucleotides to a second nucleic acid fragment (such as a second ss genomic polynucleotide) or to a linearized vector end. For example, the method may be for hybridization of the at least one member of the set of polynucleotides to a target genomic sequence in order to guide a Cas endonuclease such as Cas9 to a target genomic nucleic acid in a method of gene editing.

In some embodiments, a method is provided for assembling a plurality of polynucleotides into a synthon, that includes: combining the plurality of polynucleotides with a composition comprising a 5'-3' exonuclease, a strand displacing polymerase, optionally a ligase, a ss binding protein and a buffer wherein each polynucleotide has a 3' ss terminal polynucleotide sequence on one strand that can be hybridized to a complementary ss complementary sequence on a second polynucleotide and can be joined to form a continuous duplex polynucleotide optionally under isothermal conditions in a single container. The synthon can further be joined at its ends to the ends of a linearized plasmid for amplification and/or cloning.

In some embodiments, the entire assembly method may be carried out as a "one-step" reaction (in a single tube, which does not have to be opened during after the reaction is started). In one example, the components are mixed together in a reaction vessel and incubated at a temperature of between 40° C. to 60° C. for a period of time, e.g., 5 minutes to 12 hours, thereby producing the synthon.

In one aspect, the method includes a step of strand displacement in the polynucleotides to be joined by a polymerase having at least 90% amino acid sequence identity with SEQ ID NO:1 or SEQ ID NO:102 and/or SEQ ID NO:2 or SEQ ID NO:3. In embodiments of the method, no additional steps of 3'-5' exonuclease chew back are required. Another aspect further comprises enhancing the efficiency of the assembly reaction by including a potassium salt at a minimum concentration of 7 mM in the reaction mixture where the potassium salt is exemplified by KCl.

In one aspect, a method is provided, wherein the polynucleotides contain a random sequence between defined sequence ends. In another aspect, the method further comprises screening the random sequences for hybridizing activity with a genomic DNA and identifying the random sequence with the hybridizing activity. In another aspect, the method comprises performing gene editing by transcribing the random sequences with hybridizing activity to form RNA and using the RNA for gene editing in the presence of a Cas endonuclease.

In one embodiment of the composition, kit, or method of the invention, the strand-displacing polymerase used in the composition, kit, or method of the invention may be non-naturally occurring, such as a mutant or fusion protein. In the composition, kit, or method of the invention, the non-natural strand-displacing fusion polymerase may be characterized by an amino acid composition of the polymerase moiety that is at least 90% or 95% or 99% or 100% identical to any of SEQ ID NOS: 33-55 or SEQ ID NO:1 or of the DNA binding moiety that is at least 90% or 95% or 99% or 100% identical to any of SEQ ID NOS: 56-98 or SEQ ID NO:2. In one embodiment, the polymerase moiety may have an amino acid sequence that has 90% or 95% or 98% or 99% amino acid sequence identity with SEQ ID NO:102 fused to a heterologous DNA binding moiety selected from a polypeptide that has at least 90% or 95% or 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 56-98.

In general in one aspect, a preparation is provided that includes a composition having an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:3. The preparation may further comprise a 5'-3' exonuclease, for example a T5 exonuclease. The preparation may further comprise a ss DNA binding protein, for example, an ET SSB, *E. coli* recA, T7 gene 2.5 product, phage lambda RedB or Rac prophage RecT, more particularly a thermostable ss binding protein such as ET SSB. The preparation may further comprise a ligase. In one aspect, a preparation including the composition may further comprise a ss binding domain and a 5-3' exonuclease, wherein the preparation does not comprise a crowding agent and/or a non-strand-displacing polymerase. The preparation may further include a potassium salt.

In one aspect, the preparation including the composition may further comprise a plurality of polynucleotides in a set wherein at least a polynucleotide in the set has a sequence that overlaps with another polynucleotide in the set; and wherein the polynucleotides are selected from: (i) ds polynucleotides; (ii) ss oligonucleotides; (iii) at least one ds polynucleotide and at least one ss oligonucleotide; and (iv) a subpopulation of polynucleotides that are otherwise identical to one another except for a sequence that varies between the members of the sub-population. In one aspect the set of polynucleotides has at least 3 members or at least 4 members or at least 5 members.

In general, a method for producing a synthon, that includes: incubating a composition of claim 1 further comprising a 5'-3' exonuclease and, optionally, a ligase and a ss

DNA binding protein, with a plurality of polynucleotides that form a set, wherein members of the set have sequences that overlap under suitable reaction conditions; and joining at least two the polynucleotides to produce a synthon. In one aspect, the set of polynucleotides contains at least 3 members or at least 4 members or at least 5 members. In one aspect, the preparation further includes a ligase. In one aspect, the preparation, further includes a ss DNA binding protein. In one aspect, the polynucleotides are ds and the ds polynucleotides are overlapping PCR products, overlapping restriction fragments or assembled from ss oligonucleotides. In one aspect, the polynucleotides are ss oligonucleotides. In one aspect, the set of polynucleotides comprises at least one ds polynucleotide and at least one ss oligonucleotide.

In general, a kit is provided that includes a preparation according to claim 1 and a 5'-3' exonuclease such as for example T5 exonuclease. In one aspect, the kit may further include a ss binding protein. In another aspect, the kit may include a ligase. In another aspect, the kit may include a buffering agent. In one aspect, the kit does not include a crowding agent. In one aspect, the composition and the 5'-3' exonuclease are in the same vessel. In another aspect, the composition and the 5'-3' exonuclease are in different vessels optionally in buffers suitable for combining into a single vessel.

In general, a composition is provided for assembling a synthon, that includes: a 5'-3' exonuclease, which in one aspect has ss endonuclease activity, for example having 90% sequence identity with SEQ ID NO:98; a strand-displacing polymerase, including a Family B strand displacing polymerase that is preferably non-naturally occurring such as a mutant or a fusion protein derived from a naturally occurring polymerase that may additionally be thermostable; optionally a ss DNA binding protein, such as for example the ss DNA binding protein is ET SSB, *E. coli* recA, T7 gene 2.5 product, phage lambda RedB or Rac prophage RecT; and a non-naturally occurring buffering agent, wherein the composition does not comprise a crowding agent and/or a non-strand-displacing polymerase. In one aspect, the composition further includes a ligase and/or a ss binding domain. In one aspect, the composition includes a set of at least two polynucleotides (a plurality of polynucleotides). In one aspect, the composition does not include a non-strand-displacing polymerase. In another aspect, the composition does not include 9° N, Phusion, Vent or Pfu DNA polymerases.

In one aspect, the strand-displacing polymerase in the composition is a fusion protein wherein the polymerase moiety has an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:102, or any of SEQ ID NOS:33-55. For example, the fusion protein may have an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or 102 and SEQ ID NO:2. For example, the strand-displacing polymerase may have at least 90% sequence identity to SEQ ID NO:3. In one aspect, the composition may include a potassium salt having a concentration of at least 7 mM. In one aspect, the composition may include a set of polynucleotides in which at least one polynucleotide in the set has a sequence that overlaps with another polynucleotide in the set; and wherein the polynucleotides are selected from: (i) ds polynucleotides; (ii) ss oligonucleotides; (iii) at least one ds polynucleotide and at least one ss oligonucleotide; and (iv) a subpopulation of polynucleotides that are otherwise identical to one another except for a sequence that varies between the members of the sub-population. In one aspect, at least one member of the set of polynucleotides contains a random sequence positioned between a defined sequence at each end for hybrid-

izing to a second ss genomic polynucleotide where for example, the random sequence is ss and is capable of hybridizing to a target genomic sequence for guiding a Cas protein to a target genomic nucleic acid for gene editing.

In general, a method for forming a synthon, is provided that includes incubating any of the compositions described above that contain a set of polynucleotides having sequences that overlap under suitable reaction conditions; and joining at least some of the polynucleotides to other polynucleotides to produce a synthon. In one aspect of the method, all or a portion of the polynucleotides in the set are ds. In another aspect, the ds polynucleotides are overlapping PCR products; overlapping restriction fragments, or synthetic ds molecules assembled from complementary ss oligonucleotides where these oligonucleotides may have been made in a synthesizer. In one aspect, all or a portion of the polynucleotides in the set are ss oligonucleotides. In one aspect, the set of polynucleotides comprises at least one ds polynucleotide and at least one ss oligonucleotide. In one aspect, the set of polynucleotides comprises a subpopulation of polynucleotides that are otherwise identical to one another except for a sequence that varies between the members of the sub-population. In one aspect, the overlapping sequences of the polynucleotides are less than 2 kilobases in length. In one aspect of the method, the strand-displacing polymerase comprises an amino acid sequence that is at least 90% identical to any of SEQ ID NOS:1, 2, 3, 33-96, or 102. In one aspect of the method, at least one member of the set of polynucleotides contains a random sequence between defined sequence ends. Another aspect of the method includes screening the random sequences for hybridizing activity with a genomic DNA and identifying the random sequence with the hybridizing activity. Another aspect of the method includes performing gene editing by transcribing the random sequences with hybridizing activity to form RNA and using the RNA for gene editing in the presence of a Cas protein.

In general, a kit for polynucleotide assembly is provided that includes: a 5'-3' exonuclease; a strand-displacing polymerase; and optionally a ss DNA binding protein wherein the kit optionally does not comprise a crowding agent and/or a non-strand-displacing polymerase. In one aspect, the kit includes a ligase. In another aspect, the kit includes dNTPs. In another aspect, the kit includes a buffering agent. In another aspect, the individual components of the kit may be in the same or separate containers such as one or more different storage or reaction containers.

In general, a composition is provided that includes a polymerase fusion protein, wherein the polymerase fusion protein includes an amino acid sequence that is at least 90% identical to any of SEQ ID NOS:2, 56-96 and a heterologous polymerase domain. In one aspect, the polymerase fusion protein includes an amino acid sequence that is at least 90% identical to any of SEQ ID NO:2; and a heterologous polymerase domain.

In general, a composition is provided that includes a polymerase fusion protein is provided wherein the polymerase fusion protein includes a polymerase domain that has an amino acid sequence that is at least 90% identical to any of SEQ ID NOS:1, 33-55, or 102; and a heterologous DNA binding domain. In one aspect, the polymerase fusion protein, the polymerase domain that has an amino acid sequence that is at least 90% identical to SEQ ID NO:1; and a heterologous DNA binding domain. In one aspect, the polymerase fusion protein has a polymerase domain that has an amino acid sequence that is at least 90% identical to SEQ ID NO:102; and a heterologous DNA binding domain. In

one aspect, the polymerase fusion protein has an amino acid sequence that is at least 90% identical to SEQ ID NO:3.

In one aspect, the compositions above further include a 5'-3' exonuclease such as T5 exonuclease. In one aspect, the composition further includes a single-strand DNA binding protein for example a single-strand binding protein selected from an ET SSB, *E. coli* recA, T7 gene 2.5 product, phage lambda RedB or Rac prophage RecT. In one aspect, the composition may include a ligase. In one aspect, the ligase is thermostable. In one aspect, the composition does not include a crowding agent and/or a non-strand-displacing polymerase. In another aspect, the composition further includes dNTPs. In another aspect, the composition further includes a potassium salt having a concentration of at least 7 mM. One aspect of the composition includes a set of polynucleotides wherein at least a polynucleotide in the set has a sequence that overlaps with another polynucleotide in the set; and wherein the polynucleotides are selected from:

- (i) ds polynucleotides;
- (ii) ss oligonucleotides;
- (iii) at least one ds polynucleotide and at least one ss oligonucleotide; and
- (iv) a subpopulation of polynucleotides that are otherwise identical to one another except for a sequence that varies between the members of the sub-population.

In general, a method is provided for producing a synthon, that includes incubating a set of polynucleotides where individual polynucleotides contain sequences that overlap with sequences in other polynucleotides, where the overlapping sequences of different polynucleotides are capable of cross-hybridizing under suitable reaction conditions, and where for example the overlapping region is less than 2 kilobases, with a composition comprising a polymerase characterized above, wherein the composition further includes a 5'-3' exonuclease and, optionally, a ligase and a ss DNA binding protein; and joining the polynucleotides to produce a synthon.

In different aspects, the composition includes a ligase; and/or a ss DNA binding protein. In another aspect, one or more polynucleotides in the set are ds, where the ds polynucleotides are PCR products, overlapping restriction fragments or assembled from ss oligonucleotides and/or one or more polynucleotides are ss oligonucleotides; and/or the set of polynucleotides includes at least one ds polynucleotide and at least one ss oligonucleotide.

In general, a kit for polynucleotide assembly is provided that includes a polymerase fusion protein, as described above and a 5'-3' exonuclease; and a ss DNA binding protein. In one aspect, the kit may include any or all of a ligase, dNTPs, and buffering agent where the components of the kit may be in the same vessel or in different vessels.

BRIEF DESCRIPTION OF THE FIGURES

The skilled artisan will understand that the drawings, described below, are for illustration purposes only. The drawings are not intended to limit the scope of the present teachings in any way.

FIG. 1A-1E shows how the assay described in Example 1 differentiates between a strand displacing and non-strand displacing polymerase. This assay confirms that T4 DNA polymerase is non-strand displacing and terminates synthesis of a template DNA at 44 nucleotides in length at a blocking oligonucleotide (2) (FIG. 1C) whereas Bst polymerase (FIG. 1D) and a non-natural polymerase (FIG. 1E) are strand displacing and can continue DNA synthesis of a FAM primer (1) by displacing the blocking oligonucleotide (27 nucleotides in length).

11

FIG. 1A shows the sequence and position of the primer (**1**) and a blocking oligonucleotide (**2**) on a DNA template used in the assay for the enzymes below.

FIG. 1B shows fluorescence observed in samples obtained after capillary electrophoresis where no enzyme was added and the starting material formed a peak at a position corresponding to 24 nucleotides of the FAM primer.

FIG. 1C shows the result of adding T4 DNA polymerase. The primer was extended to a final length of 44 nucleotides (24 nucleotides plus 20 nucleotides) but was terminated by the blocking oligonucleotide.

FIG. 1D shows that Bst DNA polymerase (large fragment strand-displaces the blocking oligonucleotide and copies template by extending the primer to a total length of 72 nucleotides (24+20+27+dA).

FIG. 1E shows a family B strand displacing DNA polymerase which is a proof reading polymerase that strand displaces blocking oligonucleotides and copies template by extending the primer by 71 nucleotides (24+20+27).

FIG. 2A-2C show the steps in a DNA assembly method.

FIG. 2A shows the incorporation of the amplicons of each of 5 fragments into 5 plasmids with ampicillin resistance markers. The 5 fragments were initially amplified with primers that generated amplicons which had overlapping regions as well as flanked by NotI restriction sites. The NotI cleavage produces sticky ends. NotI restriction (**3**) permitted release of each amplicon from the vectors. The restriction enzyme cleaved fragments have an 80 base pair overlap region (**4**) with the adjacent fragment. In FIG. 2C, the overlap between the first fragment and an adjacent reagent vector end and a last fragment and adjacent reagent vector end is 15-25 nucleotides, for example, 20 nucleotides, for convenience and cost reduction but this is not intended to be limiting.

FIG. 2B shows NotI cleaved optionally sequenced fragments (**5**) where the amplicon is retrieved from a vector and the 5' ends of Frag. 1 are SEQ ID NO:103 and 104 and of Frag. 2 top strand is SEQ ID NO:105. These fragments were then treated with an enzyme mixture that included T5/5'-3' exonuclease, DNA polymerase with 3'-5' exonuclease activity, a ss binding protein SSB (New England Biolabs, Ipswich, Mass.) and DNA ligase in a single reaction vessel (**6**-**8**). Although NotI is used here, other restriction endonucleases may be used for cleavage depending on convenience. Double digestion with two or more restriction endonucleases may be used. For example, double digestion of vector DNA with two restriction endonucleases has been found to reduce background from uncut vector. The overlapping ss DNA sequences hybridized to adjacent fragments. The T5 exonuclease chewed back a DNA strand from 5' to 3' on each fragment to expose a 3' ss region (**6**) which allowed the fragments to anneal together in the presence of ss binding protein (**7**). Removal of the 2 base flap was achieved by means of the 3'-5' exonuclease activity associated with a strand displacing polymerase followed by extension by the strand displacing polymerase to fill the gap in the assembled product (**8**). Any residual nick or 5' flap may be repaired by a ligase and/or T5 exonuclease.

FIG. 2C shows the 5 fragments (Frag 1-Frag 5) now joined in sequence and inserted into a second plasmid carrying chloramphenicol resistance gene (Cam) for transformation into a bacterial host.

FIGS. 3A and 3B show chloramphenicol plates were used to select colonies for growth on plates and those colonies that contained the lacZ gene generated blue colonies in the presence of IPTG and X-Gal. The assay provides a quanti-

12

tative assessment of clones in which genes are assembled efficiently and in a functional form.

FIG. 3A shows chloramphenicol only.

FIG. 3B shows chloramphenicol+IPTG+Xgal.

FIG. 4 shows that the plasmids did in fact contain the entire gene. Amplification by PCR of assembly product shown in FIG. 2B was performed to confirm all fragments were joined and ligated prior transformation. Lane 1 and 2 are duplicate PCR results. Lane M is 2-log DNA ladder from New England Biolabs, Ipswich, Mass.

FIG. 5 shows the effect of KCl in the assembly mix as determined by the number of colonies. The increase in accuracy/efficiency of assembly using a strand displacing polymerase in an assembly mix is demonstrated using an increased concentration of KCl in the buffer. The histogram on the left (T26) does not contain KCl whereas the histogram on the right (T26K) contains 25 mM KCl showing a 1.5 fold enhancement of efficiency. This improvement occurs regardless of the assembly condition. A similar relative enhancement of efficiency is expected if PEG or other crowding agent were used in the absence of ss binding protein.

FIG. 6 shows a comparison between the mixture described in Example 2 (Strand displacing polymerase/ss binding protein/5'-3' exonuclease/ligase)(Mix1) and the commercial Gibson Assembly® Mix (GAMM) (non-strand displacing polymerase and polyethylene glycol) (Synthetic Genomics, La Jolla, Calif./New England Biolabs, Ipswich, Mass.) following the protocol provided by the manufacturer. Mix 1 results in significantly higher efficiencies of DNA assembly and transformation.

FIG. 7 shows a general diagram of DNA assembly between ss DNA oligonucleotides and ds DNA fragments. ss target DNA oligonucleotide is inserted into a DNA vector.

The ss target DNA oligonucleotide has been synthesized so as to have an overlapping region of 20-30 nucleotides on each end with the 3' vector ends. However, the size of the oligonucleotide may have an overlapping region of less than 20 nucleotides for example less than 15 nucleotides or less than 10 nucleotides or alternatively more than 30 nucleotides, for example, at least 40 or 50 or 60 nucleotides or more. Beyond the overlapping regions, the oligonucleotide preferably has 1 or more nucleotides that are not overlapping positioned between the ends. The assembly master mix which contains a 5'-3' exonuclease, strand displacing polymerase, ligase and ss binding protein is added to the mixture of ss oligonucleotide and the vectors so as to permit the 5' end of the ds DNA vector to be chewed back so as to produce ss overhangs (**9**). The 3' end of the ss DNA is then able to anneal to a 5' end of the vector and the DNA polymerase then replicates the ss template to fill the gap and produce a blunt ended ds DNA. The nick is sealed by ligase (**10**). Again, the exonuclease (here T5 exonuclease) chews back the 5' end this time on the blunt end of the target DNA producing 3' ss regions so as to permit annealing of the complementary sequences and completion of the ds integration of target DNA into the DNA vector (**11**). Fragments can anneal with DNA polymerase filling the gap and ligase sealing the nick. (**12**) to produce a synthon.

FIG. 8A-8C shows the workflow for bridging ds DNA by a short ss oligonucleotide. (The protocol is described in FIG. 7).

FIG. 8A provides an example of a sequence of a short ss oligonucleotide for integration into a ds DNA vector shown here as a CRISPR Nuclease Vector with OFP Reporter

FIG. 8B shows the workflow starting with a ss oligonucleotide and a ds CRISPR Nuclease Vector (9424 bp)

13

treated with 5'-3' exonuclease, strand displacing polymerase, a ligase and ass binding protein (13) to produce a complete ds circular DNA. This DNA was transformed into competent cells (14). After an overnight incubation, the colonies were analyzed by a mini-prep and then the plasmids sequenced (15). FIG. 8C shows the insert and adjacent sequences (SEQ ID NO:106) of U6 promoter sequence (vector) including the designed ss oligonucleotide (71mer), and scaffold template-specific sequence (vector). The ss oligonucleotide (71mer) including an overlap region of 25 nucleotides at each end (21 nucleotides of the target DNA in bold) was properly integrated into the vector in host cells.

FIG. 9A-9C show that a similar workflow to that in FIG. 8 can be used for an ss oligonucleotide having degenerate bases between the overlapping ends. Again the starting sequence in FIG. 9A is shown above the workflow (FIG. 9B) and the Sanger-sequencing results from colonies from assembly pool is shown below (FIG. 9C) with the solid line referring to a pool of sgRNA targeting sequences. The sgRNA targeting sequence contained 21 variable nucleotide positions providing 4²¹ variants. The pool contained every possible variant and each variant was amenable to cloning reflecting the degeneracy of the sequence between the overlapping ends and the vector. FIG. 9A shows the sequence of a ss oligonucleotide containing degenerate bases (SEQ ID NO:29). The sgRNA targeting sequence of FIG. 9A was inserted between a U6 promoter sequence and a scaffold template specific sequence of the vector (16), transformed into host cells (17) and analyzed for synthons by miniprep and sequencing (18) as described above and herein. Sanger sequencing was performed on clones from the assembly pool. An example of a sequence is provided in FIG. 9C (SEQ ID NO:108).

FIG. 10 presents the results of 187 colonies selected from a plate after the assembly reaction products were transformed into *E. coli*. Each colony was PCR amplified and sequenced to confirm the insertion of the ss DNA and the distribution of degenerate bases were analyzed. The results shown here confirmed that indeed different colonies contained different degenerate sequences. No bias was detected. Analysis was carried out by first converting the sequences into a fastq file and then using the fastx_quality_stats tool from the fastx toolkit on github. The sequence logo was created using weblogo from Berkeley.

DESCRIPTION OF TERMS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2D ED., John Wiley and Sons, New York (1994), and Hale & Markham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, N.Y. (1991) provide one of skill with the general meaning of many of the terms used herein. Still, certain terms are defined below for the sake of clarity and ease of reference.

As used herein, the term "synthon" as used in the field of gene synthesis refers to a polynucleotide assembly. Polynucleotide assembly may include assembling overlapping fragments of a size that can be prepared on an oligonucleotide synthesizer which at the present time is generally 2000-3000 bases for each synthetic polynucleic acid. Alternatively, overlapping fragments may be obtained by PCR from naturally occurring nucleic acid to which adaptors have been attached to provide the overlapping sequences. For

14

assembly purposes there is no limitation on the size of each fragment. Many fragments can be assembled end to end relying on overlapping sequences at the ends to enable constructs of any desirable length to be made accurately and efficiently. Preferably a synthon is a continuous longer polynucleotide that does not contain gaps or nicks that are formed from the assembly of shorter polynucleotides. The length of synthons resulting from assembly of nucleic acid fragments is not limited to any particular size however.

10 As used herein, the term "5'-3' exonuclease", refers to an exonuclease that degrades DNA from the 5' end, i.e., in the 5' to 3' direction. 5'-3' exonucleases of interest can remove nucleotides from the 5' end of a strand of ds DNA at a blunt end and, in certain embodiments, at a 3' and or 5' overhang. 15 T5 exonuclease, lambda exonuclease and T7 exonuclease are examples of 5'-3' exonucleases. In certain embodiments, T5 exonuclease is preferred. T5 exonuclease additionally has a ss endonuclease activity.

As used herein, the term "ligase", refers to an enzyme that 20 can covalently join a 3' end of a DNA molecule to a 5' end of another DNA molecule, particularly at a nick. Examples of ligases include T7 ligase, T4 DNA ligase, *E. coli* DNA ligase and Taq ligase, although many others are known and may be used herein.

25 As used herein, the term "strand-displacing polymerase", refers to a polymerase that is able to displace one or more nucleotides, such as at least 10 or 100 or more nucleotides that are downstream from the enzyme. Strand displacing polymerases can be differentiated from Phusion where the 30 art recognized definition of Phusion is a non-strand displacing polymerase. In some embodiments, the strand displacing polymerase is stable and active at a temperature of at least 50° C. or at least 55° C. (including the strand displacing activity). Taq polymerase is a nick translating polymerase and, as such, is not a strand displacing polymerase.

As used herein, the term "single strand (ss) DNA binding protein", refers to proteins that bind to ss DNA and prevent 35 premature annealing, protect the ss DNA from being digested by nucleases, and polymerases and/or remove secondary structure from the DNA to allow other enzymes to function effectively upon it. Inclusion of a ss binding protein in the compositions described herein is preferable to optimize the efficiency of synthon formation. Examples of ss 40 DNA binding proteins are T4 gene 32 protein, *E. coli* SSB, T7 gp2.5 SSB, and phage phi29 SSB, and ET SSB although many others, e.g., RedB of lambda phage, RecT of Rac prophage and the sequences listed below, are known and may be used herein. A thermostable ss DNA binding protein that is stable at 50° C. may be used in some cases. Thus, in 45 one embodiment of the composition, kit, or method of the invention, the ss DNA binding protein is T4 gene 32 protein, *E. coli* SSB, T7 gp2.5 SSB, phage phi29 SSB, ET SSB, RedB of lambda phage, or RecT of Rac prophage. In one embodiment, the ss DNA binding protein is ET SSB. In one embodiment of the composition, kit, or method of the invention, the ss DNA binding protein is thermostable (i.e. stable at 40° C.-60° C.).

As used herein, the term "buffering agent", refers to an 50 agent that allows a solution to resist changes in pH when acid or alkali is added to the solution. Examples of suitable non-naturally occurring buffering agents that may be used in the compositions, kits, and methods of the invention include, for example, Tris, HEPES, TAPS, MOPS, tricine, or MES.

The term "non-naturally occurring" refers to a composition 55 that does not exist in nature.

Any protein described herein may be non-naturally occurring, where the term "non-naturally occurring" refers to a

protein that has an amino acid sequence and/or a post-translational modification pattern that is different to the protein in its natural state. For example, a non-naturally occurring protein may have one or more amino acid substitutions, deletions or insertions at the N-terminus, the C-terminus and/or between the N- and C-termini of the protein. A “non-naturally occurring” protein may have an amino acid sequence that is different to a naturally occurring amino acid sequence (i.e., having less than 100% sequence identity to the amino acid sequence of a naturally occurring protein) but that that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% identical to the naturally occurring amino acid sequence. In certain cases, a non-naturally occurring protein may contain an N-terminal methionine or may lack one or more post-translational modifications (e.g., glycosylation, phosphorylation, etc.) if it is produced by a different (e.g., bacterial) cell. A “mutant” protein may have one or more amino acid substitutions relative to a wild-type protein and may include a “fusion” protein. The term “fusion protein” refers to a protein composed of a plurality of polypeptide components that are unjoined in their native state. Fusion proteins may be a combination of two, three or even four or more different proteins. The term polypeptide includes fusion proteins, including, but not limited to, a fusion of two or more heterologous amino acid sequences, a fusion of a polypeptide with: a heterologous targeting sequence, a linker, an immunologically tag, a detectable fusion partner, such as a fluorescent protein, β -galactosidase, luciferase, etc., and the like. A fusion protein may have one or more heterologous domains added to the N-terminus, C-terminus, and/or the middle portion of the protein. If two parts of a fusion protein are “heterologous”, they are not part of the same protein in its natural state.

In the context of a nucleic acid, the term “non-naturally occurring” refers to a nucleic acid that contains: a) a sequence of nucleotides that is different to a nucleic acid in its natural state (i.e. having less than 100% sequence identity to a naturally occurring nucleic acid sequence), b) one or more non-naturally occurring nucleotide monomers (which may result in a non-natural backbone or sugar that is not G, A, T or C) and/or c) may contain one or more other modifications (e.g., an added label or other moiety) to the 5'-end, the 3' end, and/or between the 5'- and 3'-ends of the nucleic acid.

In the context of a preparation, the term “non-naturally occurring” refers to: a) a combination of components that are not combined by nature, e.g., because they are at different locations, in different cells or different cell compartments; b) a combination of components that have relative concentrations that are not found in nature; c) a combination that lacks something that is usually associated with one of the components in nature; d) a combination that is in a form that is not found in nature, e.g., dried, freeze dried, crystalline, aqueous; and/or e) a combination that contains a component that is not found in nature. For example, a preparation may contain a “non-naturally occurring” buffering agent (e.g., Tris, HEPES, TAPS, MOPS, tricine or MES), a detergent, a dye, a reaction enhancer or inhibitor, an oxidizing agent, a reducing agent, a solvent or a preservative that is not found in nature.

It may be desirable to use a strand displacing polymerase that has 3' exonuclease activity. While not wishing to be limited by theory, the 3' exonuclease activity is desirable to remove a flap sequence on the 3' end of a duplex where the flap sequence may be the result of enzyme cleavage to extract the target polynucleotide from the plasmid in which

it is placed. This is the case when NotI is used as described in the examples. However, if a restriction endonuclease is used that creates a blunt end on the excised fragment, 3'exonuclease activity may not be required.

The 3' exonuclease activity can be routinely determined by using a standard DNA template and primers where the primers either have or do not have non-hybridized 3' nucleotides. If the polymerase has 3' exonuclease activity, an amplicon will be detected using either primer pair. If the polymerase lacks the 3' exonuclease activity, no amplicon will be detected using those primers having a non-hybridized 3' nucleotide.

As used herein, the term “potassium salt”, refers to a salt of potassium including, but not limited to, KCl. The term “sodium salt”, refers to a salt of sodium including, but not limited to, NaCl.

As used herein, the term “polynucleotide” encompasses oligonucleotides and refers to a nucleic acid of any length. Polynucleotides may be DNA or RNA. Polynucleotides may be ss or ds unless specified. Polynucleotides may be synthetic, for example, synthesized in a DNA synthesizer, or naturally occurring, for example, extracted from a natural source, or derived from cloned or amplified material. Polynucleotides referred to herein may contain modified bases.

As used herein, the term “set of polynucleotides”, refers to a collection of at least 2 polynucleotides. In some embodiments, a set of polynucleotides may comprise at least 5, at least 10, at least 12 or at least 15 or more polynucleotides.

As used herein, the term “overlapping sequence”, refers to a sequence that is complementary in two polynucleotides and where the overlapping sequence is ss, on one polynucleotide it can be hybridized to another overlapping complementary ss region on another polynucleotide. By way of example, the overlapping sequence may be complementary in at least 5, 10, 15, or more polynucleotides in a set of polynucleotides. An overlapping sequence may be at or close to (e.g., within about 5, 10, 20 nucleotides of) the 3' ends of two distinct molecules (e.g., the 3' ends of two ss oligonucleotides, or the 3' end of the top strand of first ds polynucleotide and the 3' end of the bottom strand of a second ds molecule), where, if the non-overlapping sequence is at the 3' ends then the non-overlapping sequence may be removed using a 3'-5' exonuclease activity of a polymerase. An overlapping sequence may vary in length and, in some cases, may be at least 12 nucleotides in length (e.g. at least 15, 20 or more nucleotides in length) and/or may be up 100 nucleotides in length (e.g., up to 50, up to 30, up to 20 or up to 15 nucleotides in length). Alternatively, overlapping sequences in the set of polynucleotides may be 2 kb or less, or 1 kb or less or less than 900 bases, 800 bases, 700 bases, 600 bases, 500 bases, 400 bases, 300 bases, 200 bases or 100 bases. Preferably the overlapping sequence length is in the range of 15 nucleotides-80 nucleotides for example up to 20, up to 25, up to 30, up to 35, up to 40, up to 45, up to 50, up to 55, up to 60, up to 65, up to 70, up to 75, or up to 80 nucleotides. The minimum length of the overlap may be defined by a Tm that is preferably equal to or greater than 48° C.

As used herein, the term “polynucleotide assembly”, refers to a reaction in which two or more, four or more, six or more, eight or more, ten or more, 12 or more 15 or more polynucleotides, e.g., four or more polynucleotides are joined to another to make a longer polynucleotide. The product of a polynucleotide assembly reaction, i.e., the “assembled polynucleotide” or “synthon” in many embodiments should contain one copy of each of the overlapping sequences.

As used herein, the term "incubating under suitable reaction conditions", refers to maintaining a reaction a suitable temperature and time to achieve the desired results, i.e., polynucleotide assembly. Reaction conditions suitable for the enzymes and reagents used in the present method are known (e.g. as described in the Examples herein) and, as such, suitable reaction conditions for the present method can be readily determined. These reactions conditions may change depending on the enzymes used (e.g., depending on their optimum temperatures, etc.).

As used herein, the term "isothermal" refers to temperature conditions that do not require active modulation of temperature for assembly to occur. Insignificant variations in the temperature of a water bath or heating block are within the scope of the meaning of the term isothermal. By way of example, the term "isothermal", may refer to reaction conditions that do not require a heat denaturation step after the reaction has started. More specifically, isothermal methods do not involve thermocycling, i.e., cycling between a denaturation temperature of above 90° C. and an annealing/extension temperature. Isothermal conditions usually involve incubation at a temperature that is below 90° C. for a period of time (e.g., 5 minutes to 12 hours or more). In one embodiment, isothermal amplification reactions were performed at a temperature in the range of 30° C.-75° C., for example, 40° C.-60° C.

As used herein, the term "joining", refers to the production of covalent linkage between two sequences.

As used herein, the term "composition" refers to a combination of reagents that may contain other reagents, e.g., glycerol, salt, dNTPs, etc., in addition to those listed. A composition may be in any form, e.g., aqueous or lyophilized, and may be at any state (e.g., frozen or in liquid form).

As used herein a "vector" is a suitable DNA into which a fragment or a synthon may be integrated such that the engineered vector can be replicated in a host cell. A linearized vector may be created restriction endonuclease digestion of a circular vector or by PCR. The concentration of fragments and/or linearized vectors can be determined by gel electrophoresis or other means.

Any one or more of the proteins (e.g., the ligase, SSBP, 5'-3' exonuclease or polymerase, etc.) used herein may be temperature sensitive or thermostable where, as used herein, the term "temperature sensitive" refers to an enzyme that loses at least 95% of its activity after 10 minutes at a temperature of 65° C., and the term "thermostable" refers to an enzyme that retains at least 95% of its activity after 10 minutes at a temperature of 65° C.

DETAILED DESCRIPTION OF EMBODIMENTS

Before various embodiments are described in greater detail, it is to be understood that the teachings of this disclosure are not limited to the particular embodiments described, and as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present teachings will be limited only by the appended claims.

While the present teachings are described in conjunction with various embodiments, it is not intended that the present teachings be limited to such embodiments. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the present disclosure.

Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present teachings, the some exemplary methods and materials are now described.

The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present claims are not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided can be different from the actual publication dates which can need to be independently confirmed.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims can be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which can be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present teachings. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

The sequences that overlap in the set of polynucleotides may be of any suitable length such as 2 kb or less, or 1 kb or less or less than 900 bases, 800 bases, 700 bases, 600 bases, 500 bases, 400 bases, 300 bases, 200 bases or 100 bases. The overlapping region may be as few as 8 nucleotides. Preferably the overlapping sequence length is in the range of 15 nucleotides-80 nucleotides for example up to 20, up to 25, up to 30, up to 35, up to 40, up to 45, up to 50, up to 55, up to 60, up to 65, up to 70, up to 75, or up to 80 nucleotides. For example, the minimum length of the overlap may be defined by a Tm that is preferably equal to or greater than 48° C.

Synthetic oligonucleotides and polynucleotides may contain errors created during their synthesis prior to their use in synthon assembly. To correct these errors prior to assembly, it is desirable to perform a mismatch repair step. To this end, various methods have been described to achieve mismatch repair of the synthetic nucleic acids prior to assembly. A population of synthetic nucleic acids may have random errors so that denaturation and renaturation of the preparation may reveal mismatches. Proteins that have been isolated from nature such as mutHLS, cel-1 nuclease, T7 endo 1, uvrD, T4 EndoVII, *E. coli* EndoV, (see U.S. Pat. No. 7,851,192 and U.S. Pat. No. 8,048,664) that can bind selectively to DNA duplexes containing mismatches; cleave nucleic acids at the mismatched bases and optionally replace with correct bases based on the nucleotide sequences of the templates.

Despite teaching in the art that a non-strand displacing polymerase must be utilized with a ss binding protein, 5'-3'-exonuclease and ligase to assemble fragments of DNA, it has been surprisingly shown herein that a strand displacing polymerase may be used under conditions where strand

displacement occurs and that this is efficient at surprising low concentrations of starting polynucleotide fragments to effectively generate a single nucleic acid from a plurality of fragments.

Examples of strand displacing polymerases that may be used in embodiments of an assembly mixture, composition, kit, or method of the invention include members of family B polymerases, such as (but not limited to) any of those identified in Table 1 (SEQ ID NOS:33-55). In addition, fusions of such polymerases may be used, for example fusions between a plurality of polymerases and/or ss binding domains (such as shown in Table 2) (SEQ ID NOS: 56-97). In embodiments any of the polymerase moieties in Table 1 or proteins having at least 80%, 85%, 90%, 95% 98%, 99% or 100% amino acid sequence identity to any of these protein moieties in Table 1 may be fused at the N-terminal end or the C-terminal end to any of the DNA binding domains described in Table 2 or a protein moiety have at least 80%, 85%, 90%, 95% 98%, 99% or 100% amino acid sequence identity to any of the DNA binding moieties in Table 2 to form a strand displacing fusion polymerase for use herein. The DNA binding domain may optionally be fused to the N-terminal end or the C-terminal end of the polymerase.

Variants of other polymerases or novel isolates that are revealed to be strand displacing as determined by the assay provided herein (see for example, FIG. 1A-1E and Example 1) may also be used. Sequences of the polymerases found from these sources are readily accessible through GenBank. Because of the high degree of conservation of strand displacing sequences, any variant having 80%, 85%, 90%, or 95% amino acid sequence identity with such wild type polymerases might be expected to have strand displacing

properties that can be quickly and easily verified in the assay provided in Example 1 in a preselected buffer without undue experimentation.

In one embodiment, the reaction mixture, composition, kit, or method of the invention comprises or uses a strand displacing polymerase having at least 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity with SEQ ID NO:1 or SEQ ID NO:102 (e.g. 100% sequence identity with SEQ ID NO:1 or SEQ ID NO:102). In another embodiment, the reaction mixture, composition, kit, or method of the invention comprises or uses a polymerase having a binding domain having at least 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity with SEQ ID NO:2 (e.g. 100% sequence identity with SEQ ID NO:2). In another embodiment, the reaction mixture, composition, kit, or method of the invention comprises or uses a polymerase having at least 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity with SEQ ID NO:1, or SEQ ID NO:102 and SEQ ID NO:2, or SEQ ID NO:3 or any of SEQ ID NOS:33-97 (e.g. 100% sequence identity with SEQ ID NO:1 or SEQ ID NO: 102, and SEQ ID NO:2 or SEQ ID NO:3 or any of SEQ ID NOS:33-97). These compositions may be used in reaction conditions in which the polymerase is strand displacing. The compositions may be used in reaction conditions in which any 3'-5' exonuclease activity associated with the polymerase activity is active. This may be helpful when a restriction enzyme is used in the reaction such as NotI. In this case, the 3'-5' exonuclease may remove a flap sequence on the 3' end of the duplex. However, if a restriction endonuclease is used that creates a blunt end on the excised fragment, 3'-5' exonuclease activity may not be required. The assembly reaction may be performed under isothermal conditions. In one embodiment the isothermal conditions are 50° C.

TABLE 1

Table of polymerases			
<i>Methanocaldococcus vulcanius</i> M7	SP-13	gi 502573182	SEQ ID NO: 33
<i>Archaeoglobus fulgidus</i> DSM 4304	SP-16	gi 499180464	SEQ ID NO: 34
<i>Archaeoglobus profundus</i> DSM 5631	SP-17	gi 502704426	SEQ ID NO: 35
<i>Caldicellulosiruptor hydrothermalis</i> 108	SP-19	gi 503168530	SEQ ID NO: 36
<i>Desulfurococcus mucosus</i> DSM 2162	SP-27	gi 503328138	SEQ ID NO: 37
<i>Pyrolobus fumarii</i>	SP-29	gi 503791850	SEQ ID NO: 38
<i>Pyrobaculum oguniense</i> CH	SP-30	gi 379003208	SEQ ID NO: 39
<i>Staphylothermus marinus</i> F1	SP-33	gi 500164563	SEQ ID NO: 40
<i>Pyrococcus yataosii</i> CH1	SP-42	gi 503672202	SEQ ID NO: 41
<i>Thermococcus</i> sp. AM4-del	SP-43	gi 503888003	SEQ ID NO: 42
<i>Thermococcus hydrothermalis</i>	SP-44	gi 17375628	SEQ ID NO: 43
<i>Thermococcus thioreducens</i>	SP-45	gi 117958105	SEQ ID NO: 44
<i>Thermococcus waiotapuensis</i>	SP-46	gi 378813034	SEQ ID NO: 45
<i>Thermococcus sibiricus</i> MM 739	SP-47	gi 506329477	SEQ ID NO: 46
<i>Pyrococcus glycovorans</i>	SP-48	gi 7288074	SEQ ID NO: 47
<i>Pyrococcus</i> sp. NA2	SP-49	gi 503513858	SEQ ID NO: 48
<i>Ferroglobus placidus</i> DSM 10642	SP-61	gi 502730992	SEQ ID NO: 49
<i>Palaeococcus ferrophilus</i> DSM 13482	SP-5	gi 851288004	SEQ ID NO: 50
<i>Thermococcus gammafermentans</i> EJ3	SP-50	gi 506339349	SEQ ID NO: 51
<i>Thermococcus celericrescens</i>	SP-51	gi 332308985	SEQ ID NO: 52
<i>Vulcanisaeta distributa</i> DSM 14429	SP-60	gi 503101260	SEQ ID NO: 53
<i>Methanopyrus kandleri</i> AV19	SP-7	gi 20094475	SEQ ID NO: 54
<i>Thermoproteus neutrophilus</i> V24Sta	SP-9	gi 171185774	SEQ ID NO: 55

TABLE 2

DNA binding proteins			
DNA-binding protein Tfx	BD-51	gi 499321160	SEQ ID NO: 56
AbrB/MazE/MraZ-like	BD-52	gi 499321199	SEQ ID NO: 57
"Winged helix" DNA-binding domain	BD-54	gi 499322061	SEQ ID NO: 58
Ribbon-helix-helix protein, copG family	BD-62	gi 499321149	SEQ ID NO: 59
lambda repressor-like DNA-binding domains	BD-63	gi 499322443	SEQ ID NO: 60

TABLE 2-continued

DNA binding proteins			
Resolvase-like	BD-67	gi 499322676	SEQ ID NO: 61
"Winged helix" DNA-binding domain	BD-71	gi 499322676	SEQ ID NO: 62
"Winged helix" DNA-binding domain	BD-74	gi 499322255	SEQ ID NO: 63
"Winged helix" DNA-binding domain	BD-75	gi 499322388	SEQ ID NO: 64
"Winged helix" DNA-binding domain	BD-81	gi 499322131	SEQ ID NO: 65
"Winged helix" DNA-binding domain	BD-82	gi 499321342	SEQ ID NO: 66
"Winged helix" DNA-binding domain	BD-85	gi 499321130	SEQ ID NO: 67
"Winged helix" DNA-binding domain	BD-86	gi 499322705	SEQ ID NO: 68
"Winged helix" DNA-binding domain	BD-88	gi 499320855	SEQ ID NO: 69
"Winged helix" DNA-binding domain	BD-89	gi 499322250	SEQ ID NO: 70
"Winged helix" DNA-binding domain	BD-91	gi 499321633	SEQ ID NO: 71
"Winged helix" DNA-binding domain	BD-92	gi 490170077	SEQ ID NO: 72
"Winged helix" DNA-binding domain	BD-93	gi 499321272	SEQ ID NO: 73
"Winged helix" DNA-binding domain	BD-94	gi 499320919	SEQ ID NO: 74
"Winged helix" DNA-binding domain	BD-97	gi 499320853	SEQ ID NO: 75
"Winged helix" DNA-binding domain	BD-98	gi 499321734	SEQ ID NO: 76
"Winged helix" DNA-binding domain	BD-100	gi 499322439	SEQ ID NO: 77
"Winged helix" DNA-binding domain	BD-102	gi 499322707	SEQ ID NO: 78
"Winged helix" DNA-binding domain	BD-109	gi 499321112	SEQ ID NO: 79
HCP-like	BD-02	gi 351675391	SEQ ID NO: 80
Helix-turn-helix domain, rpiR family	BD-03	gi 500479591	SEQ ID NO: 81
Helix-turn-helix domain, rpiR family	BD-04	gi 15643984	SEQ ID NO: 82
Bacterial regulatory proteins, lacI family	BD-07	gi 15643711	SEQ ID NO: 83
Bacterial regulatory proteins, lacI family	BD-08	gi 15643974	SEQ ID NO: 84
Bacterial regulatory proteins, lacI family	BD-09	gi 15643956	SEQ ID NO: 85
Bacterial regulatory proteins, lacI family	BD-11	gi 500480095	SEQ ID NO: 86
lambda repressor-like DNA-binding domains	BD-12	gi 15643421	SEQ ID NO: 87
"Winged helix" DNA-binding domain	BD-14	gi 15644350	SEQ ID NO: 88
"Winged helix" DNA-binding domain	BD-16	gi 24159093	SEQ ID NO: 89
"Winged helix" DNA-binding domain	BD-18	gi 15643139	SEQ ID NO: 90
"Winged helix" DNA-binding domain	BD-23	gi 15642807	SEQ ID NO: 91
"Winged helix" DNA-binding domain	BD-24	gi 15643159	SEQ ID NO: 92
"Winged helix" DNA-binding domain	BD-30	gi 15643333	SEQ ID NO: 93
"Winged helix" DNA-binding domain	BD-32	gi 15643055	SEQ ID NO: 94
"Winged helix" DNA-binding domain	BD-37	gi 15643827	SEQ ID NO: 95
"Winged helix" DNA-binding domain	BD-43	gi 15643699	SEQ ID NO: 96
Homeodomain-like	BD-45	gi 15643788	SEQ ID NO: 97

35

In an embodiment of the invention, the reaction mixture, composition, kit or method may include or use a 5'-3' exonuclease such as T5/5'-3'-exonuclease that is temperature sensitive and can be inactivated by raising the temperature above 50° C. In one embodiment, the 5'-3' exonuclease has exonuclease activity and ss endonuclease activity. In some embodiments, a reaction mixture may further include a ligase for example, an NAD⁺ requiring ligase and/or a thermostable ligase, for example Taq ligase. In preferred embodiments, the reaction mixture may include a ss binding protein. The ss binding protein may be thermostable for example, ET SSB. The assembly reaction may be performed under isothermal conditions.

In certain embodiments, the use of a ligase is optional. For example, where an assembled fragment is introduced directly into a vector for transformation of a host cell, a ligase is not required as the host cell such as *E. coli* may be capable of repairing nicks in vivo. However, if the assembled fragment is amplified for purposes of confirming correct assembly prior to transformation, it is desirable to use a ligase to close nicks and enable a polymerase to amplify the entire target DNA.

Cloning of individual fragments may use chemically synthesized polynucleotide fragments with sequences obtained from any database or publication where the polynucleotide fragments have overlapping sequences. These can be cloned in a plasmid by inserting the polynucleotide into a site in the plasmid adjacent to restriction enzyme sites suitable for excision of the inserted polynucleotide.

Any plasmid may be used. The present examples utilize the commercially available pACYC184 that contains the

chloramphenicol gene as a selectable marker. Any selectable marker may be used in place of chloramphenicol resistance gene. Similarly a specific recognition site for any cleavage enzyme capable of specifically cleaving at the ends of the oligonucleotide to generate either staggered ends or blunt ends may be selected where the specific cleavage site does not occur in the fragments of interest in addition to the engineered position adjacent to the ends of the fragment of interest. In the present examples, the recognition site for the eight base cutter NotI (CGCCGGCG) that produces staggered ends has been introduced adjacent to the polynucleotide of interest by means of DNA synthesis. However, this site may be present in a plasmid of choice or added to the synthetic oligonucleotide of interest by a primer for amplification. Examples of specific cleavage enzymes include restriction endonucleases and homing endonucleases.

Once the oligonucleotide or DNA fragment of interest has been chemically synthesized cloned or amplified from an existing DNA and cloned into a vector with a selectable marker, it is excised preferably by enzyme cleavage. The fragments or oligonucleotides that have been synthesized or amplified so as to incorporate overlapping sequence with an adjacent fragment or oligonucleotide to which it is intended to be joined are then assembled in an assembly reaction.

Under the hybridization conditions selected, the 5'-3' exonuclease in the reaction mixture (for example, at a concentration in the range of 0.004-0.016 U/μl) chews back any ss region at the 5' end of the fragment or oligonucleotide and continues to chew back through the region of overlapping sequences and may continue further continues for a limited distance (for example, at least 100 bases) to provide

a 3' ss region (see for example, FIGS. 2A-2C and 7). At the same time, the strand-displacing polymerase as defined by the assay in FIG. 1A-1E and Example 1 (for example, at a concentration in the range of 0.005 U/μl-0.5 U/μl) repairs the gap remaining between the hybridized ds region and any residual ss region. Since the polymerase is strand-displacing, it may displace additional downstream sequences to form an ss flap. However, T5 exonuclease ss endonuclease activity will remove this flap and any associated nick may be repaired by a ligase (for example, at a concentration in the range of 0.001 U/μl-20 U/μl).

Once fragments are assembled into a larger piece of DNA which are cloned in colonies of host cells under selective pressure, the DNA from these colonies can be rescued from the vectors and again assembled with other fragments and transformed into host cells thus expanding the size of the DNA many times. The host cell may be a competent bacterial cell or may be a yeast cell or other eukaryotic cell.

The assembly process as described herein has been found to be very efficient. For example, 0.02 nM-100 nM of oligonucleotide (ss) or DNA fragment (ds) may be utilized to assemble a larger fragment where the concentration of ss oligonucleotides used in a reaction can be up to approximately 50 times more than the amount of ds DNA fragments used in a similar assembly reaction. Similarly, equal molarity of plasmid containing a single fragment and a selectable marker and a similar amount of the vector containing the assembled fragments with a different selectable marker may be used. These amounts are intended as guides but can be reduced whether the efficiency of the assembly is enhanced. For example, addition of the potassium salt, KCl can increase efficiency of productive assembly by 1.5 fold as determined by the number of colonies using the assembly of lacIZ as an indicator (see for example FIG. 5).

The assembly process for ss target oligonucleotides between two ds DNA molecules or into a linearized vector is also very efficient. An example is provided herein which is not intended to be limiting that uses specific/random sequences to identify guide RNAs for CRISPR-Cas gene editing protocols that can be introduced into cells to determine an altered phenotype. At the outset, it may not be known what sequence might be suitable for achieving this goal. The generation of a library containing degenerate sequences makes this type of analysis possible. CRISPR/Cas9-based gene editing is quickly growing in popularity in the field of genome editing. Due to the size of most commonly used Cas9-containing plasmids, construction of a sgRNA or sgRNA library into a Cas9/sgRNA expression vector can be cumbersome. This approach solves this problem, using ss DNA oligonucleotides.

In a separate embodiment, any DNA binding domain from Table 2 may be fused to a Bst polymerase, Bst large fragment or mutant thereof (see for example, U.S. Pat. No. 8,993,298 and US 2015/0152396 including all the Bst variants described and claimed therein).

Kits

Also provided by the present disclosure are kits for practicing the subject method as described above. In certain embodiments, a subject kit may contain: i. a 5'-3' exonuclease, ii. an optional a ligase, iii. a strand-displacing polymerase; and iv. a ss DNA binding protein. The components of the kit may be combined in one container, or each component may be in its own container. For example, the components of the kit may be combined in a single reaction tube or in one or more different reaction tubes. Further details of the components of this kit are described above. The kit may also contain other reagents described above and

below that may be employed in the method, e.g., a mismatch repair enzyme such as mutHLS, cel-1 nuclease, T7 endo 1, uvrD, T4 EndoVII, *E. coli* EndoV, a buffer, dNTPs, plasmids into which to insert the synthon and/or competent cells to receive the plasmids, controls etc., depending on how the method is going to be implemented. In some embodiments, the kit does not contain a non-strand displacing polymerase and/or a crowding agent.

In addition to above-mentioned components, the subject 10 kit further includes instructions for using the components of the kit to practice the subject method. The instructions for practicing the subject method are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. 15 As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that 20 includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

Compositions, kits and methods for assembling fragments 30 and forming synthons as described herein result in a product that is a ds fully sealed DNA that can serve as a template for PCR, RCA or a variety of other molecular biology applications including direct transformation or transfection of a competent bacterial or eukaryotic host cell.

In order to further illustrate the present invention, the 35 following specific examples are given with the understanding that they are being offered to illustrate the present invention and should not be construed in any way as limiting its scope.

40 All references cited herein including U.S. Provisional Ser. No. 62/042,527, filed Aug. 27, 2014, 62/189,599, filed Jul. 7, 2015 plus 62/193,168, filed on Jul. 16, 2015, are incorporated by reference.

EXAMPLES

Example 1

Assay to Establish Strand Displacement Properties of a Polymerase

An assay was developed to differentiate between strand-displacing and non-strand displacing polymerases—A 10 μl reaction containing 10 nM FAM-primer/Template/blocking 55 oligonucleotide, 1x THERMOPOL® buffer (New England Biolabs, Ipswich, Mass.) (FIG. 1A) and 0.1 mM dNTP was prepared. FIG. 1B is the control which is the FAM labeled primer absent any polymerase. When a strand displacing DNA polymerase was added to the reaction, and incubated at 50° C. for 30 minutes with 1 μl of sample diluted 10 fold and analyzed by capillary electrophoresis, the FAM primer was extended through the blocking oligonucleotide which was displaced. The results are shown in FIG. 1D-1E. The position of the peak in FIG. 2D for Bst polymerase, an established strand displacing polymerase corresponds to the peak observed for a non-natural polymerase, SPB49F. The small size shift results from a blunt end generated by 60 65

25

Example 2

In this experiment, the 5 different fragments integrated into separate plasmids were used in the following concentrations—50 ng of each PCR (source of “fragments”) and 25 ng of pMiniTi™ vector (NEB # E1202) was the ampicillin containing plasmid. The 5 fragments for assembly were first amplified using PCR. Primers used in the preparation of LacI-lacZ DNA fragments assembly system as follows:

5PLacIZ-pACYC184VF1 (SEQ ID NO: 4) 30
ttggcttgggtgtaaaaatgaATCGTCACGGCAGTTATG

5PLacIZ-pACYC184VR1 (SEQ ID NO: 5)
gggtcatttcggcgaggacTGCATCAACGCATATAGCG 20

Sequence of PCR amplified fragment 2 (SEQ ID NO: 17):
GCGGCCGCCCCactgacgcgttgcgcagaagattgtgcacccgccttacaggcttcgcacgcgcgttcaccatcgacaccaccacgcgtggcaccc
agttgatcgccgcgagatttaatcgccgcacaatttgcgcacggcgcgtgcagggccagactggaggtggcaacgccaatcagcaacgactgtttgcgc
agttgttgtgcacgcgttggaaatgttaattcagctccgcatacgccgttccacttttccgcgtttcgacaaaacgtggctggctggtcaccac
cgggaaacggctcgataagagacacccgcatactctgcgcacatcgataacgttactggttcacattcaccaccctgaattgactcttcggggcgcat
catgcataccgcgaaagggtttgcgcattcgatggtgccggatctgcacgcgtcccttatgcactctgcatttaggaagcagcccaactgttagtt
gaggccgttgagcacccgcgcgcaaggaatggtgcattgcacaggagatggcgcccaacagtccccggccacggggctgccaccataccacgcggaaaca
acgcgtcatggcccaactggcgccggatctccgcattcgatcgatccgcataatggccacccacccatggccggccat

26

-continued

Not-IZ F1
GC GGCC CGCgtccctcgccggaaaatgacccagag

Not-IZ R1
GC GGCC CGCtggtgtcgatggtagaacgaagcg

Not-IZ F2
GC GGCC CGCcccactgacgcgttgcgcgagaag

Not-IZ R2
GC GGCC CGCggctgcgcaactgttggaaaggc

Not-IZ F3
GC GGCC CGCtgcagcacatcccccttcgcccag

Not-IZ R3
GC GGCC CGCcatgatgctcgtgacggttAACGCC

Not-IZ F4
GC GGCC CGCagggtgcggattgaaaatggctgc

Not-IZ R4
GC GGCC CGCtacccgcttgcacggcgttaccca

Not-IZ F5
GC GGCC CGCgaaataccctgttccgtcatagcgat

Not-IZ R5
GC GGCC CGCtacccgatccatggatggatggatgg

The amplified fragments were cloned and sequenced to confirm that no errors during amplification had been introduced.

-continued

gtatcgctccggcgttagaggatcgcgatctcgatcccccgcaaaattaatacgcactcaactataggggaaattgtgagcgccataacaattccccctctagaaaaatttttgtttaacttaagaaggagatatacatatgaccatgattacggattcactggccgtcgtttacaacgtcgtgactggggaaaacctggcgtaacccaaacttaatcgcccttgccgcacatcccccttcgcccagctggcgtaatagcgaaggccgcaccatcgcccttccaaacagtgtgcgcagccGCGCCGC

Sequence of PCR fragment 3 (SEQ ID NO: 18):

Sequence of PCR fragment 4 (SEQ ID NO: 19):

Sequence of the fragment 1 (bp 12-107):
GGGGCCCGagggtcgccgatggaaatggctgtctgtgcacggcaagccgttgctatcgaggcgtaaccgtcacgagcatcatccctctgcattggta
ggtcatggatgagcagacgtggtcaggatatccctgtatgtggatgaagccaaacttacccgtgcgtttcgccattatccgaaccatccgcgttgttgc
caccgtgtgcgaccgtacggctgtatgtggatgaagccaaatattggaaaccacggcatggtgccaatgaatcgctgtgaccgtatccgcgttgttgc
accggcgtatggcgtggatccatctgtcgatcccccgggtgcagtatgaaggcggcggagccgacaccacggccaccgtatatttgc
tcacgacgcgttatcgctggatcaaattctgtcgatcccccgggtgcagtatgaaggcggcggagccgacaccacggccaccgtatatttgc
gatgtacgcgcgtggatgaagaccagccctccggctgtgccgaaatggccataaaaatggcttcgtacctggagagacgcgcgcgtatcc
ttgcgaatacgcgcgtggatcacagtcttggcggttcgtaaatactggcagggttcgtcagtatcccgttacagggcggctcgatgg
ctgggtggatcgtcgatggatccatctgtcgatcccccgggtgcagtatggccatacgcgcgtggatcccgatcccgatcc
gaacggtctggtcttgcgaccgcacgcgcacccgtggcggcttacggcggtgatcccgatcccgatcccgatcc
aqgtaccacgcgatccatctgtccgtcatacgcataacgcgatccacgcgcacccgtggcggcttacggcggtgatcccgatcccgatcccgatcc

Sequence of PCR fragment 5 (SEQ ID NO: 20):

Sequence of the fragment 3 (bp 15-107).
CGGGCCCCGaaatacctgttccgtcatagcgataaacggactcctgcactggatggatggcgctggatggtaagccgctggcaagcggtgaagtgcctctggat
tcgtccacaaggtaaacagttgattgaactgcctgaactaccgcagccggagagcgccggcaactctggctcacagtagcgttagtgcacccgaaacgcga
ccgcatggtcagaagccggcacatcagcgcctggcagcagtggcgctggcgaaaacctcagtgtgacgctcccgcggccccatccccatc
tgaccaccaggaaatggattttgcatcgagctggtaataaggctggcaatttaaccgcagtcaaggctttttcacagatgtggattggcgataaaa
aacaactgtcgacgcgcgtcgcgatcagttcacccgtgcacccgtggataacgcacattggctaagtgaagcgacccgattgaccctaagcgcgg
aacgctggaaggccggccattaccaggccgaagcagcgttgtgcagtgcacggcagatacacttgcgtatgcgggtgtgattacgaccgtcacgcg
ggcagcatcagggaaaaccttatttacgcggaaaacctaccggattgtatggtagtggtaatggcgattaccgttgcgttgcggatggcgagcgata
caccgcattccggcgccgtggctgaactgcgcgtggcgccgtggatggcgatggcgatggcgatggcgatggcgatggcgatggcgatggcgat
ttactgcgcgttttgcgcgtggatgcgcgttgcgcgtggatggcgatggcgatggcgatggcgatggcgatggcgatggcgatggcgatggcgat
tgaattatggcccacaccagtggcgccgcacttccagttcaacatcagccgtacagtcacacagcaactgtatggaaaccagccatcgccatctgc
cggaagaaggcacatggctgaatatgcacggttccatatgggatggcgacgcacttgcgcgtcgtatcggcgaaattccagctgagcgccg
gtcgctaccattaccagttgtctggtgtcaaatatgcacGGGGCCGC

29

The 5 fragments each had an overlapping region of 80 bp with an adjacent fragment in order of the final assembly by design (between fragment 1 and 2, 2 and 3, 3 and 4, 4 and 5). Fragment 1 and 5 also shared 20 bp overlap with the ends of vector. Any available vector may be used such as for example pACYC184 (New England Biolabs, Ipswich, Mass.). pACYC184 vector was prepared by the method of inverse PCR, which permitted assembly of fragments 1-5 in the presence of the assembly mix described above after treatment with NotI-HF® (New England Biolabs, Ipswich, Mass.) and heat-inactivation (see FIG. 2A-2C).

During assembly, the nucleotides extending from the shaded region were degraded by T5 exonuclease while nucleotides in grey were removed by the polymerase. After the fragments are assembled and transformed into *E. coli*, productive assembly determined by blue/white selection were recorded on a plate with IPTG and X-Gal.

T5 exonuclease, Taq ligase, a strand displacing DNA polymerase, and a ss binding domain (ET SSB) were combined in a reaction mixture in a buffer to form Mix 1. These enzymes were all obtained from New England Biolabs, Ipswich, Mass. Five of 150 ng of NotI-HF-digested plasmids (plasmid A, B, C, D and E) were mixed with 105 ng of vector and either with Mix 1 or GAMM in a total volume of 20 µl. The reactions were incubated at 50° C. for 60 minutes. 2 µl of the assembled products were used to transform into NEB 5-alpha (New England Biolabs, Ipswich, Mass.) competent cells. Cells were then spread on plates containing chloramphenicol. Positive assembly can be identified as a blue colony on a plate with chloramphenicol+IPTG+X-Gal and incubated at 37° C. overnight.

PCR of assembly product to confirm all fragments are joined and ligated prior transformation involved the following steps: 1 µl of assembled products were used in a PCR to ensure 5 fragments and vector are ligated together. Pairs of PCR primers that anneal on the vector were used to amplify the whole assembled LacIZ gene (5.3 kb). Lane 1 and 2 are duplicate PCR results. Lane M is 2-log DNA ladder from New England Biolabs, Ipswich, Mass. (see FIG. 4).

Sequencing results were obtained from 8 colonies that were picked and the plasmid DNA purified for the purpose of Sanger sequencing. 6 primers were used to sequence the 4.8 kb. The junction sequence between fragments as well as extension regions from the overlap region showed less than 2% sequence errors.

Primers used for sequencing the assembled DNA:

Seq Not-IZ-M0	(SEQ ID NO: 21)	aaaaccacccctggcgcccaatacgc
Seq Not-IZ-M1	(SEQ ID NO: 22)	cccggaactcggtaatggcgccat
Seq Not-IZ-M2	(SEQ ID NO: 23)	ggaagcagccccagtagttaggttga
Seq Not-IZ-M3	(SEQ ID NO: 24)	ggtgctgcgtggagtgcaggcag
Seq Not-IZ-M4	(SEQ ID NO: 25)	cggccaccgatattttggccga
Seq Not-IZ-M5	(SEQ ID NO: 26)	gattaggggccgcaagaaaactatc

30

Example 3

Assembly of Single Strand Oligonucleotides into a Linearized Vector or Two Distinct Ds DNAs

An oligonucleotide corresponding to sgRNA for targeting a gene from *H. sapiens* was designed as follows:

1. A PAM sequence was scanned for the desired target sequence. For example NGG in

5 'GCGAAGAACCTCTTCCCAAGANGG3' (SEQ ID NO: 27)

2. A 71-base, ss DNA oligonucleotide, containing a 21 nucleotide target sequence flanked by a partial U6 promoter sequence and scaffold RNA sequence was designed.

See for example FIG. 8A-C in which the ss oligonucleotide is defined as

(SEQ ID NO: 28)

5 'ATCTTGAAAGGACGAAACACCGCGAAGAACCTCTTCCAAAGAGT
25 TTTAGAGCTAGAAATAGCAAGTT3'

or FIG. 9A-C where the ss oligonucleotide is designed to create a random library:

(SEQ ID NO: 29)

5 'ATCTTGAAAGGACGAAACACCGN₂₁GTTTAGAGCTAGAAATAGC
AAGTT3'

3. The ss DNA oligonucleotide was prepared in 1×NEBuffer 2 (New England Biolabs, Ipswich, Mass.) to a final concentration of 0.2 µM.

4. A 10 µl reaction mix containing 5 µl of ss DNA oligonucleotide (0.2 µM), 30 ng of restriction enzyme-linearized vector and ddH₂O was formed.

5. A suitable vector for use in the above method is a ds vector from Life Technology (GeneArt®

CRISPR Nuclease Vector with OFP Reporter Kit Catalog number: A21174). Other vectors are provided by Addgene plasmid #42230, pX330-U6-Chimeric_BB-CB-hSpCas9. Alternatively, any plasmid containing an sgRNA scaffold under the control of a U6 promoter can be used.

6. 10 µl of a master mix containing an ss binding protein, a ligase, an exonuclease and a polymerase was added to the reaction mix, and the assembly reaction was incubated for 1 hour at 50° C.

7. NEB 10-beta Competent *E. coli* were transformed with 2 µl of the assembled product and the manufacturer's protocol followed (New England Biolabs).

8. 100 µl of transformed cells were spread on a plate with ampicillin antibiotic, and incubate overnight at 37° C.

9. 10 colonies were picked to grow, and the plasmid DNA was purified for sequencing.

Unlike traditional cloning methods, in which two oligonucleotides must be synthesized and re-annealed, this example offers a simple way to design an oligonucleotide and assemble it with the desired vector and represents a substantial improvement over traditional methods, specifically in time savings, ease-of-use and cost.

SEQ ID NO: 1

MILDADYITEDGKPIIRLFKKENGRPKVEYDRNFRPYIYALLKDDSAIDDVRKITSERHGKVRVIDVEVKKKFLGRPIEVWKLYFEH
 PQDVPAMRDKIREHPAVIDIFEYDIPFAKRYLIDKGLIPMEGNEELTFLAVDIETLYHEGEFGKGPIMISYADEEGAKVITWKKIDL
 PYVEVVANEREMIKRLIKVIREKDPDVIIITYNGDNDFPYLLKRAEKGMLPLGRDNSEPKMQRGDSLAVEIKGRIHFDFPVIRR
 TINLPTYTLEAVYEAFGKQKEKVYPHEIAEAWETGKGLERVAKYSMEDAKVTYELGKEFFPMEAQLARLVGQPLWDVSRSSTGN
 LVEWYLLRKAYERNELAPNKPDEREYERRLRESYEGGYVKEPERGLWEGLVSDFRSLYPSIIITHNVSPDTLNKEGCHEYDEAPEVG
 HRFCKDFFPGFIPSLLGSLLERQKIKKRMKESKDPVERKLLDYRQRAIKILANSFYGGYAKARWYCKECAESVTAWGRQYIELVR
 RELEERGFKVLYIDTDGLYATIPGEKNWEEIKRRALEFVNYYINSKLPGILELEYEGFYTRGFVTKKKYALIDEEGKIVTRGLEIVRRDW
 SEIAKETQAKVLEAILKHGNVEEAVKIVKEVTEKLSNYEIPVEKLVIYEQITRPLNEYKAIGPHVAVAKRLAAKGKIKPGMVIGYVVL
 GDGPISKRAIAIEFDGKHHKYDAEYYIENQVLPAPERILKAFGYKREDLRWQTKQVGLGAWLKVKKS

SEQ ID NO: 2

IINPQARLTPLEILEIIIKQKKSITITEIKEILSERRKSEYPLSLVSEYISRLERKGVKKIAKGRKKFVEALI

SEQ ID NO: 3

MILDADYITEDGKPIIRLFKKENGRPKVEYDRNFRPYIYALLKDDSAIDDVRKITSERHGKVRVIDVEVKKKFLGRPIEVWKLYFEH
 PQDVPAMRDKIREHPAVIDIFEYDIPFAKRYLIDKGLIPMEGNEELTFLAVDIETLYHEGEFGKGPIMISYADEEGAKVITWKKIDL
 PYVEVVANEREMIKRLIKVIREKDPDVIIITYNGDNDFPYLLKRAEKGMLPLGRDNSEPKMQRGDSLAVEIKGRIHFDFPVIRR
 TINLPTYTLEAVYEAFGKQKEKVYPHEIAEAWETGKGLERVAKYSMEDAKVTYELGKEFFPMEAQLARLVGQPLWDVSRSSTGN
 LVEWYLLRKAYERNELAPNKPDEREYERRLRESYEGGYVKEPERGLWEGLVSDFRSLYPSIIITHNVSPDTLNKEGCHEYDEAPEVG
 HRFCKDFFPGFIPSLLGSLLERQKIKKRMKESKDPVERKLLDYRQRAIKILANSFYGGYAKARWYCKECAESVTAWGRQYIELVR
 RELEERGFKVLYIDTDGLYATIPGEKNWEEIKRRALEFVNYYINSKLPGILELEYEGFYTRGFVTKKKYALIDEEGKIVTRGLEIVRRDW
 SEIAKETQAKVLEAILKHGNVEEAVKIVKEVTEKLSNYEIPVEKLVIYEQITRPLNEYKAIGPHVAVAKRLAAKGKIKPGMVIGYVVL
 GDGPISKRAIAIEFDGKHHKYDAEYYIENQVLPAPERILKAFGYKREDLRWQTKQVGLGAWLKVKSGTGGGIINPQARLTPL
 ELEILEIIIKQKKSITITEIKEILSERRKSEYPLSLVSEYISRLERKGVKKIAKGRKKFVEALI

SEQ ID NO: 33

MKEKAPKIDALIDCTYKTEDNRRAVILYLLLENILKREFSPYFYVEMLKDRIEKEDIDKIKEFLLKEDLLKFVENLEVNNKTILKKEIVEVK
 IIATHPQRVPKLKIKECDIVKEIYEHIDIPFAKRYLIDSIVPMTYWDFENRKQVSIEIPKLKTVSFDMEVYNRDTEPDPEKDPLMAS
 FWDDNGGKVITYKHFDSNIEVNSEKDLIKKIVEMRLQYDIFTYNGDNDFPYLKRARIYIGDIKLGRDGEELKIKRGGMFRS
 YIPGRVHIDLIPISRLLLKLTKTLEDVVNLFGIEKLKIPHTKIVDYWANNDKILIEYSLQDAKYTHKIGKYFFPLEVMFSRIVNQTPFE
 ITRMSGQMVEYLLMKNAFKENMIVPNKPDEKEYRKRLLTSYEGGYVKEPEKGMFEDIISMDFRCHPRGTVKIVKNNGLTDIENV
 KVGDYVLGIDGWQKVWRKVPYNGFLVNNGLKSTPNHKIPVIKKENGKDRVIDVSSIYLLNLKGCKILKIKNFESIGMFGKIFKK
 DTKIKKVKGLLEKIAYIDPREGLVIVKVKNEKEDEFKTVIPILKELNLYKQVDEKTIIDSIDGLKYIVTIGFNDKNEEKIKEIKEKSLEFKE
 LEDIKISIEEYEGYVYDLTLEGRPYFANGILTHNSLYPSIIAYNISPETLDCECCKDISEKILGHWFCKKREGLIPKTLRLGLIERRINIKN
 MKKMESEKEINEEYLNLDYEQRSLKILANSVYGYLAFPRARFYSRECAEVITYLGRKYILETIEEAEKFGFKVIYADSVVKDAVIKED
 GKIKEKIEDLFKKVVDYTIGKEYCILNNVETLTIEDTKLWWRKVPYIMRHRTNKKIYRVKVKDRYVDITEDHSIIGVKNNKLVELKPTEI
 KDDETKLIILNKDLKSYNFASVEEINCICKYSDYVYDIEVENTHRFFANGILVHNTDGFYAWKEKISKDDLIKALEFVKYINSKLPGT
 MELEFEGYFKRGIFITKKRYALIDENGRVIVKGLEFVRRDWSNLARITQRRVLEALLLEGDINKAKKAIQDVIKDLREKKIKKEDLIIYT
 QLTNPNEYKTTAPHVEIAKKMMREGKKIKIGDVIGYIIVKGSKSISERAKLPEEVSVIEEIDVNYYIDNQILPPVLRIMEAVGVSKNELK
 KEGTQLTLDRLK

SEQ ID NO: 34

MERVEGLIDADYETIGGKAVVRLWCKDDQGFVAYDYNFDPYFYVIGVDEDILKNAATSTRREVIKLKSFEKAQLKTLGREVEGY
 IVYAHHPQHVPKLRDYLSQLFGDVREADIPFAYRYLIDKDLACMDGIAIEGEKQGGVIRSYKIEKVERIPRME
 FPELKMLVFDCMELSSFGMPEPEKDPIIVISVKTNDDEIILTGDERKIISDFVLIKSYDPDIIVGYNQDAFDWVYLRKRAERWNIP
 DVGRDGSNVVFRGGRPKITGRLNVDLYDIAMRISDIKIKKLENVAEFLGKIEIADIEAKDIYRWSRGEKEKVLNYARQDAINTYLI

-continued

AKELLPMHYELSKMIRLPVDDVTRMGRGKQVDWLLSEAKKIGEIAPNPPEHAESYEGAFVLEPERGLHENVACLDFASMYPSIM
 IAFNISPDTYGRDCCYEAPEVGHKPRKSPDGFFKRILRMLIEKRRELKVELKNLSPESSEYKLLDIQQTALKVLTNFSYGYGMWNLA
 RWYCHPCAETTAWGRHFIRTSKIAESMGFKVLGYDTSIFVTAGMTKEDVDRLLIDKLHEELPIQIEDEYYSAIFFVEKKRYAG
 LTEDGRLVVKGLEVRRGDWCELAKKVQREVIEWEVILKEKNPEKALSLVKDVILRIKEGKVSLEEVVIYKGLTKPKSKYESMQAHVKAAL
 KAREMGIYPVSSKIGYVIVKGSGNIGDRAYPIDLIEDFDGENLRIKTSGIEIKLKDYYIDNQIIPSVRLILERFGYTEASLGSSQM
 SLDSFFS

SEQ ID NO: 35

MIKAWLLDVDYVTENDRAVIRLWCKDDKGVFVAYDRNFLPYFYVIGCKAEDVMVKVVRTNEGIITPLKVEEIAKSLGKPIKALKV
 YTRHPHQVPLKREEIKKFAEVRADIPFAYRYLIDKDLACMDGIEIEPIAVKEGLRAYEVRSVRVKEKGFPDLKILAFDCMLEAQF
 MPDPEKDPPIIAIAVKGDFEEVLHGDERDILRRFVSIIKEQDPDIIVGYNQDNFDWPVVKRAEKFGIRLDIGRDRSEISFRGGRPKI
 AGRLNVLDLYDIALKIPDVKIKTLKKVAEFLGAKVEEEDIEGRDIYKCWMRGEKEVKFHVLNDVLTTYRLALELLPMHYELSRMIRLP
 LDDVARLGRGKQVDYPLLSEAKKINEIAPNPEIEESYEGAFVLEPARGLHENVACLDFASMYPSIMINFNISPDTLVGECEDCYV
 APEVGHKFRKSPDGFFKRILKMLIEKRREMKRQMKELDPSEDYKLLDIQQTALKVLTNFSYGYGTGWNLARWYCRECAETTAW
 GRYFIKRAVKIAESMGFEVLYGTDLSFIKKNKLNLKDLKECLKLIDVISKELEPIQLEIDEFYKAIFFVEKKRYAGLTDDDRIVVKLEV
 RRGDWCELAKRVQREVIEWIIILRERNPDALKFKVNIEEIKEGKFKLEDYVYKGLTKPDKYYESQAHVKAALRAMEMGIYYPGTK
 VGFIVVKGGGSISDRAYPIELIEEPDGENLKIRTPSGIMVKIDKDYYIDHQIIPAVMRILERFGYTEASLKTTIQKTLFDFT

SEQ ID NO: 36

MKLVIFDGNSILYRAFFALPELTSSNIPTNAIYGFINVILKYLEQEKPDIYIAVAFDKRGREARKSEYQEYKANRKPMEDNLQVQIPY
 VREILYALNIPIVEFEGYEADDVIGSLVNKPNTGLDIVIITGDRDTLQLLDKNVVVKIVSTKFDRTMEDLYTIENIKEKYGVWANQVP
 DYKALVGQSDNIPGVKGIGEKAQKLLEEYSLEEYQNLDKIKGSIREKLEAGKDMAFLSKRLATIVCDLPLNVNLEDLRTKEWNK
 ERLYEILVQLEFKSIIKRLGLSENIQFEFVQORTDIPDVEQRELESISRIRSKEIPLMFVQDEKCFYLYDQESNTVFTDRHLVEEILKS
 DTVKIVYDLKNIFHQLNLEDTDNIKNCEDMIASYVLDSTRSSYELETFLFVSYLNLDIEAVKKDKKMVSVLLKRLWDDLRLIDLNS
 CQFLYENIERPLIPVLYEMEKTGFVDRDALLQYTKEIENKILKLETQIYQIAGEWFNINSPKQLSYILPEKLKLPVIKKTKTGYSTDAEV
 LEEDFDKHEIVPLILDYRMYTKILTTYCQGLLQAINPSSGRVHTTFIQTGTATGRLASSDPNLQNIPVKYDEGKLIRKVFVPEEGHVLID
 ADYSQIELRLAHISEDERLINAKNNIDIHQSAAEVFGVDIADVTPEMRSQAKAVNFGIVYGISDYGLARDIKISRKEAAEFINKYFE
 RYPKVKEYLDNIVRFARENGYVLTFLNRKRYVKDIKSANRNARYAERIAMNSPIQGSAADIMKLAMIKVYQKLKENNLKSKIILOV
 HDELLIEAPYEEKDIVKRIVKREMENAVALKVLVVEVKEGLNWYETK

SEQ ID NO: 37

MEKRVYLVDITYGLVGNSSPEIRMGVDENGEKVVILDGRFRPFYVIPEEGFEDQVARVIGKMQNVIKADVTERRLFGKPIKVVKV
 TVTVPDVKRELDRVKSIQHVKEVLEDIRFYIRYMDNDIRPGWLMFSNLKPVDNKIGGVSNVLTETPPTSLDLGIMPRLNMYMA
 LDIEVYNPRGTPDKRDPIIIALANSNGDVKLLTLDNYKHEREMLNDMMMSVIKEWDPDVLFYGNNSNKFDMPYLVNRADALNVKL
 QLSKYGTPPEQSVYGHWSIIGRAHIDLYNFIEDMDTDVKRKSLDYVAEYFGVMKRSERVNIPGHRIYQYWDDEGKRSQLIKYARDD
 VLSTLGLGKILLPYAMQLASVGLPLDQVGPASVGSRVEMMHEAYKGELAPNRVERPYETYKGAIVLEPKPGIHYNIAVLDPS
 SMYPNIMLKYNISPDTLVLDSSEGYYTAEVGYRFRKSPRGLYASLLQKLIEARREARDEMNRYPEGSPEWVLLNERQRALKIMA
 NAMYGYCGWLGARWYIREVAESVTAWGRYLLKTAMSMAKERGLTVIYGDTSFLVTDKDVADIISRINEMGFEVKIDKVKYSK
 LIFTESKKRYIGLTADGEVDIVGFEAVRGDWSELARNVQERVAELVLRSEVDEAVKYVKSVIIDLNRNRFITIDDVIIWKTLKDINEY
 KAIQPHVVAARRLMEKGYVNVNGDTVGFVIVKDSGDKLTQRAYPYVFINDVKEIDVDYYVEKQVIPAALRILEVPGVNEAALLGKT
 GKSILDYFH

SEQ ID NO: 38

MTEVVFTVLDSSYEVVGKEPQVIIWGIAENGERVVLIDRSFRPFYALLAPGADPKQVAQRIRALSRPKSPIIGVEDDKRKYFGRPR
 RVLIRTVLPEAVREYRELVKNDGVEDVLEDIRFAMRYLIDHDLFPFTWYRVEAEPLENKMGRVDKVYLVKSRPEPLYGEALA
 PTKLPDLRILAFDIEVYSKQGSPRPERDPVIVIAVKTDDGDEVLFIAEGKDDRKPIREFVEYVKRYDPDIIVGYNHHFDWPYLLRRA
 RILGIKLDRVGAEPPTSVDHGHSVPGRNLVDLYDYEEMPEIKIKSLEEVABYLGVMKKSERVIINWWIIPDYWDDPKKRPLLL

-continued

QYARDDVRATYGLAEKILPFAIQLSVTGLPLDQVGAMSVGFRLEWYLRAAFMKELVPNVERPEETYRGAIYLEPLRGVHENI
 AVLDFFSSMYPNIMIKYNVGPDTLVRPGEECGECGCGWEAPEVKHRFRCPPGFKTVLERLLELRKRVRAEMKKYPPDSPEYRLLDE
 RQKALKVLANASYGYMGWSGARWCRCRECAEAVTAWGRHLIRTAINIARKLGLKVIYGTDSDLFVTDPEKVEKFIIIEELGFEIK
 LEKVYKRVFFFTEAKKRYAGLLEDGRIDIVGFEAVRGDWCELAKEVQTKVVEIVLKTSVDVNKADEVRKIVKELEEGKVPIEKLVIWKT
 LSKRLEEEYTTEAPHVVAAKRMLSAGYRVS PGDKIGYVIVKGGRISQRAWPYFMVKDPSQIDVTYYVDHQIIPAA RLGYFGITEK
 KLKASATGQKTLFDLAKKS

SEQ ID NO: 39

MEIRVWPLDVTYIVVGGVPEVRVFGIAEGGERVVLADRSFRPYFYVDCAGCDPHAVKTHLGR TAPVEGVELVERRFLGRPRQFLK
 VVAKI PEDVRLREAAS TIPGVRGVYEADIRFYMRVIDMGVVPCSNVAEVEADEKLGS LPVYRVVKWGGAVEGFPPPLRVL
 APDIEVYNERGTPDPARDPIVMIAVQSSDGRLEVFEASGRDRGVLRSFVEYVRSFPDVVVGYNNSNNFDWPYLAERAKAVGP
 LRVDRLLGGAPQOSVYGHWSVLGRANVDLYNIVDEFPEIKLKTLDRAEYFGMRRDERVLIPGHKIYEYWRDPSKRPLLQYVID
 DVRSTYGLAERLLPFLIQLSSVGLPLDQVAASVGNRVEWMLRYAYGLGEVAPNREEREYE PYKGAI VLEPKPGLYS DVLVLD
 SMYPNVMMRYNLSPDTYLEPGE PDPPEGVYVAPEVGHFRKEPPGFIPQVRLVALRRAVREEMKKYQPDPEYRVLDERQKA
 LKIMANAMYGYTGWVGARWYKKEVAESVTAPARAILKDVIDYARRLGIVVIYGTDDSL FVKGGDLEKLARYVDEKYGIEIKVDKD
 YEKVLFT EAKKRYAGLRLDGRIDIVGFEVVRGDWSELAKEVQLKIELI LKARDLSEARQRV IYKVVDVIERLKSGKFDLDDLIWKT
 DKDLGEYKAYPPHVRAALILKKGYKVGRGTTIGYVVVKGGEKVSERSLPYILVDDLAKIDVDYYIEKQVIPAALRIAEVIGVKEGDLR
 AGRSEKSLLDFE

SEQ ID NO: 40

MSEKINLEFYPLD NSYEVIGNEPHIIIWGITRDGRVLLRDRFRPYFYAILKDKVNIEDLARKIRTYSDPKSPIIGVEPVEKKYFGRKVS
 ALKIITMIPEYVRKYREKIKSLPEVLEVVEADIRFSIRYIIDHDLRPCGHVAEVVEVPKKPIYRVDAEYEIIGDIKP LEQTLQPD LRIIAF
 DIEVYNKSGTPRPQTDP IIIIGIMNNNGDIKOFLANKYDDKISVEEFVN VTFDPDIIVGYNTDGF DWPYL IERSKYIGVKLDVTRR
 VGATPRTSTYGHISVPGRN TDLYHFAEEIPEVKVKSLENVAEYLGMKKSERVIIEYIDIPKYWD EKL RP KLLQYNNIDDVKSTYGL
 AEKFLPFAMQLSNTI GPLDQVGAASVGFRLEWYLM REAF RY GELV PN RVERA A ESYRGA VVLPVKGVHENIAVLD FSSMYPNI
 MIKYNVGPDTIVRNEKCNPDKHNIAPEVGHCFRK EPPGFFKRVLETLLRLRKQIKSEMKYPP TSYEYRLLDERQKAVKVL ANATY
 GYMGWIHARWCRC EAEAVTAWGRQTKISAI ELARKLGLKVIYGTDSSLFVTDKVEK LIEI QT KLG FEIKIDK IYK RVFFF TEAK
 KRYAGLLEDGRIDIVGFEAVRGDWAEIAKEVQE KVTEILLKENSIDKAI EYV RQVIADLKAGK I PLDKL II WKTLSKRIEEY SVDAPHV
 VAAKKLIKAGIKVSTNDKIGYVILKG GGKISSRAEPIFVKDPKLIDTEYYVDHQI VPAA RLIRL NYFGVTE TQLKRAA ASAGQKSLFDFF
 GGKK

SEQ ID NO: 41

MILDADYITENGKPVVRIFKKENGEFKVEYDRSFRPYIYALLRDDS AIEDIKKITAERHGKVVRVVEAEKVRKKFLGRPIEWKLYFEH
 PQDVPairekirehpa vidifeydipfa krylidkg lpmegneelkllafdi etlyhegdefgsgp iimisyadekgakvitwkgvdlp
 YVEVVS SEREMIKRFLRVIREKDPDVITYNGDNFDPYLLKRAEKGKLMKLPGRDGSEPKMQRMDGFAEVKGRIHF DIYVPIR
 TINLPTYTLEAVYEAVFGRPKEKVYPNEIARAWENCKGLERVAKYSMEDAKV TYELGREFFPMEAQLARLVGQPVWDVSRSS TG
 NLV EWFLLRKAYERNELAPNRD EREYERRLRES YEGGYVKEPEKGLWEGI IYLDFRSLYPSIIITHNISPDTLNKEGCNSYDVAPKV
 GHRFC KDFPGFIPSLLGQ LLDERQKIKRKM KATIDPIERKLLDYRQRAIKILANSYYGGYAKARWYCKECAESVTAWGREYIELVS
 RELEKRGFKVLYIDTDGLYATIPGSREWDKIKERALEFVKYINARLPGLLELEYEGFYKRGFVTKKKYALIDEEGKII TRGLEIVRRDW
 SEIAKETQARVLEA ILKEGNLEKAVKIVKEVTEKLSKYEVPPPEKLVIEQITRDLKDYKAVGPHVAVAKRLAARGIKVRPGMVIGYLV
 RGDPGPISRRAI PAEEFDP SRHKYDAEYYIENQVLP AVL RILEA FG YRKE DLY QKTRQAGLDAWLKRKASL

SEQ ID NO: 42

MILDADYITENGKPVIRFKKENGEFKIEYDRTFEPYFYALLKDDSAIEDVKVTA KR HGT VVRV KRAEKVQRKFLGRPIEWKLYFT
 HPQDVPairekirehpa vidiyeydipfa krylidkg lpmegdeel tmlaf di etlyhegdefgsgp ilmis yadgsearv itwkkid
 LPYDVVSTEKEMIKRFLRIVKEKDPVLI TYNGDNFD FAYLKKRCE LGIKFTLGRDGSEPKIQR MGDRFAEVKGRIHF DLYP VIR

- continued

RTINLPTYTLEAVYEAVFGPKEKVYAAEIAQAWESGEGLERVARYSMEDAKVTYELGREFFPMEAQLSRLIGQSLWDVSRSTGN
 LVEWFLLRKAYERNELAPNKPDEKELEARRGGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSPDTLNREGCKEYDVPEV
 GHFKCKDFPGFIPSLLGDLLEERQKIKRKMATVDPLEKKLLDYRQRAIKILANSYYGGYGYARWYCRECAESVTAWGREYIETTI
 REIEEKFGFKVLYADTDGFATIPGADAETVKKAKEFLKYINAKLPGLLELEYEGFYVRGFFVTKKYAVIDEEGKITTRGLEIVRRD
 WSEIAKETQARVLEAILKHGDVEEAVRIVKEVTEKLSKYEVPPKEKLVIHEQITRDLRDYKATGPHVAVAKRLAARGVKIRPGTVISYIV
 LKGSGRIGDRAIPFDEFDPDKHYDAEYYIENQVLPAPERILKAFCYRKEDLRYQKTKQVGLGAWLKVKK

SEQ ID NO: 43

MILDTDYITEDGKPVIRIFKKENGEFKIEYDREFEPYIYALLKDDSAIEEVKKITAGRHGRVVVKVRAEKVKKFLGRPievwklyfthp
 QDVPPAIRDEIRRHSAVVDIYEYDIPFAKRYLIDKGLIPMEGDEELKMMFDIETLYHEGEFGTGPILMISYADEGEARVITWKKIDL
 PYVEVSVSTEKEMIKRFLKVVKEKDPDVILITYNGDNPDFAYLKKCEKIGIKFTLRRDGSEPKIQRMGDRFAVEVKGRIHFPLYPVIRR
 TINLPTYTLEAVYEAVFGTPKEKVYYPEEITTAWETGEGLERVARYSMEDAKVTYELGREFFPMEAQLSRLIGQSLWDVSRSTGNL
 VEWFLLRKAYERNEIAPNKPDERELARRGGYAGGYVKEPERGLWDNIVYLDFMSLYPSIIITHNVSPDTFNREGCKEYDTAPQVG
 HKFCKDVQGFIPSLLGALLDERQKIKRKMASIDPLEKKLLDYRQKAIKILANSYYGGYGYARWYCRECAESVTAWGRDYIETTI
 HEIEERFGFKVLYADTDGFATIPGADAETVKKAKEFLKYINAKLPGLLELEYEGFYVRGFFVTKKYAVIDEEGKITTRGLEIVRRD
 WSEIAKETQARVLEAILRHGDVEEAVRIVKDVTTEKLSKYEVPPKEKLVIHEQITRELKDYKATGPHVIAKRLAARGIKIRPGTVISYIVL
 KGSGRIGDRAIPFDEFDPDKHYDAEYYIENQVLPAPERILKAFCYKKEELRYQKTRQVGLGAWLKLGK

SEQ ID NO: 44

MILDADYITEDGKPVVRIFKKENGEFKIEYDREFEPYIYALLRDDSIAEEIKKITADRHKVVVKVRAEKVQKKFLGRPievwklyfth
 PQDVPPAIRDEIRKHPAVVDIYEYDIPFAKRYLIDKGLIPMEGDEELKMLAFDIETLYHEGEFGTGPILMISYADEEDGARVITWKKIDL
 PYVDVSVSTEKEMIKRFLKVVKEKDPDVILITYNGDNPDFAYLKKCEKLGKFTLGRDGSEPKIQRMGDRFAVEVKGRIHFPLYPPLIR
 RTINLPTYTLEAVYEAVFGPKEKVYAAEIALAWESGEGLERVARYSMEDAKVTFELGREFFPMEAQLSRLIGQSLWDVSRSTGN
 LVEWFLLRKAYERNELAPNKPNERELARRGGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSPDTLNREGCKEYDRAPQV
 GHFKCKDVPGFIPSLLGSSLDERQKIKRKMATIDPIEKLLDYRQRAIKILANSYYGGYGYARWYCRECAESVTAWGREYIEMA
 RELEEKFGFKVLYADTDGLHATIPGADAETVKKAMEFLKYINPKLPGLLELEYEGFYARGFFVTKKYAVIDEEGKITTRGLEIVRRD
 WSEIAKETQARVLEAILRHGDVEEAVRIVKEVTEKLSKYEVPPKEKLVIHEQITRELKDYRATGPHVIAKRLAKRGIKIRPGTVISYIVL
 KGSGRIGDRAIPFDEFDPDKHYDAEYYIENQVLPAPERVLKAFCYRKDDLRYQKTRQVGLGAWLKVKR

SEQ ID NO: 45

MILDADYITEDGKPVIRVFKEKGEFKINYDRDFEPYIYALLKDDSAIEDIKKITAERHGTTRVTRAERVKKFLGRPievwklyfth
 PQDVPAIRDKIREHPAVVDIYEYDIPFAKRYLIDKGLIPMBGNEELRMLAFDIETLYHEGEFGEGPILMISYADEEGARVITWKNID
 LPYVESVSTEKEMIKRFLKVIQEKKDPDVILITYNGDNPDFAYLKKRSETLGVKFILGRDGSEPKIQRMGDRFAVEVKGRIHFPLYPVIR
 RTINLPTYTLETVYEAIFGQPKEKVYAAEIAQAWESGEGLERVARYSMEDAKATYELGKEFFPMEAQLSRLVGQSLWDVSRSTGN
 LVEWFLLRKAYERNELAPNKPDERELARRAESYAGGYVKEPEKGLWENIVYLDYKSLYPSIIITHNVSPDTLNREGCREYDVAPQVG
 HRFCKDFPGFIPSLLGDLLEERQVKKKMKATVDPIERKLLDYRQRAIKILANSYYGGYGYANARWYCRECAESVTAWGRQYIETT
 MREIEEKFGFKVLYADTDGFATIPGADAETVKKKTKEFLNYINPRLPGGLLELEYEGFYRRGFFVTKKYAVIDEEDKITTRGLEIVRR
 DWSEIAKETQARVLEAILKHGDVEEAVRIVKEVTEKLSRYEVPPKEKLVIYEQITRNLRDYRATGPHVAVAKRLAARGIKIRPGTVISYI
 VLKGPGRVGDRAIPFDEFDPAKHYDAEYYIENQVLPAPERVLKAFCYRKDDLRYQKTRQVGLGAWLKPKT

SEQ ID NO: 46

MILGADYITKDGKPIVRIFKKENGEFKIELDPHFQPYIYALLSEDSAIDEIKQIKGERHGKTVRIVDAVKVEKKFLKKPVVKWLILEHP
 QDVPAIRNKIREHPAVQDIDIYEYDIPFAKRYLIDNGLIPMEGDEELKMLAFDIETFYHEGDEFGKGEIIMISYADEEGARVITWKNIDL
 PYVDVVSNEREMIKRPIQIIKEKDPDVITYNGDNFDLPLYLIKRAEKLGLRLILSRDNENPVPKIQRMGNSFAVEIKGRIHFPLFPVVK
 RAVNLPTYTLEAVYETVLGKHKSCLGAEEIAAIWETEEGLKLAQYSMEDAKATYELGREFFPMEEVALKLIGQSVWDVSRSTGN
 LVEWYMLRVAYERNELAPNRPSDEBYKRRRLRTTYLGGYVKEPERGLWENIITYLDFRSLYPSIIVTHNVSPDTLERKGQCQNYDVAPIV
 GYKFCKDFSGFIPSILEDLIETRQKIKKEMKSTIDPIKKMLDYRQRAVKLLANSYYGYGMGPKARWYSKECAESVTAWGRHYIEMT

-continued

I~~R~~EIEEKFGFKVLYADTDGFYATIPGADPETIKKKAKEFLNYINSKPGLELEYEGFYLRGFFVTKKRYAVIDEEEKITTRGLEVVRRD
WSEIAKETQARVLEAILREGSVEKAIVEIVKEVVEA~~I~~T~~K~~YKVPLEKLI~~I~~H~~E~~QITREL~~R~~DYKAVGPHVAIAKRLAAKG~~I~~K~~I~~KPG~~T~~IISYIVLRG
SGKISDRV~~V~~LLTEYDPRKH~~K~~YDPDYYIENQVLP~~A~~VL~~R~~ILEAFGYRKEDL~~K~~YQSSKQTGLESWLKK

SEQ ID NO: 47

MILDADYITEDGKPIIRIFKKENGEPKVEYDRNFRPYIYALLKDDSQIDEVKKITAERHGKIVRIVDVEVKKKFLGRPIEVWKLYFEHP
QDVP~~A~~IRD~~K~~I~~R~~H~~P~~AVVD~~I~~F~~E~~YD~~I~~PF~~A~~K~~R~~YL~~I~~D~~K~~GL~~I~~P~~M~~EG~~D~~EE~~L~~K~~L~~A~~F~~D~~I~~ET~~L~~YHEGE~~E~~FA~~G~~K~~P~~IIM~~I~~SYADEEGAKVITWKKV~~D~~LPY
VEVVSS~~E~~REMIKRFLKVIREKD~~P~~D~~V~~IITYNGDSF~~D~~LPYLV~~K~~RAE~~K~~LG~~I~~K~~L~~PLGRDG~~S~~EP~~K~~QM~~R~~LD~~M~~TA~~V~~E~~I~~K~~G~~RIHF~~D~~LYH~~V~~IRRTI
NLPT~~T~~LEAVYEAI~~F~~G~~K~~P~~K~~KE~~V~~YA~~H~~EIAEAWET~~G~~~~K~~GL~~E~~V~~A~~K~~S~~ME~~D~~AK~~V~~TYELG~~R~~EFFP~~M~~EA~~Q~~LSRLVG~~Q~~PLWD~~V~~S~~R~~STGN~~L~~V
EWYLLR~~K~~AYERNELAPNKPD~~E~~REYERRL~~R~~ESYAGGYV~~K~~PE~~K~~GL~~W~~EG~~L~~V~~S~~LD~~F~~RS~~L~~Y~~P~~SII~~I~~THNVSPDTLN~~R~~EGCM~~E~~YDV~~A~~PEVK
HKFCKDFPGFIPSLLKRL~~L~~DERQEI~~K~~RM~~K~~AS~~K~~D~~P~~I~~E~~KKMLDYRQRAIKILANSYYGGYAKARWYCKECAESVTAWGREYIEFVR
KELEEKFGFKVLYIDTDGLYATIPGAK~~P~~EEIKRKA~~L~~E~~F~~VEYINAKL~~P~~GL~~L~~E~~L~~YEGFYV~~R~~GF~~V~~TKKKYALIDEEGKII~~T~~R~~G~~LEIVRRDWS
EIAKETQAKVLEAILKHGN~~V~~EEAVKIV~~K~~EV~~T~~KE~~L~~SK~~Y~~E~~I~~P~~P~~KE~~L~~VIYEQITRPL~~H~~HEYKAI~~G~~PH~~V~~AV~~A~~KRLAARGV~~K~~V~~R~~PGM~~V~~IGYIVLR
GDGPISKRAILAE~~E~~FD~~P~~RKH~~K~~YDA~~Y~~YIENQVLP~~A~~VL~~R~~ILEAFGYRKEDL~~R~~WQTKQTGLTAWLN~~V~~KKK

SEQ ID NO: 48

MILDADYITEDGKPIIRLFKKENGRPKVEYDRNFRPYIYALLKDDSAIDDVRKITSERHGKVV~~R~~VID~~V~~E~~K~~V~~KK~~FLGRPIEVWKLYFEH
PQDVPAMRD~~K~~I~~R~~H~~P~~AVD~~I~~F~~E~~YD~~I~~PF~~A~~K~~R~~YL~~I~~D~~K~~GL~~I~~P~~M~~EG~~N~~EEL~~T~~FLAVD~~I~~ET~~L~~YHEGE~~E~~FG~~K~~G~~P~~IIM~~I~~SYADEEGAKVITWKKIDL
PYVEV~~V~~ANEREMIKR~~L~~IKVIREKD~~P~~D~~V~~IITYNGDNFD~~P~~Y~~L~~L~~K~~RAE~~K~~LG~~M~~KL~~L~~GRDN~~S~~EP~~K~~QM~~R~~LG~~D~~S~~A~~VE~~I~~K~~G~~RIHF~~D~~LP~~V~~IRR
TINLPT~~T~~LEAVYEAI~~F~~G~~K~~Q~~E~~KV~~P~~H~~E~~IAEAWET~~G~~~~K~~GL~~E~~V~~A~~K~~S~~ME~~D~~AK~~V~~TYELG~~R~~EFFP~~M~~EA~~Q~~LSRLVG~~Q~~PLWD~~V~~S~~R~~STGN
LVEWYLLR~~K~~AYERNELAPNKPD~~E~~REYERRL~~R~~ESYEGGYV~~K~~PERGL~~W~~EG~~I~~V~~S~~LD~~F~~RS~~L~~Y~~P~~SII~~I~~THNVSPDTLN~~K~~EGC~~G~~GEYDEAPEVG
HR~~F~~CKDFPGFIPSLLGSLLEERQ~~K~~IK~~R~~M~~K~~ES~~K~~D~~P~~VER~~K~~LLDYRQRAIKILANSFYGGYAKARWYCKECAESVTAWGRQYIELVR
RELEERGF~~K~~VLYIDTDGLYATIPG~~E~~KN~~W~~E~~I~~K~~R~~RA~~E~~F~~V~~NYIN~~S~~KL~~P~~G~~I~~LE~~L~~YEGFY~~T~~R~~G~~F~~V~~TKKKYALIDEEGKIV~~T~~R~~G~~LEIVRRD~~W~~
SEIAKETQAKVLEAILKHGN~~V~~EEAVKIV~~K~~EV~~T~~KE~~L~~SK~~Y~~E~~I~~P~~P~~KE~~L~~VIYEQITRPL~~N~~EYKA~~G~~PH~~V~~AV~~A~~KRLAAG~~K~~IK~~P~~GM~~V~~IGYIV~~V~~LR
GDGPISKRAIAIE~~E~~FD~~G~~KKH~~K~~YDA~~Y~~YIENQVLP~~A~~VER~~I~~L~~K~~AF~~G~~Y~~K~~RED~~L~~R~~W~~Q~~T~~K~~Q~~V~~G~~LA~~W~~L~~K~~V~~K~~KS

SEQ ID NO: 49

MEGWLLADYITAEDGRAV~~V~~R~~L~~W~~C~~KDFDGNTFVVYDRNFQPYFYAF~~K~~NG~~L~~S~~K~~EDI~~E~~K~~I~~V~~V~~K~~S~~REG~~V~~I~~K~~PF~~K~~V~~E~~V~~R~~R~~K~~V~~F~~GE~~V~~E
VF~~K~~IYAYHPQH~~V~~PKL~~R~~EEL~~K~~KITEV~~R~~READ~~I~~PF~~A~~Y~~R~~YL~~I~~D~~K~~LACMDG~~I~~R~~V~~EG~~K~~V~~R~~ER~~G~~L~~K~~V~~I~~DAE~~H~~VER~~F~~E~~I~~PL~~P~~EP~~K~~V~~L~~A~~F~~DC~~E~~ML~~T~~
ELGMPDPEKD~~K~~III~~I~~GV~~K~~CG~~D~~FE~~E~~I~~I~~T~~G~~NERE~~I~~LL~~R~~F~~V~~E~~I~~IKEQDP~~D~~V~~I~~V~~G~~YNQDN~~F~~D~~W~~P~~Y~~IR~~K~~RAE~~K~~LS~~V~~KL~~N~~I~~G~~RD~~G~~SE~~I~~S~~F~~RG~~G~~RP~~K~~
IA~~G~~RL~~N~~V~~D~~LY~~I~~AM~~K~~LD~~V~~K~~V~~KT~~L~~EN~~V~~AE~~F~~LG~~R~~K~~V~~E~~L~~AD~~I~~E~~A~~K~~I~~Y~~K~~R~~W~~T~~S~~GD~~K~~E~~S~~VL~~K~~Y~~S~~Q~~D~~V~~L~~NT~~Y~~FA~~E~~ELL~~P~~M~~H~~Y~~E~~LS~~R~~M~~I~~R~~I~~P~~R~~
TDDVARIGRGKQVDW~~F~~LL~~S~~SEAYKIGEIA~~P~~NE~~E~~SYEGAF~~V~~LE~~P~~S~~R~~GL~~H~~KN~~V~~CL~~F~~AS~~M~~Y~~S~~IM~~I~~AY~~N~~IS~~P~~D~~T~~Y~~V~~FG~~K~~CC~~D~~CY
VAPEVGH~~K~~FR~~K~~H~~P~~DF~~G~~FK~~R~~K~~I~~L~~K~~M~~L~~I~~E~~K~~R~~RE~~I~~K~~N~~QM~~K~~SL~~R~~N~~S~~RE~~Y~~LL~~N~~IK~~Q~~Q~~T~~L~~K~~IL~~T~~NS~~F~~Y~~G~~Y~~T~~WG~~S~~AR~~Y~~CR~~Q~~CA~~E~~ATT~~A~~W
GR~~H~~LI~~K~~SAVEIA~~K~~KL~~G~~FEV~~L~~Y~~G~~D~~T~~DS~~I~~F~~V~~K~~K~~GN~~L~~S~~L~~E~~K~~IR~~G~~E~~V~~E~~K~~L~~I~~E~~I~~SE~~K~~FP~~V~~Q~~I~~E~~V~~DE~~Y~~Y~~K~~TIFF~~V~~E~~K~~RY~~A~~G~~L~~T~~E~~D~~G~~I~~L~~V~~V~~K~~G~~LE~~V~~
RGDWCELAKEVQKKVIEIILKEENPEKAAYVRKVINDIKSG~~K~~V~~K~~LED~~V~~VIY~~K~~GL~~T~~K~~R~~PD~~K~~YES~~K~~QAHV~~K~~AA~~L~~R~~A~~ME~~L~~G~~I~~V~~Y~~N~~V~~GS~~K~~
VGFVVVEGAGNVGDRAYPIDLIEEF~~D~~GEN~~L~~V~~I~~R~~T~~SG~~S~~I~~V~~K~~L~~D~~K~~D~~Y~~Y~~I~~H~~Q~~I~~I~~PS~~V~~LR~~I~~LER~~F~~GY~~N~~E~~A~~SL~~K~~G~~A~~T~~Q~~T~~L~~DA~~F~~W

SEQ ID NO: 50

MILDADYITEDGKPV~~V~~R~~I~~F~~K~~KENGE~~P~~KVEYDRN~~F~~EP~~I~~Y~~I~~Y~~A~~L~~L~~K~~D~~DS~~A~~I~~E~~E~~I~~KK~~I~~TAERHG~~K~~V~~V~~R~~I~~T~~K~~AE~~K~~VER~~K~~PL~~G~~RP~~V~~E~~V~~W~~K~~LY~~F~~TH
PQDVP~~A~~IRD~~K~~I~~R~~H~~P~~AV~~V~~DI~~Y~~EP~~I~~PF~~A~~K~~R~~YL~~I~~D~~K~~GL~~I~~P~~M~~EG~~D~~EE~~L~~K~~L~~A~~F~~D~~I~~ET~~L~~YHEGE~~E~~FA~~G~~P~~I~~L~~M~~Y~~S~~AD~~E~~SE~~A~~R~~V~~I~~T~~W~~K~~V~~D~~
LPY~~V~~DA~~V~~ST~~E~~K~~M~~I~~K~~A~~F~~LR~~V~~V~~K~~E~~K~~D~~P~~V~~L~~I~~T~~Y~~N~~G~~D~~N~~F~~F~~A~~Y~~L~~KK~~R~~C~~E~~KL~~G~~V~~K~~F~~I~~L~~G~~R~~D~~G~~S~~EP~~K~~I~~Q~~R~~M~~G~~R~~F~~A~~V~~D~~V~~K~~G~~R~~I~~H~~F~~D~~LY~~P~~V~~I~~
R~~T~~INLPT~~T~~LEAVYEAI~~F~~GR~~P~~KE~~V~~Y~~A~~E~~E~~I~~A~~Q~~A~~W~~E~~L~~N~~E~~G~~L~~R~~V~~A~~Y~~R~~ARS~~M~~ED~~A~~K~~V~~TYELG~~K~~EF~~F~~FP~~M~~EA~~Q~~LS~~R~~LI~~G~~Q~~Q~~PLWD~~V~~S~~R~~ST~~G~~
NL~~V~~EWF~~L~~LR~~K~~AYERNELAPNKPS~~G~~RE~~Y~~DR~~R~~GGYAGGYV~~K~~KE~~P~~KL~~W~~EN~~I~~Y~~L~~D~~Y~~K~~S~~LY~~P~~SII~~I~~THNVSPDTLN~~R~~EGC~~K~~Y~~D~~V~~A~~P~~O~~
VGHR~~F~~CKDFPGFIPSLLGDL~~L~~ERQ~~K~~IK~~R~~MK~~A~~T~~I~~PI~~R~~LLDYRQRAIKILANSYYGGYARARWYCKECAESVTAWGREYI~~M~~

-continued

SIREIEEKYGFVLYADTDGFHATIPGEDAETIKKKAMEFLKYINSKLPGALEYEGFYRRGFFVTKKYAVIDEEGKITTRGLEIVRR
 DWSEIAKETQARVLEALLKDGNVEEAVSIVKEVTEKLSKYEVPPPEKLVIEHQITRELKDYKATGPHVAIAKRLAARGVKIRPGTVISYI
 VLKGSGRIGDRAIPFDEFDPAKHRYDAEYYIENQVLPAAVERILKAFCGYRKEDLRYQKTRQVGLGAWLKPKGKK

SEQ ID NO: 51

MILDTDYITENGKPVIRVFKKENGEPKIEYDRTFEPEPYFALLKDDSAIEDVKKVTAKRHGAVVKVRAEKVQRKFLGRPIEWKLYFT
 HPQDVPPAIRDKIRAHPAVVDIYEYDIPFAKRYLIDKGLIPMEGDEELRMLAFDIETLYHEGEFGTGPILMISYADENEARVITWKKI
 DPLYDVVSTEKEMIKRFLRVVKEKDPDVLLITYNGDNPDFAYLKKCEKLGIKFTLGRDGSEPKIORMGDRFAVEVKGRIFPDLYPV
 IRRTINLPTYTLEAVYEAVFGKPKEKVYAEETEAWESGEGLERVARYSMEDAKVTYELGREFFPMEAQLSLIGQSLWDVSRSSTG
 NLVEWFLLRKAYERNELAPNKPDERELARRRESYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSPDTLNREGCKEYDVAPEV
 GHKFCKDFPGFIPSLLGDLLEERQKIKRKMATIDPLEKKLLDYRQRAIKILANSFYGGYAKARWYCKECAESVTAWGREYIETTI
 REIEEKFGFKVLYADTDGFFATIPGADAETVKKKAKEFLKYINAKLPGGLELEYEGFYVRGFFVTKKYAVIDEEGKITTRGLEIVRRD
 WSEIAKETQARVLEAILKHGDVEEAVRIVKEVTEKLSKYEVPPPEKLVIEHQITRDLRDYKATGPHVAVAKRLAAGVKIRPGTVISYIV
 LKGSGRIGDRAIPADEFDPTKHYDAEYYIENQVLPAAVERILKAFCGYRKEDLRYQKTRQVGLGAWLKVKKGKK

SEQ ID NO: 52

MILDTDYITEDGKPVIRIFKKDNGEFKIEYDRNFPEPYIYALLRDDSIAEDVKKITAERHGRVVKVRAEKVKKFLGRPVEVWKLKYFTR
 PQDVPPAIRDRIRAHPAVVDIYEYDIPFAKRYLIDKGIIPMEGDEELKMLAFDIETLYHEGEFAEGPILMISYADENEARVITWKIDL
 PFDVSVSTEKEMIKRFLKVIKEKDPDVLLITYNGDNPDFAYLKKCEKFGIKFTLGRDGSDPKIORMGDRFAVEVKGRIFPDLYPVILR
 TVNLPTYTLEAVYEAIFGTPKEKVYPPEITTAWETGEGLERVARYSMEDAKVTFELGREFFPMEAQLSLVGQSFWDVSRSSTGNL
 VEWFLLRKAYERNELAPNKPDERELVRRNSYTGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSPDTLNREGCKEYDEAPQVG
 HKFCKDFPGFIPSLLGNLLDERQKIKRKMATIDPLEKKLLDYRQRAIKILANSYYGGYAYARARWYCKECAESVTAWGREYIEMSIR
 EIEEKFGFKVLYADTDGFHATIPGADAETVKKKAKEFLKYINAKLPGALELEYEGFYKRGFFVTKKYAVIDEEGKITTRGLEIVRRD
 WSEIAKETQARVLEALLKDGNVEEAVSIVKEVTEKLGKYEVPPEKLVIEHQITRELKDYKATGPHVAIAKRLAARGVKIRPGTVISYIV
 LKGSGRIGDRAIPFDEFDPDKHYDAEYYIENQVLPAAVERILKAFCGYRAEDLRYQKTRQVGLGVWLQPKGKK

SEQ ID NO: 53

MELAFWLLDITYGVIGNTPELRLFGITDDGKRVLVLDLDRSFRPYFYVIPSGDVNAVNNVKRLEGKVLNVEVIKRKMFNEVDAIR
 VTATIPEKVRELRELAAEVPGVEDVLEADIRFSQRYLLDMGVKPSNWIVVDQCEEVKGNYQVDLVCALKSRPRMIEEHKLPSFRVL
 AFDIEVYNPRGMNPDRDPVIIISTMTKEDGVKMFVVDNNKNDAKIIREFLDYFRKYDPDIVVGNNNGFDWPYLVNRSSRVG
 RLALSRMGNPPESVYGHWSIIGRANVDLYNFIEEISEIKVSLDRAAEFFGIMKRSERVLIPGHRHEYWDDKNKRDLLLKYARD
 VVSTYGLAEKLLPFAIQLSSIQLPLDQVGAAVGARVEWMIFYEAVKRGELAPNREERPETYKGAVVLEPRPGLHENIAVIDFSS
 MYP SIMMKYNVSPDTLVLGDCDCYVAPEVNYKFRRSPEGLYPGLLRLVESRRVRDLMKKYPENSPEWVLLNERQRALKVMA
 NAMYGYCGWL GARWYRREVAEAVTAWGRNLLRTVIEKARS LGLPIIYGDTSFLVRNISDKVDALINYVNELGFEVKVDKYRR
 VLFTEAKKRYVGLTVEGEVDIVGFEAVRGDWAEIAKDVQENVAEIVLTTGDVGKAISYVKSVIDVKAYQFDIDDVIIWKTLDKSLN
 EYKVLT PHVAAAKQLVEAGYKVGKGMIGYVVVKGGGAKLAYKVKPYILIKDIREVDVDDYVEKQIVPAAMRILEV LGVKESQLM
 EGKAGKSILDYFS

SEQ ID NO: 54

MLRTVWVDYARKGEPDVILVGRREDGNPAALVVKGFRPYFYAEVEDGFDPSEVERLSGVVEVEVLLEHPYGGDRVELLRIVATY
 PKVVPKLRQVKKLDGVKEVYEADI PFVRRRAVDLNLPPASEVDVSDLDTGWSGLPAYFADVEDARELDHRYPYPIEDLVVASFDL
 EVLAEPGTTIKGASGPIIAISFAYSTPDGERRNYITWKGEDESPEVDGVETEVICRSEAALRRFFDEFRRVDPVVFTYNGDEF
 LPYLOHRAGKLGIDVSPLARPAGKRGII LKHGGGRYASDIFGRAHVDLHYTARKNLKLERFTLEEAVKDVLGVEKEEMELADINEA
 WKRGNLDELMRYSaedahytLELGLAQLEELSYLTRLPLDATRFSFGQLAEWRAIYKARQEDILVPNKPTRDEYKRRRKAY
 KGAIVFPEPEI GLHENVVCVDFA SLYPNVMVAHNISPDTFDCDCPRTVVEVDDPDTAVAPDVGHKFCRKRGFFPRLVEGLIER
 RRELKRLRKLDTESHPHEAKILDVRQQAYKVLANSYYGYMGWANARWFCRECAESVTAWGRYYISEVRRIAEEKYGLKVVYGD
 TDSLFBVKLPPADLEETIERVKEFLKEVNGLPVELEDAYKRI LFVTKKKYAGYTEDGKIVTKGLEVVRRDWAPIARETORVVLKRIL

-continued

ADNDPEAALKEIHEVLERLKSGDVDIDELAVTSQQLKKPSEYVQKGPHVRAALRLARHLGVEPEPGTIVRYVIVRGPGSVSDKAYPV
 ELVREEGKEPDVYDYYIEHQILPAVERIMRAIGYSRGQIVGETASQKTLDDQFFG

SEQ ID NO: 55

MELKIWPLDVTVYAVVGGYPEVRVFGLTEGGGRVVLVDRSFKPYFYVDCPTCEVGVVKSLSRVAPVDEVAERRFLGRPRRFLM
 VVARVPEDVRRLREAAAQIPGVAGVYEADIRFYMRYMIDVGLLPCSWNRAEVEGGGKVGLPQYTVVQWLGPAGGFPPPLRV
 LAFDIEVYNERGTPDPARDPVMIAVKTDDGREEVFEAEGRDRGVLRSPVEFVKSYPDPVVVGNSNGFDWPYLAGRARAIGV
 PLRVDRLGGLPQQSVYGHWSIVGRANVDLYGIVEEFPEIKLKTLDRVAEYFGVMRREERVLIPGHKIYEYWRDPGKRPLLROVLD
 DVRSTLGLADKLLPFLIQLSSVGLPLDQVAAASVGNRVEWMLRAYRLGEVAPNREEREYEPEYKGAIKLEPKPGMYEDVLVLDF
 SSMYPNIMMKYNLSPDTYLEPGEPPPEGVNAAPEVGHFRRSPLGFVPQVLKSLVELRKAVREEAKRPPDSPEFRILDERQRAL
 KVMANAMYGYLGWVGARWYKREVAESVTAFARAILKDVIEQARRLGIVVVYGDTSLFVKKHVNVDKLIQYVEEKYGIEIKVDK
 DYAKVLFTAEKKRYAGLLRDGRIDIVGFEVVRGDWSELAKEVQLKVVEIILNSRDVAEARRRVTQYVREIIERLREYKFNVDDLIWK
 TLDKELGEYKAYPPHVHAALILKRHGYKVGKGNMVGYVVVKGGKISEKALPYILLDDVKKIDVEYYIERQIIPAALRIAEVIGVKEA
 DLKTGKSERSLLDFF

SEQ ID NO: 56

MKTFLTEQQIKVLMRLAKGYKQSEIAKILGTSRANSILEKRAMIEKIEKARNTLLWEQINSKVIVEIKAGEDIFSPEKFFFKA
 VKVYSTAEIITFLVEHAPVEDRLAKRDFVLFLDSKNKLIGDCLVIEEIKED

SEQ ID NO: 57

MPITKVTRNYQITIPAEIRKALGIKEGELLEVRLENGKIIERLKKERKTLKLGKLTLEEIEKAEEGMKQCMQ

SEQ ID NO: 58

TKIEILRLKEREMYAYEIWSLLGKPLKYQAVHQHIKELLELGLVEQAYRKGRVYYKITEKGLRILQNFEDELENI

SEQ ID NO: 59

MNTGAQGVSEMSRMKII SVQLPQSLIHGLDALVKRGYIYPNRSEAIRVAIRELLKKELYKEEIQEEIPEYVVK

SEQ ID NO: 60

VIIPRPIDPRDIRRIRKELGITQEEELARKAGVTQAYIAKLEAGKVDPRLSTFNKILRALIECQKAKI

SEQ ID NO: 61

NNCECMVVKEKLYTVKQASEILGVHPKTIQKWDREGKIKTVRTPGRRRIPESEIKRLLGISEEK

SEQ ID NO: 62

MLKDSAPKRKILEELRKGETVSGDYLASKLGVSRVAIWKHIRELKELGYGIADKKGYKLVYEPKKPYPWE

SEQ ID NO: 63

MIDERDKIILEILEKDARTPPTEIAKLGISETAVRKRVKALEEKGIIEGYTIKINPKKLGYSLVTITGVDTKPEKLFEVAEKLKE

SEQ ID NO: 64

MEIDDLLRKILSSLIEDSRLSYREIAKKLNVAVGTYNRIKKLEDMGVIQGFTVKNYEKLGYELTAIGIKAQGKK

SEQ ID NO: 65

EMLWMYILKLLKDRPMYAYEIRNELKKRFGFEPATVSSYVVLRLLEGGYVSSEWESEAGRPSRKYYRLTEKGEKLLEKGIE
 LNMLKS

SEQ ID NO: 66

MKVSKATASKVLRSLLENKGIVERERRGKTYLVRLTNKGLELLEEISKAGKELDEKIFAECSVDERIVL

SEQ ID NO: 67

SEDYMLQNRKVLAKVLELLNNPNKALNISELARMFGVSRDTIYNDIQQIIKNVEV

SEQ ID NO: 68

SKEISRFLKVISNPIRYGILKMLNDRMCVCLISEALEIDQTLVSHHIRLKEELDLLEERKEGKLRFYRTNKEKLREYLEK
 SKGS

SEQ ID NO: 69

MCRKDVMIIISDPKQIKALSDPTRVKILELLRYHPMTVSEISRVIGKDKSTIYRHICALEEAGLVEEVEKIGNETVYGR

SEQ ID NO: 70

MEPVFVKLNQKGKSIPLTMEAEIMEYMWEIKEATAGEVYEMKTKYPEIRRSTVSILMNRLCERGLLKRMEKGKGGIRYVYSITT

TREEFERKVVEKIIIESLMMNPREATPAYLSKINKK

SEQ ID NO: 71

MKKSNLDDLILLAKAGGIEKEILTTRELSKMLNVSPQTIVRWLEDLEKDGLIKKSESRKGTLVTITEEGVKFLEKLHEELSDALYR

-continued

SEQ ID NO: 72

MEIPPEISHALSEIGFTKYEILTYWTLVYGPSTAKEISTKSGIPYNRVYDTISSLKLRGFVTEIEGTPKVYAAYSPRIAFFRFKKELEDIM
KKLEIELNNNVKK

SEQ ID NO: 73

IINPQARLTPLEILEIIKQKKSITITEIKEILSERRKSEYPLSLVSEYISRLERKGYVKKIAGRKKFVEALI

SEQ ID NO: 74

GIDVVIPEIKHDPIARDIVKILFDLRRANVSQIARELKGRRGKASRNTVRKKLKELEKLGVVKEVPGERGSVTLSREVVKWLIDLIGI
PINLL

SEQ ID NO: 75

MTKRVKVITDPEVIKVMLEDTRRKILQLLRNREMTISQLSEILGKMPQTIIYHHIEKLKEAGLVEVKR

SEQ ID NO: 76

MEEIKEIMKSHTLGNPVRGLGIMIYLFFPRRAPFSHIQKALDLTPGNLDSHIKVLEKHGFVRTYKVIADRPTMVEITDYGMETRKF
LSHLKTVIDAIHF

SEQ ID NO: 77

MGEELNRLLDVLGNETRRRILFLLTKRPYFVSELSRELGVGQKAVLEHLRILEEAGLIESRVEKIPRGRPRKYYMIKKGLRLEILLTPTLF
GSEMYEAK

SEQ ID NO: 78

MRRMDKVDLQLIKILSQNSRLTYRELAEMLGTTQRVARKVDKLKLGIIRKFTIIPNLEK

SEQ ID NO: 79

GRKVRTQQNEILNLLNEKEKAVLRAILEHGGEIKQEDLPELVGYSRPTISKVIQELENKGLIKREKSGKTFVVKIERKIKLD

SEQ ID NO: 80

KSLQRFLRRNTTSIKHLSEITGVARNRLSDILNGKTQKIRGETLRKIAKAFEKSNILSF

SEQ ID NO: 81

DVIQRIKEKYDEFTNAEKKIADTILSDPKGIIESSISDLSEKAGVKSEASVVKFYKKLGLNSFQQFKVLLAQSIRAPLEIVYEDVSSEDD

TKTITEKIFKATVRAI

SEQ ID NO: 82

KIRDKILNVYTQFSPAERKVADYVLERPDDVIHYSITEFAKIVGVSETTIHRMIKKLDFEGYQAPKIALARELSGLEETIERRDFIDEEDI

LRRLKDTLD

SEQ ID NO: 83

KRRPTINDVAKLAGVSISTVSRYLKDPQSQVSEKLERIREAIKKLGYPKNKIAQGLRTGD

SEQ ID NO: 84

MASIKDVAKLAGVSATSRVINGNNVSEETRKVIDAIRKLNYPVYAVKGAVLKR

SEQ ID NO: 85

MKKKYVTIRDIAEKAGVSINTVSRALNNKPDISEETRRKILKIAQELGYVKNATASSLRSK

SEQ ID NO: 86

MPTIEDVAKLAGVSATSRVINGSGYVSEKTRYKVWKAIEELGYKPEISAKLLASKG

SEQ ID NO: 87

MРИGEKLRLRSRGLTQEELAERTDLSRSFISQLESDKTSPSIDLERILEALGTDLKHF

SEQ ID NO: 88

MHMKTVRQERLKSVIRLERSKEPVSGAQLAEELSVSRQVIVQDIAYLRLSLGYNIVATPRGYVLAGG

SEQ ID NO: 89

MNTLKKAFEILDFIGVKNPGDVSVSEIAEKFNMSVSNAYKYMVLEEKGFVLKKDKRYVPGYKLIYEYGSFVLRRF

SEQ ID NO: 90

MKISKKRRQELIRKIIHEKKISNQFOIVEELKKYGIKAVQPTVARDLKEIGAVKIMDESGNYVYKLLDETPVIDPWKELKR

SEQ ID NO: 91

MHKKLNPKSMKRENKKMVLRYLIESGPHSRVEIARKTGLAQSAIWRIIEELVNEGLVEEKGTATGRRRKAVTYGPTRSFITS

SEQ ID NO: 92

MPSPLLRRRENKIKILRYILKNGKTTRNQLASNLNLAHSTLSYIIDELLDEGFLVFEEIKKKRGRPYQILSVNPEKFTAI

SEQ ID NO: 93

MKEERLKEILDIVDRNGFISMKDLQEQLGVSMTVRRDVAELVKRNLVKKVHGGIRKVNYFEKETDFMKRLSINREAKE

US 9,447,445 B2

47

48

-continued

SEQ ID NO: 94

MFTMRSEYALRLMIVMAKEYGNYLSMTEILEKAKQSVPREFAEKILYTLKKAGLVKTRRGKGSGYMLSRPPKEIKVSEIVFLDRKS

KVFFDMPGCPDELDCCIRALWKRVENEIEKILSGVTLEDLVREQEEMKQ

SEQ ID NO: 95

MRDTKGHLKFLVLHIIQQPSHGYVIMKKISQIIGAEPPSPGALYPILSSLRKQKYIETYNEGKRKVYRLTDKGRKYLEEHKEEIKKALD

FAERF

SEQ ID NO: 96

MRHRGGGRGFRGWLASTILLVAEKPSHGYELAERLAEGIEIPGIGHMGNIYRVLADLEESGFLSTEWDTVSPPRKIYRITPQG

KLYLREILRSLEDMKRRIETLERIKRVLQEE

SEQ ID NO: 97

MLSKRDAILKAAVEVPGKKGYDRATTDEIAEKAGVAKGLIPHYNKEELYQAYMSVTEKLQKEFENFL

SEQ ID NO: 98

MSKSWGKFIEEEEAEAMSRRNLMIVDGTNLGFRFKHNNSKKPFASSYVSTIQSLAKSYSARTTIVLGDKGKSVFRLHEHLPEYKGNR

DEKYAQRTEEEKALDEQFFEYLKDAFELCKTTFPTFTIRGVEADDMAAYIVKLIGHLYDHVWLISTDGDWDTLLTDKVSRSFTTR

EYHLRDMDYHHNVDDVEQFISLKAIMGDLGDNIRGVEGIGAKRGYNIIREFGNVLIDIQLPLPGKQKYIQNLNASEELLFRNLILV

DLPTYCVDAIAAVGQDVLDKFTKDILEIAEQ

SEQ ID NO: 100

MEEKVGNLKPNCMESVNVTVRVLEASEARQIQTNGVRTISEAIVGDETGRVKLTWKGKHAGSIKEGQVVKIE

NAWTTAFKGQVQLNAGSKTKIAEASEDGFPESSQIPENTPTAPQQMRRGGGRFRGGGRYGRGGRRQENE

GEED

SEQ ID NO: 101

MTLEEARKRVNELRDLIRYHNYRYYVLADPISDAEYDRLLRELKELEERFPELKSPDSPTLQVGARPLEATFRPVHRPTRMYSLDNA

FNLDDELKAFEEIERALGRKGPFAYTVEHKVDGLSVNLYEEGVLVYGA TRGDGEVGEEVTQNLTTIPTIPRRLKGVPERLEVREM

PIEAFLRNNEELEERGERIFKNPRNAAAGSLRQKDPRTAKRGLRATFYALGLGLEEVEREGVATQFALLHWLKEKGFPVEHYARA

VGAEGVEAVYQDWLKKRALPFEADGVVVKLDDELALWRELGYTARAPRFIAIYKFPAAEKETRLLDVVFQVGRVTGPVGILEP

VPLEGSEVSRVTLHNESYIEELDIRIGDWVLVHKAGGIPEVLRVLKERRTGEERPIRWPETCPECGHRLKEGVHRCNPPLCPAK

RFEAIRHFASRKAMDIQGLGEKPLIERLLEKGLVKDVADELYRLRKEDLVGLERMGEKSAQNLLRQIEESKKRGLERLLYALGLPGVGE

VLARNLAARFGNMDRLLEASLEELLEVEEVGELTARAILETLKDPAFRDLVRRLEAGVEMEAKEKGGEALKGLTFVITGELSRPRE

EVKALLRR

SEQ ID NO: 102

MILDADYITEDGKPIIRIFKKENGEPKVEYDRNFRPYIYALLKDDSAIDDVKKITAERHGKVVRVDVEVKVKKFLGRPIEVWKLYFEH

PQDVPAIRDKIREHPAVIDIFEYDIPFAKRYLIDKGLIPMEGNEELKLLAFDIETLYHEEEFGKGPIMISYADEEGAKVITWKKVDLP

YVEVVS SEREMIKRFLKVIREKPDVIITYNGDNDFPYLLKRAEKGMLPLGRDGSEPKMQRLGDSLAVEIKGRIHF DLYPVIRRTI

NLPTYTLEAVYEAI FGPKPEKVKYPHEIAEWETGKGLERVAKYSMEDAKVTYELGREFFPMEAQLARLVQGPLWDVRSSTGNLV

EWYLLRKAYERNELAPNKPDEREYERRLRESYE GGYVKEPEKGLWE GIVSLDFRSLYPSIIITHNVSPDTLNKEGC GEYDVAPEVGH

RPFCKDFPGFIPSLLGSLLDERQKIKRKMASKDPIERKL LDYRQRAIKILANSYYGGYAKARWYCKECAESVTAWGREYIELVRRE

LEERGFVKLYIDTDGLYATI PG EKNWEEIKRRALEFVN YINAKLPGLLELEYEGFYTRGFFVTKKYALIDEEGKIITRGLIEVRRDWSEI

AKETQAKVLEAI LKHGNVEEAVKIVKEVTEKLSKYEIPPEKLVIEQI TRPLNEYKAIGPHVAVAKRLAARGIKVRPGMVIGYVVLRG

DGPISKRAIAAAEFDPKKH KYDAEYYIENQVLP A VL RILEAFGYRKEDLRWQKTKQVGLGAWLKVKKSLGAKVTD SVSRKTSYLV

GENPGSKLEKARALGVPTLTEEELYRLLEARTGKKAELV

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 108

<210> SEQ ID NO 1

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 1

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile			
1	5	10	15

Arg Leu Phe Lys Lys Glu Asn Gly Arg Phe Lys Val Glu Tyr Asp Arg			
20	25	30	

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile			
35	40	45	

Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg			
50	55	60	

Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile			
65	70	75	80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Met			
85	90	95	

Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr			
100	105	110	

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro			
115	120	125	

Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr			
130	135	140	

Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile			
145	150	155	160

Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile			
165	170	175	

Asp Leu Pro Tyr Val Glu Val Val Ala Asn Glu Arg Glu Met Ile Lys			
180	185	190	

Arg Leu Ile Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr			
195	200	205	

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu			
210	215	220	

Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys			
225	230	235	240

Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile			
245	250	255	

His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr			
260	265	270	

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu			
275	280	285	

Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly			
290	295	300	

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr			
305	310	315	320

Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu			
325	330	335	

Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu			
340	345	350	

Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala			
---	--	--	--

US 9,447,445 B2

51**52**

-continued

355 360 365

Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380

Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly
 385 390 395 400

Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415

His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr
 420 425 430

Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
 435 440 445

Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Glu Arg Gln Lys Ile
 450 455 460

Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu
 465 470 475 480

Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly
 485 490 495

Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
 500 505 510

Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu
 515 520 525

Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
 530 535 540

Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg
 545 550 555 560

Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu
 565 570 575

Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys
 580 585 590

Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly
 595 600 605

Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
 610 615 620

Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
 625 630 635 640

Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile
 645 650 655

Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn
 660 665 670

Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
 675 680 685

Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val
 690 695 700

Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu
 705 710 715 720

Phe Asp Gly Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
 725 730 735

Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys
 740 745 750

Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala
 755 760 765

Trp Leu Lys Val Lys Lys Ser
 770 775

-continued

<210> SEQ_ID NO 2
<211> LENGTH: 75
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 2

Ile	Ile	Asn	Pro	Gln	Ala	Arg	Leu	Thr	Pro	Leu	Glu	Leu	Glu	Ile	Leu
1							5		10					15	
Glu	Ile	Ile	Lys	Gln	Lys	Lys	Ser	Ile	Thr	Ile	Thr	Glu	Ile	Lys	Glu
	20						25					30			
Ile	Leu	Ser	Glu	Arg	Arg	Lys	Ser	Glu	Tyr	Pro	Leu	Ser	Leu	Val	Ser
	35					40					45				
Glu	Tyr	Ile	Ser	Arg	Leu	Glu	Arg	Lys	Gly	Tyr	Val	Lys	Lys	Ile	Ala
	50					55			60						
Lys	Gly	Arg	Lys	Lys	Phe	Val	Glu	Ala	Leu	Ile					
	65					70			75						

<210> SEQ_ID NO 3
<211> LENGTH: 856
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 3

Met	Ile	Leu	Asp	Ala	Asp	Tyr	Ile	Thr	Glu	Asp	Gly	Lys	Pro	Ile	Ile	
1							5		10					15		
Arg	Leu	Phe	Lys	Lys	Glu	Asn	Gly	Arg	Phe	Lys	Val	Glu	Tyr	Asp	Arg	
	20						25			30						
Asn	Phe	Arg	Pro	Tyr	Ile	Tyr	Ala	Leu	Leu	Lys	Asp	Asp	Ser	Ala	Ile	
	35					40			45							
Asp	Asp	Val	Arg	Lys	Ile	Thr	Ser	Glu	Arg	His	Gly	Lys	Val	Val	Arg	
	50					55			60							
Val	Ile	Asp	Val	Glu	Lys	Val	Lys	Lys	Phe	Leu	Gly	Arg	Pro	Ile		
	65					70			75		80					
Glu	Val	Trp	Lys	Leu	Tyr	Phe	Glu	His	Pro	Gln	Asp	Val	Pro	Ala	Met	
	85					90			95							
Arg	Asp	Lys	Ile	Arg	Glu	His	Pro	Ala	Val	Ile	Asp	Ile	Phe	Glu	Tyr	
	100					105			110							
Asp	Ile	Pro	Phe	Ala	Lys	Arg	Tyr	Leu	Ile	Asp	Lys	Gly	Leu	Ile	Pro	
	115					120			125							
Met	Glu	Gly	Asn	Glu	Glu	Leu	Thr	Phe	Leu	Ala	Val	Asp	Ile	Glu	Thr	
	130					135			140							
Leu	Tyr	His	Glu	Gly	Glu	Glu	Phe	Gly	Lys	Gly	Pro	Ile	Ile	Met	Ile	
	145					150			155			160				
Ser	Tyr	Ala	Asp	Glu	Glu	Gly	Ala	Lys	Val	Ile	Thr	Trp	Lys	Lys	Ile	
	165					170			175							
Asp	Leu	Pro	Tyr	Val	Glu	Val	Val	Ala	Asn	Glu	Arg	Glu	Met	Ile	Lys	
	180					185			190							
Arg	Leu	Ile	Lys	Val	Ile	Arg	Glu	Lys	Asp	Pro	Asp	Val	Ile	Ile	Thr	
	195					200			205							
Tyr	Asn	Gly	Asp	Asn	Phe	Asp	Phe	Pro	Tyr	Leu	Leu	Lys	Arg	Ala	Glu	
	210					215			220							
Lys	Leu	Gly	Met	Lys	Leu	Pro	Leu	Gly	Arg	Asp	Asn	Ser	Glu	Pro	Lys	
	225					230			235			240				

-continued

Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu
275 280 285

Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
290 295 300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
305 310 315 320

Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
325 330 335

Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
340 345 350

Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
355 360 365

Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
370 375 380

Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly
385 390 395 400

Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
405 410 415

His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr
420 425 430

Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
435 440 445

Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Glu Arg Gln Lys Ile
450 455 460

Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu
465 470 475 480

Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly
485 490 495

Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
500 505 510

Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu
515 520 525

Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
530 535 540

Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg
545 550 555 560

Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu
565 570 575

Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys
580 585 590

Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly
595 600 605

Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
610 615 620

Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
625 630 635 640

Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile
645 650 655

Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn

US 9,447,445 B2

57

-continued

58

660	665	670
Glu		
Tyr	Lys	Ala
Ile	Gly	Pro
		His
		Val
		Ala
		Val
		Ala
		Lys
		Arg
		Leu
		Ala
675	680	685
Ala	Lys	Gly
Ile	Lys	Ile
		Lys
		Pro
		Gly
		Met
		Val
		Ile
		Gly
		Tyr
		Val
690	695	700
Leu	Arg	Gly
Asp	Gly	Pro
Ile	Ser	Lys
		Arg
		Ala
		Ile
		Glu
705	710	715
		Glu
Phe	Asp	Gly
Lys	Lys	His
		Lys
		Tyr
		Asp
		Ala
		Glu
		Tyr
		Tyr
		Ile
725	730	735
Gln	Val	Leu
Leu	Pro	Ala
		Val
		Glu
		Arg
		Ile
		Leu
		Lys
		Ala
		Phe
		Gly
		Tyr
		Lys
740	745	750
Arg	Glu	Asp
Leu	Arg	Trp
		Gln
		Lys
		Thr
		Gln
		Val
		Gly
		Leu
755	760	765
Trp	Leu	Lys
Val	Lys	Lys
		Ser
		Gly
		Thr
		Gly
		Gly
770	775	780
Pro	Gln	Ala
Ala	Arg	Leu
		Thr
		Pro
		Leu
		Glu
		Leu
785	790	795
		Glu
		Ile
		Ile
		Glu
		Ile
Lys	Gln	Lys
Lys	Ser	Ile
		Thr
		Ile
		Thr
		Glu
805	810	815
Glu	Arg	Arg
Lys	Ser	Glu
		Tyr
		Pro
		Leu
		Ser
		Leu
		Val
820	825	830
Ser	Arg	Leu
Glu	Arg	Lys
		Gly
		Tyr
		Val
		Lys
835	840	845
Lys	Lys	Phe
		Val
		Glu
		Ala
		Leu
850	855	

<210> SEQ ID NO 4
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 4

ttggtctggt gtcaaaaatg aatcgtaacg gcgatttatg 40

<210> SEQ ID NO 5
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 5

gggtcattt cggcgaggac tgcatacagc catatacg 39

<210> SEQ ID NO 6
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 6

gccccccggt cctcgccgaa aatgacccag ag 32

<210> SEQ ID NO 7
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 7
gccccgcgtg gtgtcgatgg tagaacgaag cg 32

<210> SEQ ID NO 8
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 8
gccccgccc cactgacgca ttgcgcgaga ag 32

<210> SEQ ID NO 9
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 9
gccccgcgg ctgcgcaact gttggaaagg gc 32

<210> SEQ ID NO 10
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 10
gccccgcgtg cagcacatcc cccttcgcc ag 32

<210> SEQ ID NO 11
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 11
gccccgcgt gatgctcgt acggtaacg cc 32

<210> SEQ ID NO 12
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 12
gccccgcgt gtcggattt aaaatggct gc 32

<210> SEQ ID NO 13
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 13
gccccgcgt accgcttgcc agcggttac ca 32

-continued

<210> SEQ ID NO 14
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 14

gccccgcga atacctgttc cgtcatagcg at 32

<210> SEQ ID NO 15
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 15

gccccgctc attttgaca ccagaccaac tgg 33

<210> SEQ ID NO 16
<211> LENGTH: 1016
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 16

gccccgcgt cctcgccgaa aatgacccag agcgctgccg gcacacctgtcc tacgagttgc 60
atgataaaaga agacagtcat aagtgcggcg acgatagtca tgcccccgc ccaccggaaag 120
gagctgactg ggttgaaggc tctcaaggc atcggtcgag atcccggtgc ctaatgagtg 180
agctaactta cattaattgc gttcgctca ctgcccgcgtt tccagtcggg aaacctgtcg 240
tgccagctgc attaatgaat cggccaacgc gcggggagag gcgggttgcg tattgggcgc 300
caggggtgtt ttcttttca ccagtggagac gggcaacacgc tgattggcct tcaccgcctg 360
gccctgagag agttgcagca agcggtccac gctgggttgc cccagcaggc gaaaatcctg 420
tttgatggtg gttaacggcg ggtataacc aacgcgcagc cccgactcgg taatatccca 480
ctaccgagat atccgcacca acgcgcagcc cggactcggt aatggcgcgc attgcgccta 540
gccccatctg atcggtggca accagcatcg cagtggaaac gatgcctca ttcagcattt 600
gcatggttt tgaaaaccg gacatggcac tccagtcgccc ttcccggttcc gctatcggt 660
gaattttgatt gcgagtgaga tatttatgcc agccagccag acgcagacgc gcccggac 720
aacttaatgg gcccgcatac agcgcgattt gctggtgacc caatgcgacc agatgctcca 780
cgccccatcg cgtaccgtct tcatggaga aaataatact gttgatgggt gtctggtcag 840
agacatcaag aaataacgc ggaacattag tgcaggcagc ttccacagca atggcatctt 900
ggtcatccag cggatagttt atgatcggcc cactgacgcg ttgcgcgaga agatttgca 960
ccggccgttt acagggttcg acggccgttc gttctaccat cgacaccaggc ggccgc 1016

<210> SEQ ID NO 17
<211> LENGTH: 1016
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 17

gccccgcgcc cactgacgcg ttgcgcgaga agatttgca ccggccgttt acagggttcg 60

-continued

```

acgccgcttc gttctaccat cgacaccacc acgctggcac ccagttgatc ggccgcagat 120
ttaatcgccg cgacaatttg cgacggcgcg tgcaaggcca gactggaggt ggcaacgcca 180
atcagaacg actgttgcc cgccagttgt tgtgccacgc ggttggaaat gtaattcagc 240
tccgcccacg ccgcttccac ttttccccgc gtttgcagaa aaacgtggct ggcctggttc 300
accacgcggg aaacggtctg ataagagaca cccgcatact ctgcgcacatc gtataacgtt 360
actggttca cattcaccac cctgaattga ctcttcccg ggccgtatca tgccataccg 420
cgaaagggtt tgcccattc gatggtgtcc gggatctega cgctctccct tatggactc 480
ctgcattagg aagcagccca gttagtaggtt gaggccgtt agcaccgcgg ccgcaaggaa 540
tggtgcatgc aaggagatgg cgcggcaacag tccccggcc acggggccctg ccaccatacc 600
cacggccaaa caagegctca tgagccgaa gtggcgagcc cgatcttccc catcggtgat 660
gtcgccgata tagggccag caaccgcacc tgtggcccg gtgatggccgg ccacgatgcg 720
tccggcgttag aggatcgaga tctcgatccc gcgaaattaa tacgactcac tataggggaa 780
ttgtgagccg ataacaattc ccctctagaa ataattttgt ttaactttaa gaaggagata 840
tacatatgac catgattacg gattcaactgg ccgtcggtt acaacgtcgt gactggggaa 900
accctggcgt tacccaactt aatcgccctg cagcacatcc cccttccgc agctggcgta 960
atagcgaaga ggccgcacc gategcctt cccaacagt ggcgcagccgc ggccgc 1016

```

<210> SEQ ID NO 18

<211> LENGTH: 1016

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 18

```

ggggccgctg cagcacatcc cccttccgc agctggcgta atagcgaaga ggccgcacc 60
gatcgccctt cccaacagt ggcgcagccgt aatggcgaat ggccgttgc ctggttccg 120
gcaccagaag cggcgccga aagctggctg gagtgcgcattt tcctgaggg cgatactgtc 180
gtcgccccctt ccaaactggca gatgcacggcgt tacgatgcgc ccatactacac caacgtgacc 240
tatccccatcc cggtaatcc gccgtttttt cccacggaga atccgacggg ttgttactcg 300
ctcacatcca atgttgcattt aagctggcta caggaaggcc agacgcgaat tattttgtat 360
ggcggttaact cggcggttca tctgtgggtgc aacggggcgctt gggtcggtt ccggccaggac 420
agtcgtttgc cgtctgaattt tgacctgagc gcattttac ggcgcgggaga aaaccgcctc 480
ggcggtatgg tgctgcgtcg gagtgacggc agttatctgg aagatcagga tatgtggcg 540
atgagccgca tttccgtga cgtctcgatcc ctgcataaac cgactacacca aatcagcgat 600
ttccatgtttt ccactcgctt taatgtatgtat ttcagccgcgt ctgtactggaa ggctgaagtt 660
cagatgtgcg gcgagttgcg tgactaccta cggtaacag tttctttatg gcagggtgaa 720
acgcaggatcg ccagccgcac cggcccttc ggcggtaaaa ttatcgatga gcgtgggtgt 780
tatgcgcgcgc ggcgtcactt acgtctgaac gtcgaaaacc cgaaactgtg gagcgcggaa 840
atccccatcc tctatcgatcc ggtgggtgaa ctgcacaccg cccacggcac gctgattgaa 900
gcagaaggctt gcgatgtcggtt tttccgcggag gtgcggattt aaaaatggctt gctgtgtcg 960
aacggcaagc cggttgcgtat tgcaggccgtt aaccgtcagc agcatcatgc ggccgc 1016

```

<210> SEQ ID NO 19

-continued

```

<211> LENGTH: 1016
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 19

gcccccccgag gtgcggattt aaaaatggctc gctgctgtt aacggcaagc cgtttgtat 60
tcgaggcggtt aaccgtcacgt agcatcatcc tctgcattgtt caggcatggt atgagcagac 120
gatgggtgcag gatatccctgc tgatgaagca gaacaacttt aacgcctgtc gctgttcgca 180
ttatccgaac catccgttgtt ggtacacgtt gtgcgcaccc tacggcctgtt atgtgggttga 240
tgaagccaat attgaaaccc acggcatgtt gccaatgaat cgtctgaccgt atgatcccg 300
ctggctacccg gcgtatgagcc aacgcgtaac gcgaatgggtt cagcgcgtatc gtaatcaccc 360
gagtgtgatc atctggtcgc tggggaatga atcaggccac ggcgctaattc acgacgcgtt 420
gtatcgctgg atcaaattctg tcgatccttc ccggccgggtt cagttatgaag gcccggggc 480
cgacaccacg cccaccgata ttatggccc gatgtacgcg cgcgtggatg aagaccagcc 540
cttccggct gtgcccggaaat ggtccatcaa aaaaatggctt tgcgtacctgtt gagagacgcg 600
cccgctgatc ctttgccaaat acgcccacgc gatgggtaac agtcttggcg gttcgctaa 660
atactggcag gcgtttcgatc agtatccccg tttacaggccg ggcttcgtctt gggactgggt 720
ggatcagtgc ctgattaaat atgatgaaaaa cggcaaccccg tggtcggctt acggcgggtga 780
tttggcgat acgcccgaacg atcgcctgtt ctgtatgaac ggtctggctt ttggccaccg 840
cacgcccgcattt ccagcgctga cggaaagcaaa acaccagcag cagttttcc agttccgttt 900
atccggccaa accatcgaag tgaccagcga atacctgttc cgtcatagcg ataacgagct 960
ctgcactgg atgggtggcgca tggatggtaa gcccgtggca agcgggtgagc ggccgc 1016

```

```

<210> SEQ_ID NO 20
<211> LENGTH: 1168
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 20

gcccccccgca atacctgttc cgtcatagcg ataacgagct cctgcactgg atgggtggcg 60
tggatggtaa gccgcgtggca agcgggtgaa tgcctctggta tgcgtctcca caaggtaaac 120
agttgattgtt actgcgtgtt ctaccgcgc cggagagcgc cgggcacatc tggctcacag 180
tacgcgtatgtt gcaaccgaac ggcgcgtatgtt ggtcagaagc cgggcacatc agcgcgtggc 240
agcagtggcg tctggcgaa aacctcgtgtt tgacgcgttcc cggcgcgttcc caccgcgttcc 300
cgcatctgac caccagcgaa atggattttt gcatcgagct gggtaataag cggtggcaat 360
ttaaccgcgc gtcaggctt cttcacaga tggatggattggt cgataaaaaa caactgctga 420
cgccgcgtgc cgatcagtgc acccggtcac cgtggataa cgacattggc gtaagtgaag 480
cgacccgcattt tgaccctaac gcctgggtcg aacgctggaa ggccggggc cattaccagg 540
ccgaaggcgc gttgttgcag tgcacggcag atacacttgc tgcgtgggtt ctgattacgaa 600
ccgcgtacgc gtggcagcat cagggaaaaa ctttattttt cagccggaaa acctaccgaa 660
ttgatggtag tggtcataatg gcatcgatgtt tgcgtgggtt gatgcgggtt gatacaccgc 720
atccggccgcg gattggccctg aactgccagc tggcgcagggtt agcagagcgg gtaaaactggc 780
tcggattagg gcccgaagaa aactatccccg accgccttac tgcgcgttgc tttgaccgtt 840

```

-continued

```

ggatctgcc attgtcagac atgtataccc cgtacgttcc cccgagcgaa aacggtctgc      900
gtgcgggac gcgcgaattt aattatggcc cacaccatgtt ggcggcgac ttccagttca      960
acatcagccg ctacagtcaa cagcaactga tggaaaccag ccattgcacat ctgctgcacg     1020
cggagaagg cacaatggctt aatatcgacg gttccatat ggggatttgtt ggcgacgact     1080
cctggagccc gtcagtatcg gcggaaattcc agctgagcgc cggtcgctac cattaccagt    1140
tggtctggtg tcaaaaatga gggccgcg                                1168

```

```

<210> SEQ ID NO 21
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 21

```

```

aaaaccaccc tggcgccaa tacg                                         24

```

```

<210> SEQ ID NO 22
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 22

```

```

cccggaactcg gtaatggcgc gcat                                         24

```

```

<210> SEQ ID NO 23
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 23

```

```

ggaaggcagcc cagtagtagg ttga                                         24

```

```

<210> SEQ ID NO 24
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 24

```

```

ggtgctgcgc tggagtgacg gcag                                         24

```

```

<210> SEQ ID NO 25
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 25

```

```

cggccaccga tattatgtc ccga                                         24

```

```

<210> SEQ ID NO 26
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

```

-continued

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 26

gattagggcc gcaagaaaac tatc

24

<210> SEQ ID NO 27

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (22)..(22)

<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 27

gcgaagaacc tcttcccaag angg

24

<210> SEQ ID NO 28

<211> LENGTH: 71

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 28

atcttggtgaa aaggacgaaa caccggcgaa gaacctttt ccaagagttagataga

60

aatagcaagt t

71

<210> SEQ ID NO 29

<211> LENGTH: 71

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (26)..(46)

<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 29

atcttggtgaa aaggacgaaa caccgnnnnn nnnnnnnnnn nnnnnngttt tagagctaga

60

aatagcaagt t

71

<210> SEQ ID NO 30

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 30

cgccagggtt ttcccagtca cgac

24

<210> SEQ ID NO 31

<211> LENGTH: 27

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 31

gccaagcttg catgcctgca ggtcgac

27

-continued

<210> SEQ ID NO 32
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 32

gccccgtccaa aagggtcagt gctgcaacat tttgctgccg gtcacggttc gaacgtacgg	60
acgtccagct g	71

<210> SEQ ID NO 33
<211> LENGTH: 1184
<212> TYPE: PRT
<213> ORGANISM: Methanocaldococcus vulcanius

<400> SEQUENCE: 33

Met Lys Glu Lys Ala Pro Lys Ile Asp Ala Leu Ile Asp Cys Thr Tyr	
1 5 10 15	

Lys Thr Glu Asp Asn Arg Ala Val Ile Tyr Leu Tyr Leu Leu Glu Asn	
20 25 30	

Ile Leu Lys Asp Arg Glu Phe Ser Pro Tyr Phe Tyr Val Glu Met Leu	
35 40 45	

Lys Asp Arg Ile Glu Lys Glu Asp Ile Asp Lys Ile Lys Glu Phe Leu	
50 55 60	

Leu Lys Glu Asp Leu Leu Lys Phe Val Glu Asn Leu Glu Val Val Asn	
65 70 75 80	

Lys Thr Ile Leu Lys Lys Glu Ile Val Lys Ile Ile Ala Thr	
85 90 95	

His Pro Gln Arg Val Pro Lys Leu Arg Lys Ile Lys Glu Cys Asp Ile	
100 105 110	

Val Lys Glu Ile Tyr Glu His Asp Ile Pro Phe Ala Lys Arg Tyr Leu	
115 120 125	

Ile Asp Ser Asp Ile Val Pro Met Thr Tyr Trp Asp Phe Glu Asn Arg	
130 135 140	

Lys Gln Val Ser Ile Glu Ile Pro Lys Leu Lys Thr Val Ser Phe Asp	
145 150 155 160	

Met Glu Val Tyr Asn Arg Asp Thr Glu Pro Asp Pro Glu Lys Asp Pro	
165 170 175	

Ile Leu Met Ala Ser Phe Trp Asp Asn Gly Gly Lys Val Ile Thr	
180 185 190	

Tyr Lys His Phe Asp His Ser Asn Ile Glu Val Val Asn Ser Glu Lys	
195 200 205	

Asp Leu Ile Lys Lys Ile Val Glu Met Leu Arg Gln Tyr Asp Val Ile	
210 215 220	

Phe Thr Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Lys Ala Arg	
225 230 235 240	

Ala Lys Ile Tyr Gly Ile Asp Ile Lys Leu Gly Arg Asp Gly Glu Glu	
245 250 255	

Leu Lys Ile Lys Arg Gly Gly Met Glu Phe Arg Ser Tyr Ile Pro Gly	
260 265 270	

Arg Val His Ile Asp Leu Tyr Pro Ile Ser Arg Arg Leu Leu Lys Leu	
275 280 285	

Thr Lys Tyr Thr Leu Glu Asp Val Val Tyr Asn Leu Phe Gly Ile Glu	
290 295 300	

Lys Leu Lys Ile Pro His Thr Lys Ile Val Asp Tyr Trp Ala Asn Asn

US 9,447,445 B2

73

74

-continued

305	310	315	320
Asp Lys Ile Leu Ile Glu Tyr Ser Leu Gln Asp Ala Lys Tyr Thr His			
325	330	335	
Lys Ile Gly Lys Tyr Phe Phe Pro Leu Glu Val Met Phe Ser Arg Ile			
340	345	350	
Val Asn Gln Thr Pro Phe Glu Ile Thr Arg Met Ser Ser Gly Gln Met			
355	360	365	
Val Glu Tyr Leu Leu Met Lys Asn Ala Phe Lys Glu Asn Met Ile Val			
370	375	380	
Pro Asn Lys Pro Asp Glu Lys Glu Tyr Arg Lys Arg Leu Leu Thr Ser			
385	390	395	400
Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Met Phe Glu Asp			
405	410	415	
Ile Ile Ser Met Asp Phe Arg Cys His Pro Arg Gly Thr Lys Val Ile			
420	425	430	
Val Lys Asn Asn Gly Leu Thr Asp Ile Glu Asn Val Lys Val Gly Asp			
435	440	445	
Tyr Val Leu Gly Ile Asp Gly Trp Gln Lys Val Lys Arg Val Trp Lys			
450	455	460	
Tyr Pro Tyr Asn Gly Phe Leu Val Asn Val Asn Gly Leu Lys Ser Thr			
465	470	475	480
Pro Asn His Ile Pro Val Ile Lys Lys Glu Asn Gly Lys Asp Arg			
485	490	495	
Val Ile Asp Val Ser Ser Ile Tyr Leu Leu Asn Leu Lys Gly Cys Lys			
500	505	510	
Ile Leu Lys Ile Lys Asn Phe Glu Ser Ile Gly Met Phe Gly Lys Ile			
515	520	525	
Phe Lys Lys Asp Thr Lys Ile Lys Lys Val Lys Gly Leu Leu Glu Lys			
530	535	540	
Ile Ala Tyr Ile Asp Pro Arg Glu Gly Leu Val Ile Lys Val Lys Asn			
545	550	555	560
Glu Lys Glu Asp Ile Phe Lys Thr Val Ile Pro Ile Leu Lys Glu Leu			
565	570	575	
Asn Ile Leu Tyr Lys Gln Val Asp Glu Lys Thr Ile Ile Asp Ser			
580	585	590	
Ile Asp Gly Leu Leu Lys Tyr Ile Val Thr Ile Gly Phe Asn Asp Lys			
595	600	605	
Asn Glu Glu Lys Ile Lys Glu Ile Ile Lys Glu Lys Ser Phe Leu Glu			
610	615	620	
Phe Lys Glu Leu Glu Asp Ile Lys Ile Ser Ile Glu Glu Tyr Glu Gly			
625	630	635	640
Tyr Val Tyr Asp Leu Thr Leu Glu Gly Arg Pro Tyr Tyr Phe Ala Asn			
645	650	655	
Gly Ile Leu Thr His Asn Ser Leu Tyr Pro Ser Ile Ile Ala Tyr			
660	665	670	
Asn Ile Ser Pro Glu Thr Leu Asp Cys Glu Cys Cys Lys Asp Ile Ser			
675	680	685	
Glu Lys Ile Leu Gly His Trp Phe Cys Lys Lys Arg Glu Gly Leu Ile			
690	695	700	
Pro Lys Thr Leu Arg Gly Leu Ile Glu Arg Arg Ile Asn Ile Lys Asn			
705	710	715	720
Lys Met Lys Lys Met Glu Ser Glu Lys Glu Ile Asn Glu Glu Tyr Asn			
725	730	735	

-continued

Leu Leu Asp Tyr Glu Gln Arg Ser Leu Lys Ile Leu Ala Asn Ser Val
740 745 750

Tyr Gly Tyr Leu Ala Phe Pro Arg Ala Arg Phe Tyr Ser Arg Glu Cys
755 760 765

Ala Glu Val Ile Thr Tyr Leu Gly Arg Lys Tyr Ile Leu Glu Thr Ile
770 775 780

Glu Glu Ala Glu Lys Phe Gly Phe Lys Val Ile Tyr Ala Asp Ser Val
785 790 795 800

Val Lys Asp Ala Lys Val Ile Ile Lys Glu Asp Gly Lys Ile Lys Glu
805 810 815

Ile Lys Ile Glu Asp Leu Phe Lys Lys Val Asp Tyr Thr Ile Gly Asp
820 825 830

Lys Glu Tyr Cys Ile Leu Asn Asn Val Glu Thr Leu Thr Ile Glu Asp
835 840 845

Thr Lys Leu Val Trp Arg Lys Val Pro Tyr Ile Met Arg His Arg Thr
850 855 860

Asn Lys Lys Ile Tyr Arg Val Lys Val Lys Asp Arg Tyr Val Asp Ile
865 870 875 880

Thr Glu Asp His Ser Ile Ile Gly Val Lys Asn Asn Lys Leu Val Glu
885 890 895

Leu Lys Pro Thr Glu Ile Lys Asp Asp Glu Thr Lys Leu Ile Ile Leu
900 905 910

Asn Lys Asp Leu Lys Ser Tyr Asn Phe Ala Ser Val Glu Glu Ile Asn
915 920 925

Cys Ile Lys Tyr Ser Asp Tyr Val Tyr Asp Ile Glu Val Glu Asn Thr
930 935 940

His Arg Phe Phe Ala Asn Gly Ile Leu Val His Asn Thr Asp Gly Phe
945 950 955 960

Tyr Ala Val Trp Lys Glu Lys Ile Ser Lys Asp Asp Leu Ile Lys Lys
965 970 975

Ala Leu Glu Phe Val Lys Tyr Ile Asn Ser Lys Leu Pro Gly Thr Met
980 985 990

Glu Leu Glu Phe Glu Gly Tyr Phe Lys Arg Gly Ile Phe Ile Thr Lys
995 1000 1005

Lys Arg Tyr Ala Leu Ile Asp Glu Asn Gly Arg Val Ile Val Lys
1010 1015 1020

Gly Leu Glu Phe Val Arg Arg Asp Trp Ser Asn Leu Ala Arg Ile
1025 1030 1035

Thr Gln Arg Arg Val Leu Glu Ala Leu Leu Glu Gly Asp Ile
1040 1045 1050

Asn Lys Ala Lys Lys Ala Ile Gln Asp Val Ile Lys Asp Leu Arg
1055 1060 1065

Glu Lys Lys Ile Lys Lys Glu Asp Leu Ile Ile Tyr Thr Gln Leu
1070 1075 1080

Thr Lys Asn Pro Asn Glu Tyr Lys Thr Thr Ala Pro His Val Glu
1085 1090 1095

Ile Ala Lys Lys Met Met Arg Glu Gly Lys Lys Ile Lys Ile Gly
1100 1105 1110

Asp Val Ile Gly Tyr Ile Ile Val Lys Gly Ser Lys Ser Ile Ser
1115 1120 1125

Glu Arg Ala Lys Leu Pro Glu Glu Val Ser Ile Glu Glu Ile Asp
1130 1135 1140

US 9,447,445 B2

77

78

-continued

Val	Asn	Tyr	Tyr	Ile	Asp	Asn	Gln	Ile	Leu	Pro	Pro	Val	Leu	Arg
1145						1150						1155		
Ile	Met	Glu	Ala	Val	Gly	Val	Ser	Lys	Asn	Glu	Leu	Lys	Lys	Glu
1160						1165					1170			
Gly	Thr	Gln	Leu	Thr	Leu	Asp	Arg	Phe	Leu	Lys				
1175						1180								

<210> SEQ_ID NO 34
<211> LENGTH: 781
<212> TYPE: PRT
<213> ORGANISM: Archaeoglobus fulgidus
<400> SEQUENCE: 34

Met	Glu	Arg	Val	Glu	Gly	Trp	Leu	Ile	Asp	Ala	Asp	Tyr	Glu	Thr	Ile
1								10					15		
Gly	Gly	Lys	Ala	Val	Val	Arg	Leu	Trp	Cys	Lys	Asp	Asp	Gln	Gly	Ile
20								25					30		
Phe	Val	Ala	Tyr	Asp	Tyr	Asn	Phe	Asp	Pro	Tyr	Phe	Tyr	Val	Ile	Gly
35								40					45		
Val	Asp	Glu	Asp	Ile	Leu	Lys	Asn	Ala	Ala	Thr	Ser	Thr	Arg	Arg	Glu
50								55					60		
Val	Ile	Lys	Leu	Lys	Ser	Phe	Glu	Lys	Ala	Gln	Leu	Lys	Thr	Leu	Gly
65								70					75		80
Arg	Glu	Val	Glu	Gly	Tyr	Ile	Val	Tyr	Ala	His	His	Pro	Gln	His	Val
85								90					95		
Pro	Lys	Leu	Arg	Asp	Tyr	Leu	Ser	Gln	Phe	Gly	Asp	Val	Arg	Glu	Ala
100								105					110		
Asp	Ile	Pro	Phe	Ala	Tyr	Arg	Tyr	Leu	Ile	Asp	Lys	Asp	Leu	Ala	Cys
115								120					125		
Met	Asp	Gly	Ile	Ala	Ile	Glu	Gly	Glu	Lys	Gln	Gly	Val	Ile	Arg	
130								135					140		
Ser	Tyr	Lys	Ile	Glu	Lys	Val	Glu	Arg	Ile	Pro	Arg	Met	Glu	Phe	Pro
145								150					155		160
Glu	Leu	Lys	Met	Leu	Val	Phe	Asp	Cys	Glu	Met	Leu	Ser	Ser	Phe	Gly
165								170					175		
Met	Pro	Glu	Pro	Glu	Lys	Asp	Pro	Ile	Ile	Val	Ile	Ser	Val	Lys	Thr
180								185					190		
Asn	Asp	Asp	Asp	Glu	Ile	Ile	Leu	Thr	Gly	Asp	Glu	Arg	Lys	Ile	Ile
195								200					205		
Ser	Asp	Phe	Val	Lys	Leu	Ile	Lys	Ser	Tyr	Asp	Pro	Asp	Ile	Ile	Val
210								215					220		
Gly	Tyr	Asn	Gln	Asp	Ala	Phe	Asp	Trp	Pro	Tyr	Leu	Arg	Lys	Arg	Ala
225								230					235		240
Glu	Arg	Trp	Asn	Ile	Pro	Leu	Asp	Val	Gly	Arg	Asp	Gly	Ser	Asn	Val
245								250					255		
Val	Phe	Arg	Gly	Gly	Arg	Pro	Lys	Ile	Thr	Gly	Arg	Leu	Asn	Val	Asp
260								265					270		
Leu	Tyr	Asp	Ile	Ala	Met	Arg	Ile	Ser	Asp	Ile	Lys	Ile	Lys	Lys	Leu
275								280					285		
Glu	Asn	Val	Ala	Glu	Phe	Leu	Gly	Thr	Lys	Ile	Glu	Ile	Ala	Asp	Ile
290								295					300		
Glu	Ala	Lys	Asp	Ile	Tyr	Arg	Tyr	Trp	Ser	Arg	Gly	Glu	Lys	Glu	Lys
305								310					315		320
Val	Leu	Asn	Tyr	Ala	Arg	Gln	Asp	Ala	Ile	Asn	Thr	Tyr	Leu	Ile	Ala
325								330					335		

US 9,447,445 B2

79**80**

-continued

Lys Glu Leu Leu Pro Met His Tyr Glu Leu Ser Lys Met Ile Arg Leu
340 345 350

Pro Val Asp Asp Val Thr Arg Met Gly Arg Gly Lys Gln Val Asp Trp
355 360 365

Leu Leu Leu Ser Glu Ala Ala Lys Lys Ile Gly Glu Ile Ala Pro Asn Pro
370 375 380

Pro Glu His Ala Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Glu
385 390 395 400

Arg Gly Leu His Glu Asn Val Ala Cys Leu Asp Phe Ala Ser Met Tyr
405 410 415

Pro Ser Ile Met Ile Ala Phe Asn Ile Ser Pro Asp Thr Tyr Gly Cys
420 425 430

Arg Asp Asp Cys Tyr Glu Ala Pro Glu Val Gly His Lys Phe Arg Lys
435 440 445

Ser Pro Asp Gly Phe Phe Lys Arg Ile Leu Arg Met Leu Ile Glu Lys
450 455 460

Arg Arg Glu Leu Lys Val Glu Leu Lys Asn Leu Ser Pro Glu Ser Ser
465 470 475 480

Glu Tyr Lys Leu Leu Asp Ile Lys Gln Gln Thr Leu Lys Val Leu Thr
485 490 495

Asn Ser Phe Tyr Gly Tyr Met Gly Trp Asn Leu Ala Arg Trp Tyr Cys
500 505 510

His Pro Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Phe Ile Arg
515 520 525

Thr Ser Ala Lys Ile Ala Glu Ser Met Gly Phe Lys Val Leu Tyr Gly
530 535 540

Asp Thr Asp Ser Ile Phe Val Thr Lys Ala Gly Met Thr Lys Glu Asp
545 550 555 560

Val Asp Arg Leu Ile Asp Lys Leu His Glu Glu Leu Pro Ile Gln Ile
565 570 575

Glu Val Asp Glu Tyr Tyr Ser Ala Ile Phe Phe Val Glu Lys Lys Arg
580 585 590

Tyr Ala Gly Leu Thr Glu Asp Gly Arg Leu Val Val Lys Gly Leu Glu
595 600 605

Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys Lys Val Gln Arg Glu
610 615 620

Val Ile Glu Val Ile Leu Lys Glu Lys Asn Pro Glu Lys Ala Leu Ser
625 630 635 640

Leu Val Lys Asp Val Ile Leu Arg Ile Lys Glu Gly Lys Val Ser Leu
645 650 655

Glu Glu Val Val Ile Tyr Lys Gly Leu Thr Lys Lys Pro Ser Lys Tyr
660 665 670

Glu Ser Met Gln Ala His Val Lys Ala Ala Leu Lys Ala Arg Glu Met
675 680 685

Gly Ile Ile Tyr Pro Val Ser Ser Lys Ile Gly Tyr Val Ile Val Lys
690 695 700

Gly Ser Gly Asn Ile Gly Asp Arg Ala Tyr Pro Ile Asp Leu Ile Glu
705 710 715 720

Asp Phe Asp Gly Glu Asn Leu Arg Ile Lys Thr Lys Ser Gly Ile Glu
725 730 735

Ile Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asp Asn Gln Ile Ile Pro
740 745 750

-continued

Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr Thr Glu Ala Ser Leu
755 760 765

Lys Gly Ser Ser Gln Met Ser Leu Asp Ser Phe Phe Ser
770 775 780

<210> SEQ ID NO 35

<211> LENGTH: 783

<212> TYPE: PRT

<213> ORGANISM: Archaeoglobus profundus

<400> SEQUENCE: 35

Met Ile Lys Ala Trp Leu Leu Asp Val Asp Tyr Val Thr Glu Asn Asp
1 5 10 15

Arg Ala Val Ile Arg Leu Trp Cys Lys Asp Asp Lys Gly Val Phe Val
20 25 30

Ala Tyr Asp Arg Asn Phe Leu Pro Tyr Phe Tyr Val Ile Gly Cys Lys
35 40 45

Ala Glu Asp Val Met Lys Val Lys Val Arg Thr Asn Glu Gly Ile Ile
50 55 60

Thr Pro Leu Lys Val Glu Glu Ile Glu Ala Lys Ser Leu Gly Lys Pro
65 70 75 80

Ile Lys Ala Leu Lys Val Tyr Thr Arg His Pro Gln His Val Pro Lys
85 90 95

Leu Arg Glu Glu Ile Lys Lys Phe Ala Glu Val Arg Glu Ala Asp Ile
100 105 110

Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala Cys Met Asp
115 120 125

Gly Ile Glu Ile Glu Pro Ile Ala Val Lys Glu Gly Val Leu Arg Ala
130 135 140

Tyr Glu Val Arg Ser Val Arg Arg Val Glu Lys Lys Gly Phe Pro Asp
145 150 155 160

Leu Lys Ile Leu Ala Phe Asp Cys Glu Met Leu Ala Gln Phe Met Pro
165 170 175

Asp Pro Glu Lys Asp Pro Ile Ile Ala Ile Ala Val Lys Cys Gly Asp
180 185 190

Phe Glu Glu Val Leu His Gly Asp Glu Arg Asp Ile Leu Arg Arg Phe
195 200 205

Val Ser Ile Ile Lys Glu Gln Asp Pro Asp Ile Ile Val Gly Tyr Asn
210 215 220

Gln Asp Asn Phe Asp Trp Pro Tyr Val Lys Lys Arg Ala Glu Lys Phe
225 230 235 240

Gly Ile Arg Leu Asp Ile Gly Arg Asp Arg Ser Glu Ile Ser Phe Arg
245 250 255

Gly Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp Leu Tyr Asp
260 265 270

Ile Ala Leu Lys Ile Pro Asp Val Lys Ile Lys Thr Leu Lys Lys Val
275 280 285

Ala Glu Phe Leu Gly Ala Lys Val Glu Glu Asp Ile Glu Gly Arg
290 295 300

Asp Ile Tyr Lys Cys Trp Met Arg Gly Glu Lys Glu Lys Val Phe Lys
305 310 315 320

His Val Leu Asn Asp Val Leu Thr Thr Tyr Arg Leu Ala Leu Glu Leu
325 330 335

Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Leu Pro Leu Asp
340 345 350

-continued

Asp Val Ala Arg Leu Gly Arg Gly Lys Gln Val Asp Tyr Phe Leu Leu
 355 360 365
 Ser Glu Ala Lys Lys Ile Asn Glu Ile Ala Pro Asn Pro Pro Glu Ile
 370 375 380
 Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ala Arg Gly Leu
 385 390 395 400
 His Glu Asn Val Ala Cys Leu Asp Phe Ala Ser Met Tyr Pro Ser Ile
 405 410 415
 Met Ile Asn Phe Asn Ile Ser Pro Asp Thr Leu Val Lys Gly Glu Cys
 420 425 430
 Glu Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg Lys Ser
 435 440 445
 Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu Lys Arg
 450 455 460
 Arg Glu Met Lys Arg Gln Met Lys Glu Leu Asp Pro Asp Ser Glu Asp
 465 470 475 480
 Tyr Lys Leu Leu Asp Ile Lys Gln Gln Thr Leu Lys Val Leu Thr Asn
 485 490 495
 Ser Phe Tyr Gly Tyr Thr Gly Trp Asn Leu Ala Arg Trp Tyr Cys Arg
 500 505 510
 Glu Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg Tyr Phe Ile Lys Arg
 515 520 525
 Ala Val Lys Ile Ala Glu Ser Met Gly Phe Glu Val Leu Tyr Gly Asp
 530 535 540
 Thr Asp Ser Leu Phe Ile Lys Lys Asn Lys Leu Asn Leu Lys Asp Leu
 545 550 555 560
 Glu Lys Glu Cys Leu Lys Leu Ile Asp Val Ile Ser Lys Glu Leu Pro
 565 570 575
 Ile Gln Leu Glu Ile Asp Glu Phe Tyr Lys Ala Ile Phe Phe Val Glu
 580 585 590
 Lys Lys Arg Tyr Ala Gly Leu Thr Asp Asp Asp Arg Ile Val Val Lys
 595 600 605
 Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys Arg Val
 610 615 620
 Gln Arg Glu Val Ile Glu Ile Ile Leu Arg Glu Arg Asn Pro Asp Lys
 625 630 635 640
 Ala Leu Lys Phe Val Lys Asn Val Ile Glu Glu Ile Lys Glu Gly Lys
 645 650 655
 Phe Lys Leu Glu Asp Tyr Val Ile Tyr Lys Gly Leu Thr Lys Lys Pro
 660 665 670
 Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu Arg Ala
 675 680 685
 Met Glu Met Gly Ile Tyr Tyr Pro Ile Gly Thr Lys Val Gly Phe Val
 690 695 700
 Ile Val Lys Gly Gly Ser Ile Ser Asp Arg Ala Tyr Pro Ile Glu
 705 710 715 720
 Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Lys Ile Arg Thr Pro Ser
 725 730 735
 Gly Ile Met Val Lys Lys Ile Asp Lys Asp Tyr Tyr Ile Asp His Gln
 740 745 750
 Ile Ile Pro Ala Val Met Arg Ile Leu Glu Arg Phe Gly Tyr Thr Glu
 755 760 765

-continued

Ala Ser Leu Lys Thr Thr Ile Gln Lys Thr Leu Phe Asp Phe Thr
 770 775 780

<210> SEQ ID NO 36

<211> LENGTH: 849

<212> TYPE: PRT

<213> ORGANISM: Caldicellulosiruptor hydrothermalis

<400> SEQUENCE: 36

Met Lys Leu Val Ile Phe Asp Gly Asn Ser Ile Leu Tyr Arg Ala Phe
 1 5 10 15

Phe Ala Leu Pro Glu Leu Thr Thr Ser Ser Asn Ile Pro Thr Asn Ala
 20 25 30

Ile Tyr Gly Phe Ile Asn Val Ile Leu Lys Tyr Leu Glu Gln Glu Lys
 35 40 45

Pro Asp Tyr Ile Ala Val Ala Phe Asp Lys Arg Gly Arg Glu Ala Arg
 50 55 60

Lys Ser Glu Tyr Gln Glu Tyr Lys Ala Asn Arg Lys Pro Met Pro Asp
 65 70 75 80

Asn Leu Gln Val Gln Ile Pro Tyr Val Arg Glu Ile Leu Tyr Ala Leu
 85 90 95

Asn Ile Pro Ile Val Glu Phe Glu Gly Tyr Glu Ala Asp Asp Val Ile
 100 105 110

Gly Ser Leu Val Asn Lys Phe Lys Asn Thr Gly Leu Asp Ile Val Ile
 115 120 125

Ile Thr Gly Asp Arg Asp Thr Leu Gln Leu Leu Asp Lys Asn Val Val
 130 135 140

Val Lys Ile Val Ser Thr Lys Phe Asp Arg Thr Met Glu Asp Leu Tyr
 145 150 155 160

Thr Ile Glu Asn Ile Lys Glu Lys Tyr Val Trp Ala Asn Gln Val
 165 170 175

Pro Asp Tyr Lys Ala Leu Val Gly Asp Gln Ser Asp Asn Ile Pro Gly
 180 185 190

Val Lys Gly Ile Gly Glu Lys Ser Ala Gln Lys Leu Leu Glu Glu Tyr
 195 200 205

Ser Ser Leu Glu Glu Ile Tyr Gln Asn Leu Asp Lys Ile Lys Gly Ser
 210 215 220

Ile Arg Glu Lys Leu Glu Ala Gly Lys Asp Met Ala Phe Leu Ser Lys
 225 230 235 240

Arg Leu Ala Thr Ile Val Cys Asp Leu Pro Leu Asn Val Asn Leu Glu
 245 250 255

Asp Leu Arg Thr Lys Glu Trp Asn Lys Glu Arg Leu Tyr Glu Ile Leu
 260 265 270

Val Gln Leu Glu Phe Lys Ser Ile Ile Lys Arg Leu Gly Leu Ser Glu
 275 280 285

Asn Ile Gln Phe Glu Phe Val Gln Gln Arg Thr Asp Ile Pro Asp Val
 290 295 300

Glu Gln Arg Glu Leu Glu Ser Ile Ser Arg Ile Arg Ser Lys Glu Ile
 305 310 315 320

Pro Leu Met Phe Val Gln Asp Glu Lys Cys Phe Tyr Leu Tyr Asp Gln
 325 330 335

Glu Ser Asn Thr Val Phe Val Thr Arg Asp Arg His Leu Val Glu Glu
 340 345 350

Ile Leu Lys Ser Asp Thr Val Lys Ile Val Tyr Asp Leu Lys Asn Ile
 355 360 365

US 9,447,445 B2

87

-continued

Phe His Gln Leu Asn Leu Glu Asp Thr Asp Asn Ile Lys Asn Cys Glu
 370 375 380

Asp Val Met Ile Ala Ser Tyr Val Leu Asp Ser Thr Arg Ser Ser Tyr
 385 390 395 400

Glu Leu Glu Thr Leu Phe Val Ser Tyr Leu Asn Thr Asp Ile Glu Ala
 405 410 415

Val Lys Lys Asp Lys Lys Met Val Ser Val Val Leu Leu Lys Arg Leu
 420 425 430

Trp Asp Asp Leu Leu Arg Leu Ile Asp Leu Asn Ser Cys Gln Phe Leu
 435 440 445

Tyr Glu Asn Ile Glu Arg Pro Leu Ile Pro Val Leu Tyr Glu Met Glu
 450 455 460

Lys Thr Gly Phe Lys Val Asp Arg Asp Ala Leu Leu Gln Tyr Thr Lys
 465 470 475 480

Glu Ile Glu Asn Lys Ile Leu Lys Leu Glu Thr Gln Ile Tyr Gln Ile
 485 490 495

Ala Gly Glu Trp Phe Asn Ile Asn Ser Pro Lys Gln Leu Ser Tyr Ile
 500 505 510

Leu Phe Glu Lys Leu Lys Leu Pro Val Ile Lys Lys Thr Lys Thr Gly
 515 520 525

Tyr Ser Thr Asp Ala Glu Val Leu Glu Glu Phe Asp Lys His Glu Ile
 530 535 540

Val Pro Leu Ile Leu Asp Tyr Arg Met Tyr Thr Lys Ile Leu Thr Thr
 545 550 555 560

Tyr Cys Gln Gly Leu Leu Gln Ala Ile Asn Pro Ser Ser Gly Arg Val
 565 570 575

His Thr Thr Phe Ile Gln Thr Gly Thr Ala Thr Gly Arg Leu Ala Ser
 580 585 590

Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Lys Tyr Asp Glu Gly Lys
 595 600 605

Leu Ile Arg Lys Val Phe Val Pro Glu Glu Gly His Val Leu Ile Asp
 610 615 620

Ala Asp Tyr Ser Gln Ile Glu Leu Arg Ile Leu Ala His Ile Ser Glu
 625 630 635 640

Asp Glu Arg Leu Ile Asn Ala Phe Lys Asn Asn Ile Asp Ile His Ser
 645 650 655

Gln Thr Ala Ala Glu Val Phe Gly Val Asp Ile Ala Asp Val Thr Pro
 660 665 670

Glu Met Arg Ser Gln Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly
 675 680 685

Ile Ser Asp Tyr Gly Leu Ala Arg Asp Ile Lys Ile Ser Arg Lys Glu
 690 695 700

Ala Ala Glu Phe Ile Asn Lys Tyr Phe Glu Arg Tyr Pro Lys Val Lys
 705 710 715 720

Glu Tyr Leu Asp Asn Ile Val Arg Phe Ala Arg Glu Asn Gly Tyr Val
 725 730 735

Leu Thr Leu Phe Asn Arg Lys Arg Tyr Val Lys Asp Ile Lys Ser Ala
 740 745 750

Asn Arg Asn Ala Arg Ser Tyr Ala Glu Arg Ile Ala Met Asn Ser Pro
 755 760 765

Ile Gln Gly Ser Ala Ala Asp Ile Met Lys Leu Ala Met Ile Lys Val
 770 775 780

88

-continued

Tyr Gln Lys Leu Lys Glu Asn Asn Leu Lys Ser Lys Ile Ile Leu Gln
785 790 795 800

Val His Asp Glu Leu Leu Ile Glu Ala Pro Tyr Glu Glu Lys Asp Ile
805 810 815

Val Lys Arg Ile Val Lys Arg Glu Met Glu Asn Ala Val Ala Leu Lys
820 825 830

Val Pro Leu Val Val Glu Val Lys Glu Gly Leu Asn Trp Tyr Glu Thr
835 840 845

Lys

<210> SEQ_ID NO 37

<211> LENGTH: 781

<212> TYPE: PRT

<213> ORGANISM: Desulfurococcus mucosus

<400> SEQUENCE: 37

Met Glu Lys Arg Val Tyr Leu Val Asp Ile Thr Tyr Gly Leu Val Gly
1 5 10 15

Asn Ser Pro Glu Ile Arg Met Phe Gly Val Asp Glu Asn Gly Glu Lys
20 25 30

Val Val Ile Leu Asp Arg Gly Phe Arg Pro Tyr Phe Tyr Val Ile Pro
35 40 45

Glu Glu Gly Phe Glu Asp Gln Val Ala Arg Val Ile Gly Lys Met Gln
50 55 60

Asn Val Ile Lys Ala Asp Val Thr Glu Arg Arg Leu Phe Gly Lys Pro
65 70 75 80

Ile Lys Val Val Lys Val Thr Val Thr Val Pro Asp Lys Val Arg Glu
85 90 95

Leu Arg Asp Arg Val Lys Ser Ile Gln His Val Lys Glu Val Leu Glu
100 105 110

Ala Asp Ile Arg Phe Tyr Ile Arg Tyr Met Ile Asp Asn Asp Ile Arg
115 120 125

Pro Gly Trp Leu Met Phe Ser Asn Leu Lys Pro Val Asp Asn Lys Ile
130 135 140

Gly Gly Val Ser Asn Val Tyr Leu Thr Glu Thr Pro Pro Thr Ser Leu
145 150 155 160

Asp Leu Gly Ile Met Pro Arg Leu Asn Tyr Met Ala Leu Asp Ile Glu
165 170 175

Val Tyr Asn Pro Arg Gly Thr Pro Asp Pro Lys Arg Asp Pro Ile Ile
180 185 190

Ile Ile Ala Leu Ala Asn Ser Asn Gly Asp Val Lys Leu Leu Thr Leu
195 200 205

Asp Asn Tyr Lys His Glu Arg Glu Met Leu Asn Asp Met Met Ser Val
210 215 220

Ile Lys Glu Trp Asp Pro Asp Val Leu Phe Gly Tyr Asn Ser Asn Lys
225 230 235 240

Phe Asp Met Pro Tyr Leu Val Asn Arg Ala Asp Ala Leu Asn Val Lys
245 250 255

Leu Gln Leu Ser Lys Tyr Gly Thr Pro Pro Glu Gln Ser Val Tyr Gly
260 265 270

His Trp Ser Ile Ile Gly Arg Ala His Ile Asp Leu Tyr Asn Phe Ile
275 280 285

Glu Asp Met Thr Asp Val Lys Arg Lys Ser Leu Asp Tyr Val Ala Glu
290 295 300

-continued

Tyr Phe Gly Val Met Lys Arg Ser Glu Arg Val Asn Ile Pro Gly His
305 310 315 320

Arg Ile Tyr Gln Tyr Trp Asp Asp Glu Gly Lys Arg Ser Gln Leu Ile
325 330 335

Lys Tyr Ala Arg Asp Asp Val Leu Ser Thr Leu Gly Leu Gly Lys Ile
340 345 350

Leu Leu Pro Tyr Ala Met Gln Leu Ala Ser Val Ser Gly Leu Pro Leu
355 360 365

Asp Gln Val Gly Pro Ala Ser Val Gly Ser Arg Val Glu Met Met Ile
370 375 380

Met His Glu Ala Tyr Lys Met Gly Glu Leu Ala Pro Asn Arg Val Glu
385 390 395 400

Arg Pro Tyr Glu Thr Tyr Lys Gly Ala Ile Val Leu Glu Pro Lys Pro
405 410 415

Gly Ile His Tyr Asn Ile Ala Val Leu Asp Phe Ser Ser Met Tyr Pro
420 425 430

Asn Ile Met Leu Lys Tyr Asn Ile Ser Pro Asp Thr Leu Val Leu Asp
435 440 445

Ser Ser Glu Gly Asp Tyr Tyr Thr Ala Pro Glu Val Gly Tyr Arg Phe
450 455 460

Arg Lys Ser Pro Arg Gly Leu Tyr Ala Ser Leu Leu Gln Lys Leu Ile
465 470 475 480

Glu Ala Arg Arg Glu Ala Arg Asp Glu Met Arg Asn Tyr Pro Glu Gly
485 490 495

Ser Phe Glu Trp Val Leu Leu Asn Glu Arg Gln Arg Ala Leu Lys Ile
500 505 510

Met Ala Asn Ala Met Tyr Gly Tyr Cys Gly Trp Leu Gly Ala Arg Trp
515 520 525

Tyr Ile Arg Glu Val Ala Glu Ser Val Thr Ala Trp Gly Arg Tyr Leu
530 535 540

Leu Lys Thr Ala Met Ser Met Ala Lys Glu Arg Gly Leu Thr Val Ile
545 550 555 560

Tyr Gly Asp Thr Asp Ser Leu Phe Val Thr Tyr Asp Lys Asp Lys Val
565 570 575

Ala Asp Ile Ile Ser Arg Ile Asn Glu Met Gly Phe Glu Val Lys Ile
580 585 590

Asp Lys Val Tyr Ser Lys Leu Ile Phe Thr Glu Ser Lys Lys Arg Tyr
595 600 605

Ile Gly Leu Thr Ala Asp Gly Glu Val Asp Ile Val Gly Phe Glu Ala
610 615 620

Val Arg Gly Asp Trp Ser Glu Leu Ala Arg Asn Val Gln Glu Arg Val
625 630 635 640

Ala Glu Leu Val Leu Arg Glu Ser Val Asp Glu Ala Val Lys Tyr Val
645 650 655

Lys Ser Val Ile Asp Asp Leu Arg Asn Tyr Arg Phe Thr Ile Asp Asp
660 665 670

Val Ile Ile Trp Lys Thr Leu Asp Lys Asp Ile Asn Glu Tyr Lys Ala
675 680 685

Ile Gln Pro His Val Val Ala Ala Arg Arg Leu Met Glu Lys Gly Tyr
690 695 700

Val Val Asn Lys Gly Asp Thr Val Gly Phe Val Ile Val Lys Asp Ser
705 710 715 720

Gly Asp Lys Leu Thr Gln Arg Ala Tyr Pro Tyr Val Phe Ile Asn Asp

US 9,447,445 B2

93**94**

-continued

725 730 735

Val Lys Glu Ile Asp Val Asp Tyr Tyr Val Glu Lys Gln Val Ile Pro
 740 745 750

Ala Ala Leu Arg Ile Leu Glu Val Phe Gly Val Asn Glu Ala Ala Leu
 755 760 765

Leu Gly Lys Thr Gly Lys Ser Ile Leu Asp Tyr Phe His
 770 775 780

<210> SEQ ID NO 38

<211> LENGTH: 803

<212> TYPE: PRT

<213> ORGANISM: Pyrolobus fumarii

<400> SEQUENCE: 38

Met Thr Glu Val Val Phe Thr Val Leu Asp Ser Ser Tyr Glu Val Val
 1 5 10 15

Gly Lys Glu Pro Gln Val Ile Ile Trp Gly Ile Ala Glu Asn Gly Glu
 20 25 30

Arg Val Val Leu Ile Asp Arg Ser Phe Arg Pro Tyr Phe Tyr Ala Leu
 35 40 45

Leu Ala Pro Gly Ala Asp Pro Lys Gln Val Ala Gln Arg Ile Arg Ala
 50 55 60

Leu Ser Arg Pro Lys Ser Pro Ile Ile Gly Val Glu Asp Asp Lys Arg
 65 70 75 80

Lys Tyr Phe Gly Arg Pro Arg Arg Val Leu Arg Ile Arg Thr Val Leu
 85 90 95

Pro Glu Ala Val Arg Glu Tyr Arg Glu Leu Val Lys Asn Val Asp Gly
 100 105 110

Val Glu Asp Val Leu Glu Ala Asp Ile Arg Phe Ala Met Arg Tyr Leu
 115 120 125

Ile Asp His Asp Leu Phe Pro Phe Thr Trp Tyr Arg Val Glu Ala Glu
 130 135 140

Pro Leu Glu Asn Lys Met Gly Phe Arg Val Asp Lys Val Tyr Leu Val
 145 150 155 160

Lys Ser Arg Pro Glu Pro Leu Tyr Gly Glu Ala Leu Ala Pro Thr Lys
 165 170 175

Leu Pro Asp Leu Arg Ile Leu Ala Phe Asp Ile Glu Val Tyr Ser Lys
 180 185 190

Gln Gly Ser Pro Arg Pro Glu Arg Asp Pro Val Ile Val Ile Ala Val
 195 200 205

Lys Thr Asp Asp Gly Asp Glu Val Leu Phe Ile Ala Glu Gly Lys Asp
 210 215 220

Asp Arg Lys Pro Ile Arg Glu Phe Val Glu Tyr Val Lys Arg Tyr Asp
 225 230 235 240

Pro Asp Ile Ile Val Gly Tyr Asn Asn Asn His Phe Asp Trp Pro Tyr
 245 250 255

Leu Leu Arg Arg Ala Arg Ile Leu Gly Ile Lys Leu Asp Val Thr Arg
 260 265 270

Arg Val Gly Ala Glu Pro Thr Thr Ser Val His Gly His Val Ser Val
 275 280 285

Pro Gly Arg Leu Asn Val Asp Leu Tyr Asp Tyr Ala Glu Glu Met Pro
 290 295 300

Glu Ile Lys Ile Lys Ser Leu Glu Glu Val Ala Glu Tyr Leu Gly Val
 305 310 315 320

US 9,447,445 B2

95**96**

-continued

Met Lys Lys Ser Glu Arg Val Ile Ile Asn Trp Trp Glu Ile Pro Asp
325 330 335

Tyr Trp Asp Asp Pro Lys Lys Arg Pro Leu Leu Leu Gln Tyr Ala Arg
340 345 350

Asp Asp Val Arg Ala Thr Tyr Gly Leu Ala Glu Lys Ile Leu Pro Phe
355 360 365

Ala Ile Gln Leu Ser Tyr Val Thr Gly Leu Pro Leu Asp Gln Val Gly
370 375 380

Ala Met Ser Val Gly Phe Arg Leu Glu Trp Tyr Leu Ile Arg Ala Ala
385 390 395 400

Phe Lys Met Lys Glu Leu Val Pro Asn Arg Val Glu Arg Pro Glu Glu
405 410 415

Thr Tyr Arg Gly Ala Ile Val Leu Glu Pro Leu Arg Gly Val His Glu
420 425 430

Asn Ile Ala Val Leu Asp Phe Ser Ser Met Tyr Pro Asn Ile Met Ile
435 440 445

Lys Tyr Asn Val Gly Pro Asp Thr Leu Val Arg Pro Gly Glu Glu Cys
450 455 460

Gly Glu Cys Gly Cys Trp Glu Ala Pro Glu Val Lys His Arg Phe Arg
465 470 475 480

Arg Cys Pro Pro Gly Phe Phe Lys Thr Val Leu Glu Arg Leu Leu Glu
485 490 495

Leu Arg Lys Arg Val Arg Ala Glu Met Lys Lys Tyr Pro Pro Asp Ser
500 505 510

Pro Glu Tyr Arg Leu Leu Asp Glu Arg Gln Lys Ala Leu Lys Val Leu
515 520 525

Ala Asn Ala Ser Tyr Gly Tyr Met Gly Trp Ser Gly Ala Arg Trp Tyr
530 535 540

Cys Arg Glu Cys Ala Glu Ala Val Thr Ala Trp Gly Arg His Leu Ile
545 550 555 560

Arg Thr Ala Ile Asn Ile Ala Arg Lys Leu Gly Leu Lys Val Ile Tyr
565 570 575

Gly Asp Thr Asp Ser Leu Phe Val Thr Tyr Asp Pro Glu Lys Val Glu
580 585 590

Lys Phe Ile Lys Ile Ile Glu Glu Leu Gly Phe Glu Ile Lys Leu
595 600 605

Glu Lys Val Tyr Lys Arg Val Phe Phe Thr Glu Ala Lys Lys Arg Tyr
610 615 620

Ala Gly Leu Leu Glu Asp Gly Arg Ile Asp Ile Val Gly Phe Glu Ala
625 630 635 640

Val Arg Gly Asp Trp Cys Glu Leu Ala Lys Glu Val Gln Thr Lys Val
645 650 655

Val Glu Ile Val Leu Lys Thr Ser Asp Val Asn Lys Ala Val Glu Tyr
660 665 670

Val Arg Lys Ile Val Lys Glu Leu Glu Glu Gly Lys Val Pro Ile Glu
675 680 685

Lys Leu Val Ile Trp Lys Thr Leu Ser Lys Arg Leu Glu Glu Tyr Thr
690 695 700

Thr Glu Ala Pro His Val Val Ala Ala Lys Arg Met Leu Ser Ala Gly
705 710 715 720

Tyr Arg Val Ser Pro Gly Asp Lys Ile Gly Tyr Val Ile Val Lys Gly
725 730 735

Gly Gly Arg Ile Ser Gln Arg Ala Trp Pro Tyr Phe Met Val Lys Asp

US 9,447,445 B2

97**98**

-continued

740 745 750

Pro Ser Gln Ile Asp Val Thr Tyr Tyr Val Asp His Gln Ile Ile Pro
755 760 765

Ala Ala Leu Arg Ile Leu Gly Tyr Phe Gly Ile Thr Glu Lys Lys Leu
770 775 780

Lys Ala Ser Ala Thr Gly Gln Lys Thr Leu Phe Asp Phe Leu Ala Lys
785 790 795 800

Lys Ser Lys

<210> SEQ ID NO 39

<211> LENGTH: 786

<212> TYPE: PRT

<213> ORGANISM: Pyrobaculum oguniense

<400> SEQUENCE: 39

Met Glu Ile Arg Val Trp Pro Leu Asp Val Thr Tyr Ile Val Val Gly
1 5 10 15

Gly Val Pro Glu Val Arg Val Phe Gly Ile Ala Glu Gly Glu Arg
20 25 30

Val Val Leu Ala Asp Arg Ser Phe Arg Pro Tyr Phe Tyr Val Asp Cys
35 40 45

Ala Gly Cys Asp Pro His Ala Val Lys Thr His Leu Gly Arg Thr Ala
50 55 60

Pro Val Glu Gly Val Glu Leu Val Glu Arg Arg Phe Leu Gly Arg Pro
65 70 75 80

Arg Gln Phe Leu Lys Val Val Ala Lys Ile Pro Glu Asp Val Arg Arg
85 90 95

Leu Arg Glu Ala Ala Ser Thr Ile Pro Gly Val Arg Gly Val Tyr Glu
100 105 110

Ala Asp Ile Arg Phe Tyr Met Arg Tyr Val Ile Asp Met Gly Val Val
115 120 125

Pro Cys Ser Trp Asn Val Ala Glu Val Glu Val Ala Asp Glu Lys Leu
130 135 140

Gly Ser Leu Pro Val Tyr Arg Val Val Lys Trp Gly Gly Ala Val Glu
145 150 155 160

Gly Phe Pro Pro Leu Arg Val Leu Ala Phe Asp Ile Glu Val Tyr
165 170 175

Asn Glu Arg Gly Thr Pro Asp Pro Ala Arg Asp Pro Ile Val Met Ile
180 185 190

Ala Val Gln Ser Ser Asp Gly Arg Leu Glu Val Phe Glu Ala Ser Gly
195 200 205

Arg Asp Asp Arg Gly Val Leu Arg Ser Phe Val Glu Tyr Val Arg Ser
210 215 220

Phe Asp Pro Asp Val Val Val Gly Tyr Asn Ser Asn Asn Phe Asp Trp
225 230 235 240

Pro Tyr Leu Ala Glu Arg Ala Lys Ala Val Gly Val Pro Leu Arg Val
245 250 255

Asp Arg Leu Gly Gly Ala Pro Gln Gln Ser Val Tyr Gly His Trp Ser
260 265 270

Val Leu Gly Arg Ala Asn Val Asp Leu Tyr Asn Ile Val Asp Glu Phe
275 280 285

Pro Glu Ile Lys Leu Lys Thr Leu Asp Arg Val Ala Glu Tyr Phe Gly
290 295 300

Val Met Arg Arg Asp Glu Arg Val Leu Ile Pro Gly His Lys Ile Tyr

US 9,447,445 B2

99**100**

-continued

305	310	315	320
Glu Tyr Trp Arg Asp Pro Ser Lys Arg Pro Leu Leu Arg Gln Tyr Val			
325	330	335	
Ile Asp Asp Val Arg Ser Thr Tyr Gly Leu Ala Glu Arg Leu Leu Pro			
340	345	350	
Phe Leu Ile Gln Leu Ser Ser Val Ser Gly Leu Pro Leu Asp Gln Val			
355	360	365	
Ala Ala Ala Ser Val Gly Asn Arg Val Glu Trp Met Leu Leu Arg Tyr			
370	375	380	
Ala Tyr Gly Leu Gly Glu Val Ala Pro Asn Arg Glu Glu Arg Glu Tyr			
385	390	395	400
Glu Pro Tyr Lys Gly Ala Ile Val Leu Glu Pro Lys Pro Gly Leu Tyr			
405	410	415	
Ser Asp Val Leu Val Leu Asp Phe Ser Ser Met Tyr Pro Asn Val Met			
420	425	430	
Met Arg Tyr Asn Leu Ser Pro Asp Thr Tyr Leu Glu Pro Gly Glu Pro			
435	440	445	
Asp Pro Pro Glu Gly Val Tyr Val Ala Pro Glu Val Gly His Arg Phe			
450	455	460	
Arg Lys Glu Pro Pro Gly Phe Ile Pro Gln Val Leu Arg Arg Leu Val			
465	470	475	480
Ala Leu Arg Arg Ala Val Arg Glu Glu Met Lys Lys Tyr Gln Pro Asp			
485	490	495	
Thr Pro Glu Tyr Arg Val Leu Asp Glu Arg Gln Lys Ala Leu Lys Ile			
500	505	510	
Met Ala Asn Ala Met Tyr Gly Tyr Thr Gly Trp Val Gly Ala Arg Trp			
515	520	525	
Tyr Lys Lys Glu Val Ala Glu Ser Val Thr Ala Phe Ala Arg Ala Ile			
530	535	540	
Leu Lys Asp Val Ile Asp Tyr Ala Arg Arg Leu Gly Ile Val Val Ile			
545	550	555	560
Tyr Gly Asp Thr Asp Ser Leu Phe Val Lys Lys Gly Gly Asp Leu Glu			
565	570	575	
Lys Leu Ala Arg Tyr Val Asp Glu Lys Tyr Gly Ile Glu Ile Lys Val			
580	585	590	
Asp Lys Asp Tyr Glu Lys Val Leu Phe Thr Glu Ala Lys Lys Arg Tyr			
595	600	605	
Ala Gly Leu Leu Arg Asp Gly Arg Ile Asp Ile Val Gly Phe Glu Val			
610	615	620	
Val Arg Gly Asp Trp Ser Glu Leu Ala Lys Glu Val Gln Leu Lys Val			
625	630	635	640
Ile Glu Leu Ile Leu Lys Ala Arg Asp Leu Ser Glu Ala Arg Gln Arg			
645	650	655	
Val Ile Lys Tyr Val Lys Asp Val Ile Glu Arg Leu Lys Ser Gly Lys			
660	665	670	
Phe Asp Leu Asp Asp Leu Ile Ile Trp Lys Thr Leu Asp Lys Asp Leu			
675	680	685	
Gly Glu Tyr Lys Ala Tyr Pro Pro His Val Arg Ala Ala Leu Ile Leu			
690	695	700	
Lys Lys Lys Gly Tyr Lys Val Gly Arg Gly Thr Thr Ile Gly Tyr Val			
705	710	715	720
Val Val Lys Gly Gly Glu Lys Val Ser Glu Arg Ser Leu Pro Tyr Ile			
725	730	735	

-continued

Leu Val Asp Asp Leu Ala Lys Ile Asp Val Asp Tyr Tyr Ile Glu Lys
740 745 750

Gln Val Ile Pro Ala Ala Leu Arg Ile Ala Glu Val Ile Gly Val Lys
755 760 765

Glu Gly Asp Leu Arg Ala Gly Arg Ser Glu Lys Ser Leu Leu Asp Phe
770 775 780

Phe Glu
785

<210> SEQ ID NO 40

<211> LENGTH: 801

<212> TYPE: PRT

<213> ORGANISM: Staphylothermus marinus

<400> SEQUENCE: 40

Met Ser Glu Lys Ile Asn Leu Glu Phe Tyr Phe Leu Asp Asn Ser Tyr
1 5 10 15

Glu Val Ile Gly Asn Glu Pro His Ile Ile Ile Trp Gly Ile Thr Arg
20 25 30

Asp Gly Arg Arg Val Leu Leu Arg Asp Arg Arg Phe Arg Pro Tyr Phe
35 40 45

Tyr Ala Ile Leu Lys Asp Lys Val Asn Ile Glu Asp Leu Ala Arg Lys
50 55 60

Ile Arg Thr Tyr Ser Asp Pro Lys Ser Pro Ile Ile Gly Val Glu Pro
65 70 75 80

Val Glu Lys Tyr Phe Gly Arg Lys Val Ser Ala Leu Lys Ile Ile
85 90 95

Thr Met Ile Pro Glu Tyr Val Arg Lys Tyr Arg Glu Lys Ile Lys Ser
100 105 110

Leu Pro Glu Val Leu Glu Val Val Glu Ala Asp Ile Arg Phe Ser Ile
115 120 125

Arg Tyr Ile Ile Asp His Asp Leu Arg Pro Cys Gly Trp His Val Ala
130 135 140

Glu Val Val Glu Val Pro Lys Lys Pro Ile Tyr Arg Val Asp Ala Glu
145 150 155 160

Tyr Glu Ile Ile Gly Asp Ile Lys Pro Leu Glu Gln Thr Leu Gln Pro
165 170 175

Asp Leu Arg Ile Ile Ala Phe Asp Ile Glu Val Tyr Asn Lys Ser Gly
180 185 190

Thr Pro Arg Pro Gln Thr Asp Pro Ile Ile Ile Ile Gly Ile Met Asn
195 200 205

Asn Asn Gly Asp Ile Lys Gln Phe Leu Ala Asn Lys Tyr Asp Asp Lys
210 215 220

Ile Ser Val Glu Glu Phe Val Asn Tyr Val Lys Thr Phe Asp Pro Asp
225 230 235 240

Ile Ile Val Gly Tyr Asn Thr Asp Gly Phe Asp Trp Pro Tyr Leu Ile
245 250 255

Glu Arg Ser Lys Tyr Ile Gly Val Lys Leu Asp Val Thr Arg Arg Val
260 265 270

Gly Ala Thr Pro Arg Thr Ser Thr Tyr Gly His Ile Ser Val Pro Gly
275 280 285

Arg Leu Asn Thr Asp Leu Tyr His Phe Ala Glu Glu Ile Pro Glu Val
290 295 300

Lys Val Lys Ser Leu Glu Asn Val Ala Glu Tyr Leu Gly Val Met Lys

US 9,447,445 B2

103**104**

-continued

305	310	315	320
Lys Ser Glu Arg Val Ile Ile Glu Tyr Ile Asp Ile Pro Lys Tyr Trp			
325	330	335	
Asp Asp Glu Lys Leu Arg Pro Lys Leu Leu Gln Tyr Asn Ile Asp Asp			
340	345	350	
Val Lys Ser Thr Tyr Gly Leu Ala Glu Lys Phe Leu Pro Phe Ala Met			
355	360	365	
Gln Leu Ser Asn Ile Thr Gly Leu Pro Leu Asp Gln Val Gly Ala Ala			
370	375	380	
Ser Val Gly Phe Arg Leu Glu Trp Tyr Leu Met Arg Glu Ala Phe Arg			
385	390	395	400
Tyr Gly Glu Leu Val Pro Asn Arg Val Glu Arg Ala Ala Glu Ser Tyr			
405	410	415	
Arg Gly Ala Val Val Leu Lys Pro Val Lys Gly Val His Glu Asn Ile			
420	425	430	
Ala Val Leu Asp Phe Ser Ser Met Tyr Pro Asn Ile Met Ile Lys Tyr			
435	440	445	
Asn Val Gly Pro Asp Thr Ile Val Arg Asn Glu Lys Cys Asn Pro Asp			
450	455	460	
Lys His Asn Ile Ala Pro Glu Val Gly His Cys Phe Arg Lys Glu Pro			
465	470	475	480
Pro Gly Phe Phe Lys Arg Val Leu Glu Thr Leu Leu Arg Leu Arg Lys			
485	490	495	
Gln Ile Lys Ser Glu Met Lys Lys Tyr Pro Pro Thr Ser Tyr Glu Tyr			
500	505	510	
Arg Leu Leu Asp Glu Arg Gln Lys Ala Val Lys Val Leu Ala Asn Ala			
515	520	525	
Thr Tyr Gly Tyr Met Gly Trp Ile His Ala Arg Trp Tyr Cys Arg Glu			
530	535	540	
Cys Ala Glu Ala Val Thr Ala Trp Gly Arg Gln Thr Ile Lys Ser Ala			
545	550	555	560
Ile Glu Leu Ala Arg Lys Leu Gly Leu Lys Val Ile Tyr Gly Asp Thr			
565	570	575	
Asp Ser Leu Phe Val Thr Tyr Asp Lys Asp Lys Val Glu Lys Leu Ile			
580	585	590	
Glu Leu Ile Gln Thr Lys Leu Gly Phe Glu Ile Lys Ile Asp Lys Ile			
595	600	605	
Tyr Lys Arg Val Phe Phe Thr Glu Ala Lys Lys Arg Tyr Ala Gly Leu			
610	615	620	
Leu Glu Asp Gly Arg Ile Asp Ile Val Gly Phe Glu Ala Val Arg Gly			
625	630	635	640
Asp Trp Ala Glu Ile Ala Lys Glu Val Gln Glu Lys Val Thr Glu Ile			
645	650	655	
Leu Leu Lys Glu Asn Ser Ile Asp Lys Ala Ile Glu Tyr Val Arg Gln			
660	665	670	
Val Ile Ala Asp Leu Lys Ala Gly Lys Ile Pro Leu Asp Lys Leu Ile			
675	680	685	
Ile Trp Lys Thr Leu Ser Lys Arg Ile Glu Glu Tyr Ser Val Asp Ala			
690	695	700	
Pro His Val Val Ala Ala Lys Lys Leu Ile Lys Ala Gly Ile Lys Val			
705	710	715	720
Ser Thr Asn Asp Lys Ile Gly Tyr Val Ile Leu Lys Gly Gly Lys			
725	730	735	

US 9,447,445 B2

105**106**

-continued

Ile Ser Ser Arg Ala Glu Pro Tyr Ile Phe Val Lys Asp Pro Lys Leu
 740 745 750

Ile Asp Thr Glu Tyr Tyr Val Asp His Gln Ile Val Pro Ala Ala Leu
 755 760 765

Arg Ile Leu Asn Tyr Phe Gly Val Thr Glu Thr Gln Leu Lys Arg Ala
 770 775 780

Ala Ala Ser Ala Gly Gln Lys Ser Leu Phe Asp Phe Phe Gly Gly Lys
 785 790 795 800

Lys

<210> SEQ ID NO 41

<211> LENGTH: 776

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus yayaosii

<400> SEQUENCE: 41

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asn Gly Lys Pro Val Val
 1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg
 20 25 30

Ser Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Ala Ile
 35 40 45

Glu Asp Ile Lys Lys Ile Thr Ala Glu Arg His Gly Lys Val Val Arg
 50 55 60

Val Val Glu Ala Glu Lys Val Arg Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Ile
 85 90 95

Arg Glu Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
 100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125

Met Glu Gly Asn Glu Glu Leu Lys Leu Leu Ala Phe Asp Ile Glu Thr
 130 135 140

Leu Tyr His Glu Gly Asp Glu Phe Gly Ser Gly Pro Ile Ile Met Ile
 145 150 155 160

Ser Tyr Ala Asp Glu Gly Ala Lys Val Ile Thr Trp Lys Gly Val
 165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys
 180 185 190

Arg Phe Leu Arg Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
 210 215 220

Lys Leu Gly Met Lys Leu Pro Ile Gly Arg Asp Gly Ser Glu Pro Lys
 225 230 235 240

Met Gln Arg Met Gly Asp Gly Phe Ala Val Glu Val Lys Gly Arg Ile
 245 250 255

His Phe Asp Ile Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Arg Pro Lys Glu
 275 280 285

Lys Val Tyr Pro Asn Glu Ile Ala Arg Ala Trp Glu Asn Cys Lys Gly
 290 295 300

-continued

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
 325 330 335
 Val Gly Gln Pro Val Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Arg Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380
 Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Gly
 385 390 395 400
 Ile Ile Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415
 His Asn Ile Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Asn Ser Tyr
 420 425 430
 Asp Val Ala Pro Lys Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
 435 440 445
 Phe Ile Pro Ser Leu Leu Gly Gln Leu Leu Asp Glu Arg Gln Lys Ile
 450 455 460
 Lys Arg Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Arg Lys Leu Leu
 465 470 475 480
 Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly
 485 490 495
 Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
 500 505 510
 Ser Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Leu Val Ser Arg Glu
 515 520 525
 Leu Glu Lys Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
 530 535 540
 Tyr Ala Thr Ile Pro Gly Ser Arg Glu Trp Asp Lys Ile Lys Glu Arg
 545 550 555 560
 Ala Leu Glu Phe Val Lys Tyr Ile Asn Ala Arg Leu Pro Gly Leu Leu
 565 570 575
 Glu Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys
 580 585 590
 Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Ile Thr Arg Gly
 595 600 605
 Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
 610 615 620
 Ala Arg Val Leu Glu Ala Ile Leu Lys Glu Gly Asn Leu Glu Lys Ala
 625 630 635 640
 Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val
 645 650 655
 Pro Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Asp Leu Lys
 660 665 670
 Asp Tyr Lys Ala Val Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
 675 680 685
 Ala Arg Gly Ile Lys Val Arg Pro Gly Met Val Ile Gly Tyr Leu Val
 690 695 700
 Leu Arg Gly Asp Gly Pro Ile Ser Arg Arg Ala Ile Pro Ala Glu Glu
 705 710 715 720

US 9,447,445 B2

109**110**

-continued

Phe	Asp	Pro	Ser	Arg	His	Lys	Tyr	Asp	Ala	Glu	Tyr	Tyr	Ile	Glu	Asn
725									730						735

Gln	Val	Leu	Pro	Ala	Val	Leu	Arg	Ile	Leu	Glu	Ala	Phe	Gly	Tyr	Arg
740									745						750

Lys	Glu	Asp	Leu	Arg	Tyr	Gln	Lys	Thr	Arg	Gln	Ala	Gly	Leu	Asp	Ala
755									760						765

Trp	Leu	Lys	Arg	Lys	Ala	Ser	Leu								
770									775						

<210> SEQ ID NO 42

<211> LENGTH: 773

<212> TYPE: PRT

<213> ORGANISM: Thermococcus sp.AM4-del

<400> SEQUENCE: 42

Met	Ile	Leu	Asp	Thr	Asp	Tyr	Ile	Thr	Glu	Asn	Gly	Lys	Pro	Val	Ile
1									10						15

Arg	Val	Phe	Lys	Lys	Glu	Asn	Gly	Glu	Phe	Lys	Ile	Glu	Tyr	Asp	Arg
20									25						30

Thr	Phe	Glu	Pro	Tyr	Phe	Tyr	Ala	Leu	Leu	Lys	Asp	Asp	Ser	Ala	Ile
35									40						45

Glu	Asp	Val	Lys	Lys	Val	Thr	Ala	Lys	Arg	His	Gly	Thr	Val	Val	Arg
50									55						60

Val	Lys	Arg	Ala	Glu	Lys	Val	Gln	Arg	Lys	Phe	Leu	Gly	Arg	Pro	Ile
65									70						80

Glu	Val	Trp	Lys	Leu	Tyr	Phe	Thr	His	Pro	Gln	Asp	Val	Pro	Ala	Ile
85									90						95

Arg	Asp	Lys	Ile	Arg	Ala	His	Pro	Ala	Val	Ile	Asp	Ile	Tyr	Glu	Tyr
100									105						110

Asp	Ile	Pro	Phe	Ala	Lys	Arg	Tyr	Leu	Ile	Asp	Lys	Gly	Leu	Ile	Pro
115									120						125

Met	Glu	Gly	Asp	Glu	Glu	Leu	Thr	Met	Leu	Ala	Phe	Asp	Ile	Glu	Thr
130									135						140

Leu	Tyr	His	Glu	Gly	Glu	Glu	Phe	Gly	Thr	Gly	Pro	Ile	Leu	Met	Ile
145									150						160

Ser	Tyr	Ala	Asp	Gly	Ser	Glu	Ala	Arg	Val	Ile	Thr	Trp	Lys	Ile	
165									170						175

Asp	Leu	Pro	Tyr	Val	Asp	Val	Val	Ser	Thr	Glu	Lys	Met	Ile	Lys	
180									185						190

Arg	Phe	Leu	Arg	Ile	Val	Lys	Glu	Lys	Asp	Pro	Asp	Val	Leu	Ile	Thr
195									200						205

Tyr	Asn	Gly	Asp	Asn	Phe	Asp	Phe	Ala	Tyr	Leu	Lys	Lys	Arg	Cys	Glu
210									215						220

Lys	Leu	Gly	Ile	Lys	Phe	Thr	Leu	Gly	Arg	Asp	Gly	Ser	Glu	Pro	Lys
225									230						240

Ile	Gln	Arg	Met	Gly	Asp	Arg	Phe	Ala	Val	Glu	Val	Lys	Gly	Arg	Ile
245									250						255

His	Phe	Asp	Leu	Tyr	Pro	Val	Ile	Arg	Arg	Thr	Ile	Asn	Leu	Pro	Thr
260									265						270

Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Val	Phe	Gly	Lys	Pro	Lys	Glu
275									280						285

Lys	Val	Tyr	Ala	Glu	Glu	Ile	Ala	Gln	Ala	Trp	Glu	Ser	Gly	Glu	Gly
290									295						300

Leu	Glu	Arg	Val	Ala	Arg	Tyr	Ser	Met	Glu	Asp	Ala	Lys	Val	Thr	Tyr
305									310						320

-continued

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
325 330 335

Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
340 345 350

Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
355 360 365

Pro Asn Lys Pro Asp Glu Lys Glu Leu Ala Arg Arg Arg Gly Tyr
370 375 380

Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
385 390 395 400

Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
405 410 415

Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp
420 425 430

Val Ala Pro Glu Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly Phe
435 440 445

Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Ile Lys
450 455 460

Arg Lys Met Lys Ala Thr Val Asp Pro Leu Glu Lys Lys Leu Leu Asp
465 470 475 480

Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
485 490 495

Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Arg Glu Cys Ala Glu Ser
500 505 510

Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Thr Thr Ile Arg Glu Ile
515 520 525

Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
530 535 540

Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
545 550 555 560

Lys Glu Phe Leu Lys Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu Glu
565 570 575

Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys Lys
580 585 590

Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
595 600 605

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
610 615 620

Arg Val Leu Glu Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val
625 630 635 640

Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Asp Leu Arg Asp
660 665 670

Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala
675 680 685

Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
705 710 715 720

Asp Pro Thr Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

-continued

Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Arg Lys
740 745 750

Glu Asp Leu Arg Tyr Gln Lys Thr Lys Gln Val Gly Leu Gly Ala Trp
755 760 765

Leu Lys Val Lys Lys
770

<210> SEQ_ID NO 43

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Thermococcus hydrothermalis

<400> SEQUENCE: 43

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile
1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
20 25 30

Glu Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35 40 45

Glu Glu Val Lys Lys Ile Thr Ala Gly Arg His Gly Arg Val Val Lys
50 55 60

Val Lys Arg Ala Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Glu Ile Arg Arg His Ser Ala Val Val Asp Ile Tyr Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Asp Glu Glu Leu Lys Met Met Ser Phe Asp Ile Glu Thr
130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Gly Thr Gly Pro Ile Leu Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Gly Glu Ala Arg Val Ile Thr Trp Lys Lys Ile
165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ser Thr Glu Lys Glu Met Ile Lys
180 185 190

Arg Phe Leu Lys Val Val Lys Glu Asp Pro Asp Val Leu Ile Thr
195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
210 215 220

Lys Ile Gly Ile Lys Phe Thr Leu Arg Arg Asp Gly Ser Glu Pro Lys
225 230 235 240

Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Thr Pro Lys Glu
275 280 285

Lys Val Tyr Pro Glu Glu Ile Thr Thr Ala Trp Glu Thr Gly Glu Gly
290 295 300

Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
305 310 315 320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
325 330 335

-continued

Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
340 345 350

Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Ile Ala
355 360 365

Pro Asn Lys Pro Asp Glu Arg Glu Leu Ala Arg Arg Arg Gly Tyr
370 375 380

Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
385 390 395 400

Val Tyr Leu Asp Phe Met Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
405 410 415

Asn Val Ser Pro Asp Thr Phe Asn Arg Glu Gly Cys Lys Glu Tyr Asp
420 425 430

Thr Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Val Gln Gly Phe
435 440 445

Ile Pro Ser Leu Leu Gly Ala Leu Leu Asp Glu Arg Gln Lys Ile Lys
450 455 460

Lys Arg Met Lys Ala Ser Ile Asp Pro Leu Glu Lys Lys Leu Leu Asp
465 470 475 480

Tyr Arg Gln Lys Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
485 490 495

Tyr Gly Tyr Ala Arg Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
500 505 510

Val Thr Ala Trp Gly Arg Asp Tyr Ile Glu Thr Thr Ile His Glu Ile
515 520 525

Glu Glu Arg Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
530 535 540

Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Ala
545 550 555 560

Lys Glu Phe Leu Lys Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu Glu
565 570 575

Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys Lys
580 585 590

Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
595 600 605

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
610 615 620

Arg Val Leu Glu Ala Ile Leu Arg His Gly Asp Val Glu Glu Ala Val
625 630 635 640

Arg Ile Val Lys Asp Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Glu Leu Lys Asp
660 665 670

Tyr Lys Ala Thr Gly Pro His Val Ala Ile Ala Lys Arg Leu Ala Ala
675 680 685

Arg Gly Ile Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
705 710 715 720

Asp Pro Thr Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys Lys
740 745 750

-continued

Glu Glu Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp
755 760 765

Leu Lys Leu Lys Gly Lys Lys
770 775

<210> SEQ ID NO 44

<211> LENGTH: 774

<212> TYPE: PRT

<213> ORGANISM: Thermococcus thioreducens

<400> SEQUENCE: 44

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Val
1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
20 25 30

Glu Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Ala Ile
35 40 45

Glu Glu Ile Lys Lys Ile Thr Ala Asp Arg His Gly Lys Val Val Lys
50 55 60

Val Lys Arg Ala Glu Lys Val Gln Lys Lys Phe Leu Gly Arg Pro Ile
65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Glu Ile Arg Lys His Pro Ala Val Val Asp Ile Tyr Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr
130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Gly Thr Gly Pro Ile Leu Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Asp Gly Ala Arg Val Ile Thr Trp Lys Lys Ile
165 170 175

Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
180 185 190

Arg Phe Leu Lys Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
210 215 220

Lys Leu Gly Ile Lys Phe Thr Leu Gly Arg Asp Gly Ser Glu Pro Lys
225 230 235 240

Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Tyr Pro Leu Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Lys Pro Lys Glu
275 280 285

Lys Val Tyr Ala Glu Glu Ile Ala Leu Ala Trp Glu Ser Gly Glu Gly
290 295 300

Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Phe
305 310 315 320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
325 330 335

Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
340 345 350

-continued

Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
355 360 365

Pro Asn Lys Pro Asn Glu Arg Glu Leu Ala Arg Arg Arg Gly Gly Tyr
370 375 380

Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
385 390 395 400

Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
405 410 415

Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp
420 425 430

Arg Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Val Pro Gly Phe
435 440 445

Ile Pro Ser Leu Leu Gly Ser Leu Leu Asp Glu Arg Gln Lys Ile Lys
450 455 460

Arg Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Lys Lys Leu Leu Asp
465 470 475 480

Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
485 490 495

Tyr Gly Tyr Ala Arg Ala Arg Trp Tyr Cys Arg Glu Cys Ala Glu Ser
500 505 510

Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Met Ala Ile Arg Glu Leu
515 520 525

Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Leu
530 535 540

His Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
545 550 555 560

Met Glu Phe Leu Lys Tyr Ile Asn Pro Lys Leu Pro Gly Leu Leu Glu
565 570 575

Leu Glu Tyr Glu Gly Phe Tyr Ala Arg Gly Phe Phe Val Thr Lys Lys
580 585 590

Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
595 600 605

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
610 615 620

Arg Val Leu Glu Ala Ile Leu Arg His Gly Asp Val Glu Glu Ala Val
625 630 635 640

Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Glu Leu Lys Asp
660 665 670

Tyr Arg Ala Thr Gly Pro His Val Ala Ile Ala Lys Arg Leu Ala Lys
675 680 685

Arg Gly Ile Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
705 710 715 720

Asp Pro Thr Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Val Leu Lys Ala Phe Gly Tyr Arg Lys
740 745 750

Asp Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp
755 760 765

-continued

Leu Lys Val Lys Lys Arg
770

```

<210> SEQ ID NO 45
<211> LENGTH: 773
<212> TYPE: PRT
<213> ORGANISM: Thermococcus waiotapuensis

<400> SEQUENCE: 45

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile
1           5          10          15

Arg Val Phe Lys Lys Glu Lys Gly Glu Phe Lys Ile Asn Tyr Asp Arg
20          25          30

Asp Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35          40          45

Glu Asp Ile Lys Lys Ile Thr Ala Glu Arg His Gly Thr Thr Val Arg
50          55          60

Val Thr Arg Ala Glu Arg Val Lys Lys Phe Leu Gly Arg Pro Val
65          70          75          80

Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
85          90          95

Arg Asp Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Tyr Glu Tyr
100         105         110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115         120         125

Met Glu Gly Asn Glu Glu Leu Arg Met Leu Ala Phe Asp Ile Glu Thr
130         135         140

Leu Tyr His Glu Gly Glu Phe Gly Glu Gly Pro Ile Leu Met Ile
145         150         155         160

Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Ile
165         170         175

Asp Leu Pro Tyr Val Glu Ser Val Ser Thr Glu Lys Glu Met Ile Lys
180         185         190

Arg Phe Leu Lys Val Ile Gln Glu Lys Asp Pro Asp Val Leu Ile Thr
195         200         205

Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Ser Glu
210         215         220

Thr Leu Gly Val Lys Phe Ile Leu Gly Arg Asp Gly Ser Glu Pro Lys
225         230         235         240

Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
245         250         255

His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260         265         270

Tyr Thr Leu Glu Thr Val Tyr Glu Ala Ile Phe Gly Gln Pro Lys Glu
275         280         285

Lys Val Tyr Ala Glu Glu Ile Ala Gln Ala Trp Glu Ser Gly Glu Gly
290         295         300

Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Ala Thr Tyr
305         310         315         320

Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
325         330         335

Val Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
340         345         350

Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
355         360         365

```

-continued

Pro Asn Lys Pro Asp Glu Arg Glu Leu Ala Arg Arg Ala Glu Ser Tyr
 370 375 380
 Ala Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Tyr Lys Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415
 Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Arg Glu Tyr Asp
 420 425 430
 Val Ala Pro Gln Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly Phe
 435 440 445
 Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Val Lys
 450 455 460
 Lys Lys Met Lys Ala Thr Val Asp Pro Ile Glu Arg Lys Leu Leu Asp
 465 470 475 480
 Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
 485 490 495
 Tyr Gly Tyr Ala Asn Ala Arg Trp Tyr Cys Arg Glu Cys Ala Glu Ser
 500 505 510
 Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Thr Thr Met Arg Glu Ile
 515 520 525
 Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
 530 535 540
 Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Thr
 545 550 555 560
 Lys Glu Phe Leu Asn Tyr Ile Asn Pro Arg Leu Pro Gly Leu Leu Glu
 565 570 575
 Leu Glu Tyr Glu Gly Phe Tyr Arg Arg Gly Phe Phe Val Thr Lys Lys
 580 585 590
 Lys Tyr Ala Val Ile Asp Glu Glu Asp Lys Ile Thr Thr Arg Gly Leu
 595 600 605
 Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
 610 615 620
 Arg Val Leu Glu Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val
 625 630 635 640
 Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Arg Tyr Glu Val Pro
 645 650 655
 Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Asn Leu Arg Asp
 660 665 670
 Tyr Arg Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala
 675 680 685
 Arg Gly Ile Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
 690 695 700
 Lys Gly Pro Gly Arg Val Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
 705 710 715 720
 Asp Pro Ala Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
 725 730 735
 Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys
 740 745 750
 Glu Asp Leu Arg Tyr Gln Lys Thr Lys Gln Ala Gly Leu Gly Ala Trp
 755 760 765
 Leu Lys Pro Lys Thr
 770

125

126

-continued

<210> SEQ ID NO 46
 <211> LENGTH: 774
 <212> TYPE: PRT
 <213> ORGANISM: Thermococcus sibiricus

 <400> SEQUENCE: 46

Met	Ile	Leu	Gly	Ala	Asp	Tyr	Ile	Thr	Lys	Asp	Gly	Lys	Pro	Ile	Val
1				5					10					15	
Arg	Ile	Phe	Lys	Lys	Glu	Asn	Gly	Glu	Phe	Lys	Ile	Glu	Leu	Asp	Pro
		20						25					30		
His	Phe	Gln	Pro	Tyr	Ile	Tyr	Ala	Leu	Leu	Ser	Glu	Asp	Ser	Ala	Ile
		35					40					45			
Asp	Glu	Ile	Lys	Gln	Ile	Lys	Gly	Glu	Arg	His	Gly	Lys	Thr	Val	Arg
		50				55				60					
Ile	Val	Asp	Ala	Val	Lys	Val	Glu	Lys	Phe	Leu	Lys	Lys	Pro	Val	
		65			70			75					80		
Lys	Val	Trp	Lys	Leu	Ile	Leu	Glu	His	Pro	Gln	Asp	Val	Pro	Ala	Ile
		85				90							95		
Arg	Asn	Lys	Ile	Arg	Glu	His	Pro	Ala	Val	Gln	Asp	Ile	Tyr	Glu	Tyr
		100				105							110		
Asp	Ile	Pro	Phe	Ala	Lys	Arg	Tyr	Leu	Ile	Asp	Asn	Gly	Leu	Ile	Pro
		115				120						125			
Met	Glu	Gly	Asp	Glu	Glu	Leu	Lys	Met	Leu	Ala	Phe	Asp	Ile	Glu	Thr
		130				135						140			
Phe	Tyr	His	Glu	Gly	Asp	Glu	Phe	Gly	Lys	Gly	Glu	Ile	Ile	Met	Ile
		145			150				155				160		
Ser	Tyr	Ala	Asp	Glu	Glu	Gly	Ala	Arg	Val	Ile	Thr	Trp	Lys	Asn	Ile
		165				170						175			
Asp	Leu	Pro	Tyr	Val	Asp	Val	Val	Ser	Asn	Glu	Arg	Met	Ile	Lys	
		180				185						190			
Arg	Phe	Ile	Gln	Ile	Ile	Lys	Glu	Lys	Asp	Pro	Asp	Val	Ile	Ile	Thr
		195				200						205			
Tyr	Asn	Gly	Asp	Asn	Phe	Asp	Leu	Pro	Tyr	Leu	Ile	Lys	Arg	Ala	Glu
		210				215						220			
Lys	Leu	Gly	Leu	Arg	Leu	Ile	Leu	Ser	Arg	Asp	Asn	Glu	Asn	Pro	Val
		225			230				235				240		
Pro	Lys	Ile	Gln	Arg	Met	Gly	Asn	Ser	Phe	Ala	Val	Glu	Ile	Lys	Gly
			245				250					255			
Arg	Ile	His	Phe	Asp	Leu	Phe	Pro	Val	Val	Lys	Arg	Ala	Val	Asn	Leu
		260				265						270			
Pro	Thr	Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Thr	Val	Leu	Gly	Lys	His
		275			280							285			
Lys	Ser	Lys	Leu	Gly	Ala	Glu	Glu	Ile	Ala	Ala	Ile	Trp	Glu	Thr	Glu
		290				295					300				
Glu	Gly	Leu	Lys	Lys	Leu	Ala	Gln	Tyr	Ser	Met	Glu	Asp	Ala	Lys	Ala
		305				310				315				320	
Thr	Tyr	Glu	Leu	Gly	Arg	Glu	Phe	Phe	Pro	Met	Glu	Val	Glu	Leu	Ala
			325				330						335		
Lys	Leu	Ile	Gly	Gln	Ser	Val	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly
			340				345						350		
Asn	Leu	Val	Glu	Trp	Tyr	Met	Leu	Arg	Val	Ala	Tyr	Glu	Arg	Asn	Glu
			355				360						365		
Leu	Ala	Pro	Asn	Arg	Pro	Ser	Asp	Glu	Glu	Tyr	Lys	Arg	Arg	Leu	Arg
			370			375						380			

-continued

Thr Thr Tyr Leu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp
 385 390 395 400
 Glu Asn Ile Ile Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile
 405 410 415
 Val Thr His Asn Val Ser Pro Asp Thr Leu Glu Arg Lys Gly Cys Gln
 420 425 430
 Asn Tyr Asp Val Ala Pro Ile Val Gly Tyr Lys Phe Cys Lys Asp Phe
 435 440 445
 Ser Gly Phe Ile Pro Ser Ile Leu Glu Asp Leu Ile Glu Thr Arg Gln
 450 455 460
 Lys Ile Lys Lys Glu Met Lys Ser Thr Ile Asp Pro Ile Lys Lys Lys
 465 470 475 480
 Met Leu Asp Tyr Arg Gln Arg Ala Val Lys Leu Leu Ala Asn Ser Tyr
 485 490 495
 Tyr Gly Tyr Met Gly Tyr Pro Lys Ala Arg Trp Tyr Ser Lys Glu Cys
 500 505 510
 Ala Glu Ser Val Thr Ala Trp Gly Arg His Tyr Ile Glu Met Thr Ile
 515 520 525
 Arg Glu Ile Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr
 530 535 540
 Asp Gly Phe Tyr Ala Thr Ile Pro Gly Ala Asp Pro Glu Thr Ile Lys
 545 550 555 560
 Lys Lys Ala Lys Glu Phe Leu Asn Tyr Ile Asn Ser Lys Leu Pro Gly
 565 570 575
 Leu Leu Glu Leu Glu Tyr Glu Gly Phe Tyr Leu Arg Gly Phe Phe Val
 580 585 590
 Thr Lys Lys Arg Tyr Ala Val Ile Asp Glu Glu Glu Lys Ile Thr Thr
 595 600 605
 Arg Gly Leu Glu Val Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu
 610 615 620
 Thr Gln Ala Arg Val Leu Glu Ala Ile Leu Arg Glu Gly Ser Val Glu
 625 630 635 640
 Lys Ala Val Glu Ile Val Lys Glu Val Val Glu Ala Ile Thr Lys Tyr
 645 650 655
 Lys Val Pro Leu Glu Lys Leu Ile Ile His Glu Gln Ile Thr Arg Glu
 660 665 670
 Leu Arg Asp Tyr Lys Ala Val Gly Pro His Val Ala Ile Ala Lys Arg
 675 680 685
 Leu Ala Ala Lys Gly Ile Lys Ile Lys Pro Gly Thr Ile Ile Ser Tyr
 690 695 700
 Ile Val Leu Arg Gly Ser Gly Lys Ile Ser Asp Arg Val Val Leu Leu
 705 710 715 720
 Thr Glu Tyr Asp Pro Arg Lys His Lys Tyr Asp Pro Asp Tyr Tyr Ile
 725 730 735
 Glu Asn Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly
 740 745 750
 Tyr Arg Lys Glu Asp Leu Lys Tyr Gln Ser Ser Lys Gln Thr Gly Leu
 755 760 765
 Glu Ser Trp Leu Lys Lys
 770

US 9,447,445 B2

129

130

-continued

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus glycovorans

<400> SEQUENCE: 47

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile			
1	5	10	15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg		
20	25	30

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Gln Ile		
35	40	45

Asp Glu Val Lys Lys Ile Thr Ala Glu Arg His Gly Lys Ile Val Arg		
50	55	60

Ile Val Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile			
65	70	75	80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Ile		
85	90	95

Arg Asp Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr		
100	105	110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro		
115	120	125

Met Glu Gly Asp Glu Glu Leu Lys Leu Leu Ala Phe Asp Ile Glu Thr		
130	135	140

Leu Tyr His Glu Gly Glu Glu Phe Ala Lys Gly Pro Ile Ile Met Ile			
145	150	155	160

Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Val		
165	170	175

Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys		
180	185	190

Arg Phe Leu Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr		
195	200	205

Tyr Asn Gly Asp Ser Phe Asp Leu Pro Tyr Leu Val Lys Arg Ala Glu		
210	215	220

Lys Leu Gly Ile Lys Leu Pro Leu Gly Arg Asp Gly Ser Glu Pro Lys			
225	230	235	240

Met Gln Arg Leu Gly Asp Met Thr Ala Val Glu Ile Lys Gly Arg Ile		
245	250	255

His Phe Asp Leu Tyr His Val Ile Arg Arg Thr Ile Asn Leu Pro Thr		
260	265	270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu		
275	280	285

Lys Val Tyr Ala His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly		
290	295	300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr			
305	310	315	320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu		
325	330	335

Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu		
340	345	350

Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala		
355	360	365

Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser		
370	375	380

Tyr Ala Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Gly			
385	390	395	400

Leu Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415
 His Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Met Glu Tyr
 420 425 430
 Asp Val Ala Pro Glu Val Lys His Lys Phe Cys Lys Asp Phe Pro Gly
 435 440 445
 Phe Ile Pro Ser Leu Leu Lys Arg Leu Leu Asp Glu Arg Gln Glu Ile
 450 455 460
 Lys Arg Arg Met Lys Ala Ser Lys Asp Pro Ile Glu Lys Lys Met Leu
 465 470 475 480
 Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly
 485 490 495
 Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
 500 505 510
 Ser Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Phe Val Arg Lys Glu
 515 520 525
 Leu Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly
 530 535 540
 Leu Tyr Ala Thr Ile Pro Gly Ala Lys Pro Glu Glu Ile Lys Arg Lys
 545 550 555 560
 Ala Leu Glu Phe Val Glu Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu
 565 570 575
 Glu Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys
 580 585 590
 Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Ile Thr Arg Gly
 595 600 605
 Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
 610 615 620
 Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
 625 630 635 640
 Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Ile
 645 650 655
 Pro Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu His
 660 665 670
 Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
 675 680 685
 Ala Arg Gly Val Lys Val Arg Pro Gly Met Val Ile Gly Tyr Ile Val
 690 695 700
 Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Leu Ala Glu Glu
 705 710 715 720
 Phe Asp Pro Arg Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
 725 730 735
 Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly Tyr Arg
 740 745 750
 Lys Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Thr Gly Leu Thr Ala
 755 760 765
 Trp Leu Asn Val Lys Lys Lys
 770 775

<210> SEQ ID NO 48
 <211> LENGTH: 775
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus sp. NA2

-continued

<400> SEQUENCE: 48

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
 1 5 10 15

Arg Leu Phe Lys Lys Glu Asn Gly Arg Phe Lys Val Glu Tyr Asp Arg
 20 25 30

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45

Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg
 50 55 60

Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Met
 85 90 95

Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
 100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125

Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
 130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
 145 150 155 160

Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile
 165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ala Asn Glu Arg Glu Met Ile Lys
 180 185 190

Arg Leu Ile Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
 210 215 220

Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys
 225 230 235 240

Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
 245 250 255

His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu
 275 280 285

Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
 290 295 300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320

Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
 325 330 335

Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350

Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365

Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380

Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly
 385 390 395 400

Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415

US 9,447,445 B2

135

136

-continued

His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr
 420 425 430
 Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
 435 440 445
 Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Glu Arg Gln Lys Ile
 450 455 460
 Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu
 465 470 475 480
 Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly
 485 490 495
 Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
 500 505 510
 Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu
 515 520 525
 Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
 530 535 540
 Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg
 545 550 555 560
 Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu
 565 570 575
 Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys
 580 585 590
 Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly
 595 600 605
 Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
 610 615 620
 Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
 625 630 635 640
 Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile
 645 650 655
 Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn
 660 665 670
 Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
 675 680 685
 Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val
 690 695 700
 Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu
 705 710 715 720
 Phe Asp Gly Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
 725 730 735
 Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys
 740 745 750
 Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala
 755 760 765
 Trp Leu Lys Val Lys Lys Ser
 770 775

<210> SEQ_ID NO 49
 <211> LENGTH: 785
 <212> TYPE: PRT
 <213> ORGANISM: Ferroglobus placidus

<400> SEQUENCE: 49

Met Glu Gly Trp Leu Leu Asp Ala Asp Tyr Ile Thr Ala Glu Asp Gly

US 9,447,445 B2

137

138

-continued

1	5	10	15
Arg Ala Val Val Arg Leu Trp Cys Lys Asp Phe Asp Gly Asn Thr Phe			
20	25	30	
Val Val Tyr Asp Arg Asn Phe Gln Pro Tyr Phe Tyr Ala Phe Lys Asn			
35	40	45	
Gly Leu Ser Lys Glu Asp Ile Glu Lys Ile Val Val Lys Ser Arg Glu			
50	55	60	
Gly Val Ile Lys Pro Phe Lys Val Glu Val Arg Arg Lys Val Phe			
65	70	75	80
Gly Lys Glu Val Glu Val Phe Lys Ile Tyr Ala Tyr His Pro Gln His			
85	90	95	
Val Pro Lys Leu Arg Glu Glu Leu Lys Ile Thr Glu Val Arg Glu			
100	105	110	
Ala Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala			
115	120	125	
Cys Met Asp Gly Ile Arg Val Glu Gly Lys Val Arg Glu Glu Arg Gly			
130	135	140	
Leu Lys Val Ile Asp Ala Glu His Val Glu Arg Phe Glu Ile Pro Leu			
145	150	155	160
Pro Glu Pro Lys Val Leu Ala Phe Asp Cys Glu Met Leu Thr Glu Leu			
165	170	175	
Gly Met Pro Asp Pro Glu Lys Asp Lys Ile Ile Ile Gly Val Lys			
180	185	190	
Cys Gly Asp Phe Glu Glu Ile Ile Thr Gly Asn Glu Arg Glu Ile Leu			
195	200	205	
Leu Arg Phe Val Glu Ile Ile Lys Glu Gln Asp Pro Asp Val Ile Val			
210	215	220	
Gly Tyr Asn Gln Asp Asn Phe Asp Trp Pro Tyr Ile Arg Lys Arg Ala			
225	230	235	240
Glu Lys Leu Ser Val Lys Leu Asn Ile Gly Arg Asp Gly Ser Glu Ile			
245	250	255	
Ser Phe Arg Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp			
260	265	270	
Leu Tyr Asp Ile Ala Met Lys Leu Asp Val Lys Val Lys Thr Leu Glu			
275	280	285	
Asn Val Ala Glu Phe Leu Gly Arg Lys Val Glu Leu Ala Asp Ile Glu			
290	295	300	
Ala Lys Asp Ile Tyr Lys Arg Trp Thr Ser Gly Asp Lys Glu Ser Val			
305	310	315	320
Leu Lys Tyr Ser Lys Gln Asp Val Leu Asn Thr Tyr Phe Ile Ala Glu			
325	330	335	
Glu Leu Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Ile Pro			
340	345	350	
Thr Asp Asp Val Ala Arg Ile Gly Arg Gly Lys Gln Val Asp Trp Phe			
355	360	365	
Leu Leu Ser Glu Ala Tyr Lys Ile Gly Glu Ile Ala Pro Asn Pro Ala			
370	375	380	
Glu Val Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ser Arg			
385	390	395	400
Gly Leu His Lys Asn Val Val Cys Leu Asp Phe Ala Ser Met Tyr Pro			
405	410	415	
Ser Ile Met Ile Ala Tyr Asn Ile Ser Pro Asp Thr Tyr Val Phe Gly			
420	425	430	

US 9,447,445 B2

139

140

-continued

Lys Cys Asp Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg
435 440 445

Lys His Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu
450 455 460

Lys Arg Arg Glu Ile Lys Asn Gln Met Lys Ser Leu Asp Arg Asn Ser
465 470 475 480

Arg Glu Tyr Leu Leu Asn Ile Lys Gln Gln Thr Leu Lys Ile Leu
485 490 495

Thr Asn Ser Phe Tyr Gly Tyr Thr Gly Trp Ser Gly Ala Arg Trp Tyr
500 505 510

Cys Arg Gln Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Leu Ile
515 520 525

Lys Ser Ala Val Glu Ile Ala Lys Lys Leu Gly Phe Glu Val Leu Tyr
530 535 540

Gly Asp Thr Asp Ser Ile Phe Val Lys Lys Gly Asn Leu Ser Leu Glu
545 550 555 560

Lys Ile Arg Gly Glu Val Glu Lys Leu Ile Glu Glu Ile Ser Glu Lys
565 570 575

Phe Pro Val Gln Ile Glu Val Asp Glu Tyr Tyr Lys Thr Ile Phe Phe
580 585 590

Val Glu Lys Lys Arg Tyr Ala Gly Leu Thr Glu Asp Gly Ile Leu Val
595 600 605

Val Lys Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys
610 615 620

Glu Val Gln Lys Lys Val Ile Glu Ile Ile Leu Lys Glu Glu Asn Pro
625 630 635 640

Glu Lys Ala Ala Glu Tyr Val Arg Lys Val Ile Asn Asp Ile Lys Ser
645 650 655

Gly Lys Val Lys Leu Glu Asp Val Val Ile Tyr Lys Gly Leu Thr Lys
660 665 670

Arg Pro Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu
675 680 685

Arg Ala Met Glu Leu Gly Ile Val Tyr Asn Val Gly Ser Lys Val Gly
690 695 700

Phe Val Val Val Glu Gly Ala Gly Asn Val Gly Asp Arg Ala Tyr Pro
705 710 715 720

Ile Asp Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Val Ile Arg Thr
725 730 735

Arg Ser Gly Ser Ile Val Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asn
740 745 750

His Gln Ile Ile Pro Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr
755 760 765

Asn Glu Ala Ser Leu Lys Gly Ala Thr Gln Lys Thr Leu Asp Ala Phe
770 775 780

Trp
785

<210> SEQ_ID NO 50
<211> LENGTH: 775
<212> TYPE: PRT
<213> ORGANISM: Palaeococcus ferrophilus

<400> SEQUENCE: 50

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asn Gly Lys Pro Val Val

US 9,447,445 B2

141**142**

-continued

1	5	10	15		
Arg	Ile	Phe	Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg		
		20	25	30	
Asn	Phe	Glu Pro Tyr Ile Tyr Ala	Leu Leu Lys Asp Asp Ser Ala Ile		
		35	40	45	
Glu	Glu Ile Lys Lys Ile Thr Ala Glu Arg His Gly Thr Val Val Arg				
		50	55	60	
Ile	Thr Lys Ala Glu Lys Val Glu Arg Lys Phe Leu Gly Arg Pro Val				
		65	70	75	80
Glu	Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile				
		85	90	95	
Arg	Asp Lys Ile Arg Ser His Pro Ala Val Val Asp Ile Tyr Glu Tyr				
		100	105	110	
Asp	Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Val Pro				
		115	120	125	
Met	Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr				
		130	135	140	
Leu	Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile				
		145	150	155	160
Ser	Tyr Ala Asp Glu Ser Glu Ala Arg Val Ile Thr Trp Lys Lys Val				
		165	170	175	
Asp	Leu Pro Tyr Val Asp Ala Val Ser Thr Glu Lys Asp Met Ile Lys				
		180	185	190	
Ala	Phe Leu Arg Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr				
		195	200	205	
Tyr	Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu				
		210	215	220	
Lys	Leu Gly Val Lys Phe Ile Leu Gly Arg Asp Gly Ser Glu Pro Lys				
		225	230	235	240
Ile	Gln Arg Met Gly Asp Arg Phe Ala Val Asp Val Lys Gly Arg Ile				
		245	250	255	
His	Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr				
		260	265	270	
Tyr	Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Arg Pro Lys Glu				
		275	280	285	
Lys	Val Tyr Ala Glu Glu Ile Ala Gln Ala Trp Glu Thr Asn Glu Gly				
		290	295	300	
Leu	Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr				
		305	310	315	320
Glu	Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu				
		325	330	335	
Ile	Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu				
		340	345	350	
Val	Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala				
		355	360	365	
Pro	Asn Lys Pro Ser Gly Arg Glu Tyr Asp Glu Arg Arg Gly Gly Tyr				
		370	375	380	
Ala	Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Asn Ile				
		385	390	395	400
Val	Tyr Leu Asp Tyr Lys Ser Leu Tyr Pro Ser Ile Ile Ile Thr His				
		405	410	415	
Asn	Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp				
		420	425	430	

-continued

Val Ala Pro Gln Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly Phe
435 440 445

Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Ile Lys
450 455 460

Arg Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Arg Arg Leu Leu Asp
465 470 475 480

Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
485 490 495

Tyr Gly Tyr Ala Arg Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
500 505 510

Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Met Ser Ile Arg Glu Ile
515 520 525

Glu Glu Lys Tyr Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
530 535 540

His Ala Thr Ile Pro Gly Glu Asp Ala Glu Thr Ile Lys Lys Lys Ala
545 550 555 560

Met Glu Phe Leu Lys Tyr Ile Asn Ser Lys Leu Pro Gly Ala Leu Glu
565 570 575

Leu Glu Tyr Glu Gly Phe Tyr Arg Arg Gly Phe Phe Val Thr Lys Lys
580 585 590

Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
595 600 605

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
610 615 620

Arg Val Leu Glu Ala Leu Leu Lys Asp Gly Asn Val Glu Glu Ala Val
625 630 635 640

Ser Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Glu Leu Lys Asp
660 665 670

Tyr Lys Ala Thr Gly Pro His Val Ala Ile Ala Lys Arg Leu Ala Ala
675 680 685

Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
705 710 715 720

Asp Pro Ala Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Arg Lys
740 745 750

Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp
755 760 765

Leu Lys Pro Lys Gly Lys Lys
770 775

<210> SEQ ID NO 51

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Thermococcus gammatolerans

<400> SEQUENCE: 51

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asn Gly Lys Pro Val Ile
1 5 10 15

Arg Val Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg

US 9,447,445 B2

145

-continued

146

20	25	30
Thr Phe Glu Pro Tyr Phe Tyr Ala Leu	Leu Lys Asp Asp Ser Ala Ile	
35	40	45
Glu Asp Val Lys Lys Val Thr Ala Lys Arg His Gly Ala Val Val Lys		
50	55	60
Val Lys Arg Ala Glu Lys Val Gln Arg Lys Phe Leu Gly Arg Pro Ile		
65	70	75
Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile		
85	90	95
Arg Asp Lys Ile Arg Ala His Pro Ala Val Val Asp Ile Tyr Glu Tyr		
100	105	110
Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro		
115	120	125
Met Glu Gly Asp Glu Glu Leu Arg Met Leu Ala Phe Asp Ile Glu Thr		
130	135	140
Leu Tyr His Glu Gly Glu Glu Phe Gly Thr Gly Pro Ile Leu Met Ile		
145	150	155
Ser Tyr Ala Asp Glu Asn Glu Ala Arg Val Ile Thr Trp Lys Lys Ile		
165	170	175
Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys		
180	185	190
Arg Phe Leu Arg Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr		
195	200	205
Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu		
210	215	220
Lys Leu Gly Ile Lys Phe Thr Leu Gly Arg Asp Gly Ser Glu Pro Lys		
225	230	235
Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile		
245	250	255
His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr		
260	265	270
Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Lys Pro Lys Glu		
275	280	285
Lys Val Tyr Ala Glu Glu Ile Thr Glu Ala Trp Glu Ser Gly Glu Gly		
290	295	300
Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr		
305	310	315
Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu		
325	330	335
Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu		
340	345	350
Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala		
355	360	365
Pro Asn Lys Pro Asp Glu Arg Glu Leu Ala Arg Arg Glu Ser Tyr		
370	375	380
Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile		
385	390	395
Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His		
405	410	415
Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp		
420	425	430
Val Ala Pro Glu Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly Phe		
435	440	445

-continued

Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Ile Lys
450 455 460

Arg Lys Met Lys Ala Thr Ile Asp Pro Leu Glu Lys Lys Leu Leu Asp
465 470 475 480

Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly Tyr
485 490 495

Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
500 505 510

Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Thr Thr Ile Arg Glu Ile
515 520 525

Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
530 535 540

Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
545 550 555 560

Lys Glu Phe Leu Lys Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu Glu
565 570 575

Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys Lys
580 585 590

Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
595 600 605

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
610 615 620

Arg Val Leu Glu Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val
625 630 635 640

Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Asp Leu Arg Asp
660 665 670

Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala
675 680 685

Lys Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Ala Asp Glu Phe
705 710 715 720

Asp Pro Thr Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Arg Lys
740 745 750

Glu Asp Leu Arg Tyr Gln Lys Thr Lys Gln Val Gly Leu Gly Ala Trp
755 760 765

Leu Lys Val Lys Gly Lys Lys
770 775

<210> SEQ ID NO 52

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Thermococcus celericrescens

<400> SEQUENCE: 52

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile
1 5 10 15

Arg Ile Phe Lys Lys Asp Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
20 25 30

Asn Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Ala Ile

US 9,447,445 B2

149**150**

-continued

35 40 45

Glu Asp Val Lys Lys Ile Thr Ala Glu Arg His Gly Arg Val Val Lys
 50 55 60

Val Lys Arg Ala Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Val
 65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Thr Arg Pro Gln Asp Val Pro Ala Ile
 85 90 95

Arg Asp Arg Ile Arg Ala His Pro Ala Val Val Asp Ile Tyr Glu Tyr
 100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Ile Ile Pro
 115 120 125

Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr
 130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile
 145 150 155 160

Ser Tyr Ala Asp Glu Asn Glu Ala Arg Val Ile Thr Trp Lys Lys Ile
 165 170 175

Asp Leu Pro Phe Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
 180 185 190

Arg Phe Leu Lys Val Ile Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
 195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
 210 215 220

Lys Phe Gly Ile Lys Phe Thr Leu Gly Arg Asp Gly Ser Asp Pro Lys
 225 230 235 240

Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
 245 250 255

His Phe Asp Leu Tyr Pro Val Ile Leu Arg Thr Val Asn Leu Pro Thr
 260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Thr Pro Lys Glu
 275 280 285

Lys Val Tyr Pro Glu Glu Ile Thr Thr Ala Trp Glu Thr Gly Glu Gly
 290 295 300

Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Phe
 305 310 315 320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335

Val Gly Gln Ser Phe Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350

Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365

Pro Asn Lys Pro Asp Glu Arg Glu Leu Val Arg Arg Arg Asn Ser Tyr
 370 375 380

Thr Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
 385 390 395 400

Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415

Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp
 420 425 430

Glu Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly Phe
 435 440 445

Ile Pro Ser Leu Leu Gly Asn Leu Leu Asp Glu Arg Gln Lys Ile Lys
 450 455 460

US 9,447,445 B2

151

-continued

Lys Arg Met Lys Ala Thr Ile Asp Pro Leu Glu Lys Lys Leu Leu Asp
465 470 475 480

Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
485 490 495

Tyr Ala Tyr Ala Arg Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
500 505 510

Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Met Ser Ile Arg Glu Ile
515 520 525

Glu Glu Lys Tyr Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
530 535 540

His Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
545 550 555 560

Met Glu Phe Leu Lys Tyr Ile Asn Ala Lys Leu Pro Gly Ala Leu Glu
565 570 575

Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys Lys
580 585 590

Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
595 600 605

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
610 615 620

Arg Val Leu Glu Ala Leu Leu Lys Asp Gly Asn Val Glu Glu Ala Val
625 630 635 640

Ser Ile Val Lys Glu Val Thr Glu Lys Leu Gly Lys Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Glu Leu Lys Asp
660 665 670

Tyr Lys Ala Thr Gly Pro His Val Ala Ile Ala Lys Arg Leu Ala Ala
675 680 685

Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
705 710 715 720

Asp Pro Thr Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Arg Ala
740 745 750

Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Val Trp
755 760 765

Leu Gln Pro Lys Gly Lys Lys
770 775

<210> SEQ ID NO 53
<211> LENGTH: 784
<212> TYPE: PRT
<213> ORGANISM: Vulcanisaeta distributa

<400> SEQUENCE: 53

Met Glu Leu Ala Phe Trp Leu Leu Asp Ile Thr Tyr Gly Val Ile Gly
1 5 10 15

Asn Thr Pro Glu Leu Arg Leu Phe Gly Ile Thr Asp Asp Gly Lys Arg
20 25 30

Val Leu Val Leu Asp Arg Ser Phe Arg Pro Tyr Phe Tyr Val Ile Pro
35 40 45

Ser Gly Asp Val Asn Ala Val Phe Asn Asn Val Lys Arg Lys Leu Glu

152

US 9,447,445 B2

153

-continued

50	55	60
Gly Lys Val Leu Asn Val Glu Val Ile Lys Arg Lys Met Phe Gly Asn		
65	70	75
80		
Glu Val Asp Ala Ile Arg Val Thr Ala Thr Ile Pro Glu Lys Val Arg		
85	90	95
Glu Leu Arg Glu Leu Ala Ala Glu Val Pro Gly Val Glu Asp Val Leu		
100	105	110
Glu Ala Asp Ile Arg Phe Ser Gln Arg Tyr Leu Leu Asp Met Gly Val		
115	120	125
Lys Pro Ser Asn Trp Ile Val Val Asp Gln Cys Glu Glu Val Lys Gly		
130	135	140
Asn Tyr Gln Val Asp Leu Val Cys Leu Ala Lys Ser Arg Pro Arg Met		
145	150	155
160		
Ile Glu Glu His Leu Pro Ser Phe Arg Val Leu Ala Phe Asp Ile		
165	170	175
Glu Val Tyr Asn Pro Arg Gly Met Pro Asn Pro Asp Arg Asp Pro Val		
180	185	190
Ile Ile Ile Ser Thr Met Thr Lys Glu Asp Gly Val Lys Met Phe Val		
195	200	205
Val Asp Asp Asn Lys Asn Asp Ala Lys Ile Ile Arg Glu Phe Leu Asp		
210	215	220
Tyr Phe Arg Lys Tyr Asp Pro Asp Ile Val Val Gly Tyr Asn Asn Asn		
225	230	235
240		
Gly Phe Asp Trp Pro Tyr Leu Val Asn Arg Ser Ser Arg Val Gly Val		
245	250	255
Arg Leu Ala Leu Ser Arg Met Gly Asn Pro Pro Glu Pro Ser Val Tyr		
260	265	270
Gly His Trp Ser Ile Ile Gly Arg Ala Asn Val Asp Leu Tyr Asn Phe		
275	280	285
Ile Glu Glu Ile Ser Glu Ile Lys Val Lys Ser Leu Asp Arg Ala Ala		
290	295	300
Glu Phe Phe Gly Ile Met Lys Arg Ser Glu Arg Val Leu Ile Pro Gly		
305	310	315
320		
His Arg Ile His Glu Tyr Trp Asp Asp Lys Asn Lys Arg Asp Leu Leu		
325	330	335
Leu Lys Tyr Ala Arg Asp Asp Val Val Ser Thr Tyr Gly Leu Ala Glu		
340	345	350
Lys Leu Leu Pro Phe Ala Ile Gln Leu Ser Ser Ile Ser Gly Leu Pro		
355	360	365
Leu Asp Gln Val Gly Ala Ala Ser Val Gly Ala Arg Val Glu Trp Met		
370	375	380
Ile Phe Tyr Glu Ala Val Lys Arg Gly Glu Leu Ala Pro Asn Arg Glu		
385	390	395
400		
Glu Arg Pro Tyr Glu Thr Tyr Lys Gly Ala Val Val Leu Glu Pro Arg		
405	410	415
Pro Gly Leu His Glu Asn Ile Ala Val Ile Asp Phe Ser Ser Met Tyr		
420	425	430
Pro Ser Ile Met Met Lys Tyr Asn Val Ser Pro Asp Thr Leu Val Leu		
435	440	445
Gly Asp Cys Gly Asp Cys Tyr Val Ala Pro Glu Val Asn Tyr Lys Phe		
450	455	460
Arg Arg Ser Pro Glu Gly Leu Tyr Pro Gly Leu Leu Arg Ile Leu Val		
465	470	475
480		

US 9,447,445 B2

155

-continued

Glu Ser Arg Arg Arg Val Arg Asp Leu Met Lys Lys Tyr Pro Glu Asn
 485 490 495
 Ser Pro Glu Trp Val Leu Leu Asn Glu Arg Gln Arg Ala Leu Lys Val
 500 505 510
 Met Ala Asn Ala Met Tyr Gly Tyr Cys Gly Trp Leu Gly Ala Arg Trp
 515 520 525
 Tyr Arg Arg Glu Val Ala Glu Ala Val Thr Ala Trp Gly Arg Asn Leu
 530 535 540
 Leu Arg Thr Val Ile Glu Lys Ala Arg Ser Leu Gly Leu Pro Ile Ile
 545 550 555 560
 Tyr Gly Asp Thr Asp Ser Leu Phe Val Arg Asn Ile Ser Asp Lys Val
 565 570 575
 Asp Ala Leu Ile Asn Tyr Val Asn Asn Glu Leu Gly Phe Glu Val Lys
 580 585 590
 Val Asp Lys Val Tyr Arg Arg Val Leu Phe Thr Glu Ala Lys Lys Arg
 595 600 605
 Tyr Val Gly Leu Thr Val Glu Gly Glu Val Asp Ile Val Gly Phe Glu
 610 615 620
 Ala Val Arg Gly Asp Trp Ala Glu Ile Ala Lys Asp Val Gln Glu Asn
 625 630 635 640
 Val Ala Glu Ile Val Leu Thr Thr Gly Asp Val Gly Lys Ala Ile Ser
 645 650 655
 Tyr Val Lys Ser Val Ile Asp Lys Val Lys Ala Tyr Gln Phe Asp Ile
 660 665 670
 Asp Asp Val Ile Ile Trp Lys Thr Leu Asp Lys Ser Leu Asn Glu Tyr
 675 680 685
 Lys Val Leu Thr Pro His Val Ala Ala Ala Lys Gln Leu Val Glu Ala
 690 695 700
 Gly Tyr Lys Val Gly Lys Gly Asp Met Ile Gly Tyr Val Val Val Lys
 705 710 715 720
 Gly Gly Ala Lys Leu Ala Tyr Lys Val Lys Pro Tyr Ile Leu Ile
 725 730 735
 Lys Asp Ile Arg Glu Val Asp Val Lys Tyr Tyr Val Glu Lys Gln Ile
 740 745 750
 Val Pro Ala Ala Met Arg Ile Leu Glu Val Leu Gly Val Lys Glu Ser
 755 760 765
 Gln Leu Met Glu Gly Lys Ala Gly Lys Ser Ile Leu Asp Tyr Phe Ser
 770 775 780

<210> SEQ ID NO 54

<211> LENGTH: 830

<212> TYPE: PRT

<213> ORGANISM: Methanopyrus kandleri

<400> SEQUENCE: 54

Met Leu Arg Thr Val Trp Val Asp Tyr Ala Arg Lys Gly Glu Pro Asp
 1 5 10 15
 Val Ile Leu Val Gly Arg Arg Glu Asp Gly Asn Pro Ala Ala Leu Val
 20 25 30
 Val Lys Gly Phe Arg Pro Tyr Phe Tyr Ala Glu Val Glu Asp Gly Phe
 35 40 45
 Asp Pro Ser Glu Val Glu Arg Leu Ser Gly Val Val Glu Val Glu Glu
 50 55 60
 Val Leu Leu Glu His Pro Tyr Gly Asp Arg Val Glu Leu Leu Arg

156

US 9,447,445 B2

157

-continued

158

65	70	75	80
Ile Val Ala Thr Tyr Pro Lys Val Val Pro Lys Leu Arg Glu Gln Val			
85	90	95	
Lys Lys Leu Asp Gly Val Lys Glu Val Tyr Glu Ala Asp Ile Pro Phe			
100	105	110	
Val Arg Arg Ala Ala Val Asp Leu Asn Leu Pro Pro Ala Ser Glu Val			
115	120	125	
Asp Val Ser Asp Leu Asp Thr Gly Ser Trp Ser Gly Leu Pro Ala Tyr			
130	135	140	
Phe Ala Asp Val Glu Asp Ala Arg Glu Leu Asp His Arg Pro Tyr Pro			
145	150	155	160
Ile Glu Asp Leu Val Val Ala Ser Phe Asp Leu Glu Val Leu Ala Glu			
165	170	175	
Pro Gly Thr Thr Ile Lys Gly Ala Ser Gly Pro Ile Ile Ile Ser			
180	185	190	
Phe Ala Tyr Ser Thr Pro Asp Gly Glu Arg Arg Asn Tyr Val Ile Thr			
195	200	205	
Trp Lys Gly Glu Asp Glu Ser Phe Glu Val Asp Gly Val Glu Thr Glu			
210	215	220	
Val Ile Val Cys Arg Ser Glu Ala Ala Ala Leu Arg Arg Phe Phe Asp			
225	230	235	240
Glu Phe Arg Arg Val Asp Pro Asp Val Val Phe Thr Tyr Asn Gly Asp			
245	250	255	
Glu Phe Asp Leu Pro Tyr Leu Gln His Arg Ala Gly Lys Leu Gly Ile			
260	265	270	
Asp Val Ser Pro Leu Ala Arg Pro Ala Gly Lys Arg Gly Ile Ile Leu			
275	280	285	
Lys His Gly Gly Arg Tyr Ala Ser Asp Ile Phe Gly Arg Ala His			
290	295	300	
Val Asp Leu Tyr His Thr Ala Arg Lys Asn Leu Lys Leu Glu Arg Phe			
305	310	315	320
Thr Leu Glu Glu Ala Val Lys Asp Val Leu Gly Val Glu Lys Glu Glu			
325	330	335	
Met Glu Leu Ala Asp Ile Asn Glu Ala Trp Lys Arg Gly Asn Leu Asp			
340	345	350	
Glu Leu Met Arg Tyr Ser Ala Glu Asp Ala His Tyr Thr Leu Glu Leu			
355	360	365	
Gly Leu Glu Leu Ala Gln Val Glu Leu Glu Leu Ser Tyr Leu Thr Arg			
370	375	380	
Leu Pro Leu Pro Asp Ala Thr Arg Phe Ser Phe Gly Gln Leu Ala Glu			
385	390	395	400
Trp Arg Ala Ile Tyr Lys Ala Arg Gln Glu Asp Ile Leu Val Pro Asn			
405	410	415	
Lys Pro Thr Arg Asp Glu Tyr Lys Arg Arg Arg Lys Ala Tyr Lys			
420	425	430	
Gly Ala Ile Val Phe Glu Pro Glu Ile Gly Leu His Glu Asn Val Val			
435	440	445	
Cys Val Asp Phe Ala Ser Leu Tyr Pro Asn Val Met Val Ala His Asn			
450	455	460	
Ile Ser Pro Asp Thr Phe Asp Cys Asp Cys Cys Pro Arg Val Thr Val			
465	470	475	480
Glu Glu Val Asp Asp Pro Thr Asp Ala Thr Val Ala Pro Asp Val Gly			
485	490	495	

US 9,447,445 B2

159

-continued

His Lys Phe Cys Lys Arg Arg Lys Gly Phe Phe Pro Arg Leu Val Glu
 500 505 510
 Gly Leu Ile Glu Arg Arg Arg Glu Leu Lys Arg Arg Leu Arg Lys Leu
 515 520 525
 Asp Thr Glu Ser His Pro His Glu Ala Lys Ile Leu Asp Val Arg Gln
 530 535 540
 Gln Ala Tyr Lys Val Leu Ala Asn Ser Tyr Tyr Gly Tyr Met Gly Trp
 545 550 555 560
 Ala Asn Ala Arg Trp Phe Cys Arg Glu Cys Ala Glu Ser Val Thr Ala
 565 570 575
 Trp Gly Arg Tyr Tyr Ile Ser Glu Val Arg Arg Ile Ala Glu Glu Lys
 580 585 590
 Tyr Gly Leu Lys Val Val Tyr Gly Asp Thr Asp Ser Leu Phe Val Lys
 595 600 605
 Leu Pro Asp Ala Asp Leu Glu Glu Thr Ile Glu Arg Val Lys Glu Phe
 610 615 620
 Leu Lys Glu Val Asn Gly Arg Leu Pro Val Glu Leu Glu Leu Glu Asp
 625 630 635 640
 Ala Tyr Lys Arg Ile Leu Phe Val Thr Lys Lys Lys Tyr Ala Gly Tyr
 645 650 655
 Thr Glu Asp Gly Lys Ile Val Thr Lys Gly Leu Glu Val Val Arg Arg
 660 665 670
 Asp Trp Ala Pro Ile Ala Arg Glu Thr Gln Arg Arg Val Leu Lys Arg
 675 680 685
 Ile Leu Ala Asp Asn Asp Pro Glu Ala Ala Leu Lys Glu Ile His Glu
 690 695 700
 Val Leu Glu Arg Leu Lys Ser Gly Asp Val Asp Glu Leu Ala
 705 710 715 720
 Val Thr Ser Gln Leu Thr Lys Lys Pro Ser Glu Tyr Val Gln Lys Gly
 725 730 735
 Pro His Val Arg Ala Ala Leu Arg Leu Ala Arg His Leu Gly Val Glu
 740 745 750
 Pro Glu Pro Gly Thr Ile Val Arg Tyr Val Ile Val Arg Gly Pro Gly
 755 760 765
 Ser Val Ser Asp Lys Ala Tyr Pro Val Glu Leu Val Arg Glu Glu Gly
 770 775 780
 Lys Glu Pro Asp Val Asp Tyr Tyr Ile Glu His Gln Ile Leu Pro Ala
 785 790 795 800
 Val Glu Arg Ile Met Arg Ala Ile Gly Tyr Ser Arg Gly Gln Ile Val
 805 810 815
 Gly Glu Thr Ala Ser Gln Lys Thr Leu Asp Gln Phe Phe Gly
 820 825 830

160

<210> SEQ ID NO 55
 <211> LENGTH: 784
 <212> TYPE: PRT
 <213> ORGANISM: Thermoproteus neutrophilus

<400> SEQUENCE: 55

Met Glu Leu Lys Ile Trp Pro Leu Asp Val Thr Tyr Ala Val Val Gly
 1 5 10 15
 Gly Tyr Pro Glu Val Arg Val Phe Gly Leu Thr Glu Gly Gly Arg
 20 25 30
 Val Val Leu Val Asp Arg Ser Phe Lys Pro Tyr Phe Tyr Val Asp Cys

US 9,447,445 B2

161

-continued

162

35	40	45
Pro Thr Cys Glu Val Gly Val Val Lys Ser Ser Leu Ser Arg Val Ala		
50	55	60
Pro Val Asp Glu Val Ser Ala Ala Glu Arg Arg Phe Leu Gly Arg Pro		
65	70	75
Arg Arg Phe Leu Met Val Val Ala Arg Val Pro Glu Asp Val Arg Arg		
85	90	95
Leu Arg Glu Ala Ala Ala Gln Ile Pro Gly Val Ala Gly Val Tyr Glu		
100	105	110
Ala Asp Ile Arg Phe Tyr Met Arg Tyr Met Ile Asp Val Gly Leu Leu		
115	120	125
Pro Cys Ser Trp Asn Arg Ala Glu Val Glu Gly Gly Lys Val Gly		
130	135	140
Gly Leu Pro Gln Tyr Thr Val Val Gln Trp Leu Gly Pro Ala Gly Gly		
145	150	155
Phe Pro Pro Pro Leu Arg Val Leu Ala Phe Asp Ile Glu Val Tyr Asn		
165	170	175
Glu Arg Gly Thr Pro Asp Pro Ala Arg Asp Pro Val Val Met Ile Ala		
180	185	190
Val Lys Thr Asp Asp Gly Arg Glu Glu Val Phe Glu Ala Glu Gly Arg		
195	200	205
Asp Asp Arg Gly Val Leu Arg Ser Phe Val Glu Phe Val Lys Ser Tyr		
210	215	220
Asp Pro Asp Val Val Val Gly Tyr Asn Ser Asn Gly Phe Asp Trp Pro		
225	230	235
Tyr Leu Ala Gly Arg Ala Arg Ala Ile Gly Val Pro Leu Arg Val Asp		
245	250	255
Arg Leu Gly Gly Leu Pro Gln Gln Ser Val Tyr Gly His Trp Ser Ile		
260	265	270
Val Gly Arg Ala Asn Val Asp Leu Tyr Gly Ile Val Glu Glu Phe Pro		
275	280	285
Glu Ile Lys Leu Lys Thr Leu Asp Arg Val Ala Glu Tyr Phe Gly Val		
290	295	300
Met Arg Arg Glu Glu Arg Val Leu Ile Pro Gly His Lys Ile Tyr Glu		
305	310	315
Tyr Trp Arg Asp Pro Gly Lys Arg Pro Leu Leu Arg Gln Tyr Val Leu		
325	330	335
Asp Asp Val Arg Ser Thr Leu Gly Leu Ala Asp Lys Leu Leu Pro Phe		
340	345	350
Leu Ile Gln Leu Ser Ser Val Ser Gly Leu Pro Leu Asp Gln Val Ala		
355	360	365
Ala Ala Ser Val Gly Asn Arg Val Glu Trp Met Leu Leu Arg Tyr Ala		
370	375	380
Tyr Arg Leu Gly Glu Val Ala Pro Asn Arg Glu Glu Arg Glu Tyr Glu		
385	390	395
400		
Pro Tyr Lys Gly Ala Ile Val Leu Glu Pro Lys Pro Gly Met Tyr Glu		
405	410	415
Asp Val Leu Val Leu Asp Phe Ser Ser Met Tyr Pro Asn Ile Met Met		
420	425	430
Lys Tyr Asn Leu Ser Pro Asp Thr Tyr Leu Glu Pro Gly Glu Pro Asp		
435	440	445
Pro Pro Glu Gly Val Asn Ala Ala Pro Glu Val Gly His Arg Phe Arg		
450	455	460

-continued

Arg Ser Pro Leu Gly Phe Val Pro Gln Val Leu Lys Ser Leu Val Glu
 465 470 475 480
 Leu Arg Lys Ala Val Arg Glu Glu Ala Lys Arg Tyr Pro Pro Asp Ser
 485 490 495
 Pro Glu Phe Arg Ile Leu Asp Glu Arg Gln Arg Ala Leu Lys Val Met
 500 505 510
 Ala Asn Ala Met Tyr Gly Tyr Leu Gly Trp Val Gly Ala Arg Trp Tyr
 515 520 525
 Lys Arg Glu Val Ala Glu Ser Val Thr Ala Phe Ala Arg Ala Ile Leu
 530 535 540
 Lys Asp Val Ile Glu Gln Ala Arg Arg Leu Gly Ile Val Val Val Tyr
 545 550 555 560
 Gly Asp Thr Asp Ser Leu Phe Val Lys Lys His Val Asn Val Asp Lys
 565 570 575
 Leu Ile Gln Tyr Val Glu Glu Lys Tyr Gly Ile Glu Ile Lys Val Asp
 580 585 590
 Lys Asp Tyr Ala Lys Val Leu Phe Thr Glu Ala Lys Lys Arg Tyr Ala
 595 600 605
 Gly Leu Leu Arg Asp Gly Arg Ile Asp Ile Val Gly Phe Glu Val Val
 610 615 620
 Arg Gly Asp Trp Ser Glu Leu Ala Lys Glu Val Gln Leu Lys Val Val
 625 630 635 640
 Glu Ile Ile Leu Asn Ser Arg Asp Val Ala Glu Ala Arg Arg Val
 645 650 655
 Thr Gln Tyr Val Arg Glu Ile Ile Glu Arg Leu Arg Glu Tyr Lys Phe
 660 665 670
 Asn Val Asp Asp Leu Ile Ile Trp Lys Thr Leu Asp Lys Glu Leu Gly
 675 680 685
 Glu Tyr Lys Ala Tyr Pro Pro His Val His Ala Ala Leu Ile Leu Lys
 690 695 700
 Arg His Gly Tyr Lys Val Gly Lys Gly Asn Met Val Gly Tyr Val Val
 705 710 715 720
 Val Lys Gly Gly Lys Ile Ser Glu Lys Ala Leu Pro Tyr Ile Leu
 725 730 735
 Leu Asp Asp Val Lys Lys Ile Asp Val Glu Tyr Tyr Ile Glu Arg Gln
 740 745 750
 Ile Ile Pro Ala Ala Leu Arg Ile Ala Glu Val Ile Gly Val Lys Glu
 755 760 765
 Ala Asp Leu Lys Thr Gly Lys Ser Glu Arg Ser Leu Leu Asp Phe Phe
 770 775 780

<210> SEQ_ID NO 56
 <211> LENGTH: 142
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 56

Met Lys Thr Phe Leu Thr Glu Gln Ile Lys Val Leu Met Leu Arg
 1 5 10 15
 Ala Lys Gly Tyr Lys Gln Ser Glu Ile Ala Lys Ile Leu Gly Thr Ser
 20 25 30
 Arg Ala Asn Val Ser Ile Leu Glu Lys Arg Ala Met Glu Lys Ile Glu
 35 40 45
 Lys Ala Arg Asn Thr Leu Leu Leu Trp Glu Gln Ile Asn Ser Lys Val

US 9,447,445 B2

165

-continued

50	55	60
Ile Val Glu Ile Lys Ala Gly Glu Asp Ile Phe Ser Ile Pro Glu Lys		
65	70	75
Phe Phe Lys Lys Ala Asp Lys Val Gly Val Lys Val Pro Tyr Ser Thr		
85	90	95
Ala Glu Ile Ile Thr Phe Leu Val Glu His Ala Pro Val Glu Asp Arg		
100	105	110
Leu Ala Lys Arg Asp Phe Val Leu Phe Leu Asp Ser Lys Asn Lys Leu		
115	120	125
Arg Ile Gly Asp Cys Leu Val Ile Glu Glu Ile Lys Glu Asp		
130	135	140

<210> SEQ ID NO 57
<211> LENGTH: 75
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 57

Met Pro Ile Thr Lys Val Thr Arg Asn Tyr Gln Ile Thr Ile Pro Ala			
1	5	10	15
Glu Ile Arg Lys Ala Leu Gly Ile Lys Glu Gly Glu Leu Leu Glu Val			
20	25	30	
Arg Leu Glu Asn Gly Lys Ile Ile Glu Arg Leu Lys Lys Glu Arg			
35	40	45	
Lys Thr Leu Lys Leu Gly Lys Lys Leu Thr Leu Glu Glu Ile Glu Lys			
50	55	60	
Ala Ile Glu Glu Gly Met Lys Gln Cys Met Gln			
65	70	75	

<210> SEQ ID NO 58
<211> LENGTH: 76
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 58

Thr Lys Ile Glu Ile Leu Arg Leu Leu Lys Glu Arg Glu Met Tyr Ala			
1	5	10	15
Tyr Glu Ile Trp Ser Leu Leu Gly Lys Pro Leu Lys Tyr Gln Ala Val			
20	25	30	
His Gln His Ile Lys Glu Leu Leu Glu Leu Gly Leu Val Glu Gln Ala			
35	40	45	
Tyr Arg Lys Gly Lys Arg Val Tyr Tyr Lys Ile Thr Glu Lys Gly Leu			
50	55	60	
Arg Ile Leu Gln Asn Phe Glu Asp Leu Glu Asn Ile			
65	70	75	

<210> SEQ ID NO 59
<211> LENGTH: 72
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 59

Met Asn Thr Gly Ala Gln Gly Val Ser Glu Met Ser Arg Met Lys Ile			
1	5	10	15
Ile Ser Val Gln Leu Pro Gln Ser Leu Ile His Gly Leu Asp Ala Leu			
20	25	30	
Val Lys Arg Gly Ile Tyr Pro Asn Arg Ser Glu Ala Ile Arg Val Ala			
35	40	45	

166

-continued

```
Ile Arg Glu Leu Leu Lys Lys Glu Leu Tyr Lys Glu Glu Ile Gln Glu
 50          55          60
```

```
Glu Ile Pro Glu Tyr Val Val Lys
 65           70
```

```
<210> SEQ ID NO 60
<211> LENGTH: 67
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus
```

```
<400> SEQUENCE: 60
```

```
Val Ile Ile Pro Arg Pro Ile Asp Pro Arg Asp Ile Arg Arg Ile Arg
 1           5           10          15
```

```
Lys Glu Leu Gly Ile Thr Gln Glu Leu Ala Arg Lys Ala Gly Val
 20          25          30
```

```
Thr Gln Ala Tyr Ile Ala Lys Leu Glu Ala Gly Lys Val Asp Pro Arg
 35          40          45
```

```
Leu Ser Thr Phe Asn Lys Ile Leu Arg Ala Leu Ile Glu Cys Gln Lys
 50          55          60
```

```
Ala Lys Ile
 65
```

```
<210> SEQ ID NO 61
<211> LENGTH: 65
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus
```

```
<400> SEQUENCE: 61
```

```
Asn Asn Cys Glu Cys Met Val Val Lys Glu Lys Leu Tyr Thr Val Lys
 1           5           10          15
```

```
Gln Ala Ser Glu Ile Leu Gly Val His Pro Lys Thr Ile Gln Lys Trp
 20          25          30
```

```
Asp Arg Glu Gly Lys Ile Lys Thr Val Arg Thr Pro Gly Gly Arg Arg
 35          40          45
```

```
Arg Ile Pro Glu Ser Glu Ile Lys Arg Leu Leu Gly Ile Ser Glu Glu
 50          55          60
```

```
Lys
 65
```

```
<210> SEQ ID NO 62
<211> LENGTH: 71
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus
```

```
<400> SEQUENCE: 62
```

```
Met Leu Lys Asp Ser Ala Pro Lys Arg Lys Ile Leu Glu Glu Leu Arg
 1           5           10          15
```

```
Lys Gly Glu Thr Val Ser Gly Asp Tyr Leu Ala Ser Lys Leu Gly Val
 20          25          30
```

```
Ser Arg Val Ala Ile Trp Lys His Ile Arg Glu Leu Lys Glu Leu Gly
 35          40          45
```

```
Tyr Gly Ile Ile Ala Asp Lys Lys Gly Tyr Lys Leu Val Tyr Glu Pro
 50           55          60
```

```
Lys Lys Pro Tyr Pro Trp Glu
 65           70
```

```
<210> SEQ ID NO 63
<211> LENGTH: 86
```

-continued

<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 63

```

Met Ile Asp Glu Arg Asp Lys Ile Ile Leu Glu Ile Leu Glu Lys Asp
1           5          10          15

Ala Arg Thr Pro Phe Thr Glu Ile Ala Lys Lys Leu Gly Ile Ser Glu
20          25          30

Thr Ala Val Arg Lys Arg Val Lys Ala Leu Glu Glu Lys Gly Ile Ile
35          40          45

Glu Gly Tyr Thr Ile Lys Ile Asn Pro Lys Lys Leu Gly Tyr Ser Leu
50          55          60

Val Thr Ile Thr Gly Val Asp Thr Lys Pro Glu Lys Leu Phe Glu Val
65          70          75          80

Ala Glu Lys Leu Lys Glu
85

```

<210> SEQ_ID NO 64

<211> LENGTH: 77

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 64

```

Met Glu Ile Asp Asp Leu Asp Arg Lys Ile Leu Ser Leu Leu Ile Glu
1           5          10          15

Asp Ser Arg Leu Ser Tyr Arg Glu Ile Ala Lys Lys Leu Asn Val Ala
20          25          30

Val Gly Thr Ile Tyr Asn Arg Ile Lys Lys Leu Glu Asp Met Gly Val
35          40          45

Ile Gln Gly Phe Thr Val Lys Leu Asn Tyr Glu Lys Leu Gly Tyr Glu
50          55          60

Leu Thr Ala Ile Ile Gly Ile Lys Ala Gln Gly Lys Lys
65          70          75

```

<210> SEQ_ID NO 65

<211> LENGTH: 94

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 65

```

Glu Met Leu Trp Met Tyr Ile Leu Lys Leu Leu Lys Asp Arg Pro Met
1           5          10          15

Tyr Ala Tyr Glu Ile Arg Asn Glu Leu Lys Lys Arg Phe Gly Phe Glu
20          25          30

Pro Ala Thr Val Ser Ser Tyr Val Val Leu Tyr Arg Leu Glu Glu Gly
35          40          45

Gly Tyr Val Ser Ser Glu Trp His Glu Ser Glu Ala Gly Arg Pro Ser
50          55          60

Arg Lys Tyr Tyr Arg Leu Thr Glu Lys Gly Glu Lys Leu Leu Glu Lys
65          70          75          80

Gly Ile Glu Thr Ile Glu Asp Val Leu Asn Met Leu Lys Ser
85          90

```

<210> SEQ_ID NO 66

<211> LENGTH: 68

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 66

-continued

Met Lys Val Ser Lys Ala Thr Ala Ser Lys Val Leu Arg Ser Leu Glu
 1 5 10 15

Asn Lys Gly Ile Val Glu Arg Glu Arg Arg Gly Lys Thr Tyr Leu Val
 20 25 30

Arg Leu Thr Asn Lys Gly Leu Glu Leu Glu Glu Ile Ser Lys Ala
 35 40 45

Gly Lys Glu Leu Asp Glu Lys Ile Phe Ala Glu Met Ser Val Asp Glu
 50 55 60

Arg Ile Val Leu
 65

<210> SEQ ID NO 67
 <211> LENGTH: 56
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 67

Ser Glu Asp Tyr Met Leu Gln Asn Arg Arg Lys Val Leu Ala Lys Val
 1 5 10 15

Leu Glu Leu Leu Asn Tyr Asn Pro Lys Ala Leu Asn Ile Ser Glu Leu
 20 25 30

Ala Arg Met Phe Gly Val Ser Arg Asp Thr Ile Tyr Asn Asp Ile Gln
 35 40 45

Gln Ile Ile Lys Asn Val Glu Val
 50 55

<210> SEQ ID NO 68
 <211> LENGTH: 94
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 68

Ser Lys Glu Ile Ser Arg Phe Leu Lys Val Ile Ser Asn Pro Ile Arg
 1 5 10 15

Tyr Gly Ile Leu Lys Met Leu Asn Asp Arg Trp Met Cys Val Cys Leu
 20 25 30

Ile Ser Glu Ala Leu Glu Ile Asp Gln Thr Leu Val Ser His His Ile
 35 40 45

Arg Ile Leu Lys Glu Leu Asp Leu Leu Glu Glu Arg Lys Glu Gly Lys
 50 55 60

Leu Arg Phe Tyr Arg Thr Asn Lys Glu Lys Leu Arg Glu Tyr Leu Glu
 65 70 75 80

Lys Val Leu Glu Asp Phe Asn His Gly Thr Ser Lys Gly Ser
 85 90

<210> SEQ ID NO 69
 <211> LENGTH: 78
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 69

Met Cys Arg Lys Asp Val Met Ile Ile Ser Asp Pro Lys Gln Ile Lys
 1 5 10 15

Ala Leu Ser Asp Pro Thr Arg Val Lys Ile Leu Glu Leu Arg Tyr
 20 25 30

His Pro Met Thr Val Ser Glu Ile Ser Arg Val Ile Gly Lys Asp Lys
 35 40 45

-continued

Ser Thr Ile Tyr Arg His Ile Lys Ala Leu Glu Glu Ala Gly Leu Val
 50 55 60

Glu Glu Val Glu Lys Ile Gly Asn Glu Thr Val Tyr Gly Arg
 65 70 75

<210> SEQ ID NO 70
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 70

Met Glu Pro Val Glu Phe Lys Leu Asn Gln Lys Gly Ile Lys Ser Ile
 1 5 10 15

Leu Pro Thr Met Glu Ala Glu Ile Met Glu Tyr Met Trp Glu Ile Lys
 20 25 30

Glu Ala Thr Ala Gly Glu Val Tyr Glu Tyr Met Lys Thr Lys Tyr Pro
 35 40 45

Glu Ile Arg Arg Ser Thr Val Ser Ile Leu Met Asn Arg Leu Cys Glu
 50 55 60

Arg Gly Leu Leu Lys Arg Arg Met Glu Lys Gly Lys Gly Ile Arg
 65 70 75 80

Tyr Val Tyr Ser Ile Thr Thr Arg Glu Glu Phe Glu Arg Lys Val
 85 90 95

Val Glu Lys Ile Ile Glu Ser Leu Met Met Asn Phe Arg Glu Ala Thr
 100 105 110

Phe Ala Tyr Leu Ser Lys Ile Asn Lys Lys
 115 120

<210> SEQ ID NO 71
 <211> LENGTH: 87
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 71

Met Lys Lys Ser Asn Leu Asp Leu Leu Ile Leu Ala Lys Ala Gly
 1 5 10 15

Gly Ile Glu Lys Glu Ile Leu Thr Thr Ser Arg Glu Leu Ser Lys Met
 20 25 30

Leu Asn Val Ser Pro Gln Thr Ile Val Arg Trp Leu Glu Asp Leu Glu
 35 40 45

Lys Asp Gly Leu Ile Lys Lys Ser Glu Ser Arg Lys Gly Thr Leu Val
 50 55 60

Thr Ile Thr Glu Glu Gly Val Lys Phe Leu Glu Lys Leu His Glu Glu
 65 70 75 80

Leu Ser Asp Ala Leu Tyr Arg
 85

<210> SEQ ID NO 72
 <211> LENGTH: 104
 <212> TYPE: PRT
 <213> ORGANISM: Unknown
 <220> FEATURE:
 <223> OTHER INFORMATION: Thermococcaceae

<400> SEQUENCE: 72

Met Glu Ile Pro Pro Glu Ile Ser His Ala Leu Ser Glu Ile Gly Phe
 1 5 10 15

Thr Lys Tyr Glu Ile Leu Thr Tyr Trp Thr Leu Leu Val Tyr Gly Pro
 20 25 30

-continued

Ser Thr Ala Lys Glu Ile Ser Thr Lys Ser Gly Ile Pro Tyr Asn Arg
 35 40 45
 Val Tyr Asp Thr Ile Ser Ser Leu Lys Leu Arg Gly Phe Val Thr Glu
 50 55 60
 Ile Glu Gly Thr Pro Lys Val Tyr Ala Ala Tyr Ser Pro Arg Ile Ala
 65 70 75 80
 Phe Phe Arg Phe Lys Lys Glu Leu Glu Asp Ile Met Lys Lys Leu Glu
 85 90 95
 Ile Glu Leu Asn Asn Val Lys Lys
 100

<210> SEQ ID NO 73
<211> LENGTH: 75
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 73

Ile Ile Asn Pro Gln Ala Arg Leu Thr Pro Leu Glu Leu Glu Ile Leu
 1 5 10 15
 Glu Ile Ile Lys Gln Lys Lys Ser Ile Thr Ile Thr Glu Ile Lys Glu
 20 25 30
 Ile Leu Ser Glu Arg Arg Lys Ser Glu Tyr Pro Leu Ser Leu Val Ser
 35 40 45
 Glu Tyr Ile Ser Arg Leu Glu Arg Lys Gly Tyr Val Lys Lys Ile Ala
 50 55 60
 Lys Gly Arg Lys Lys Phe Val Glu Ala Leu Ile
 65 70 75

<210> SEQ ID NO 74
<211> LENGTH: 94
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 74

Gly Ile Asp Val Val Ile Pro Glu Ile Lys His Asp Pro Ile Ala Arg
 1 5 10 15
 Asp Ile Val Lys Ile Leu Phe Asp Leu Arg Arg Ala Asn Val Ser Gln
 20 25 30
 Ile Ala Arg Glu Leu Lys Gly Arg Arg Gly Lys Ala Ser Arg Asn Thr
 35 40 45
 Val Arg Lys Leu Lys Glu Leu Glu Lys Leu Gly Val Val Lys Glu
 50 55 60
 Val Pro Gly Glu Arg Gly Ser Val Tyr Thr Leu Ser Arg Glu Val Val
 65 70 75 80
 Lys Lys Trp Leu Asp Leu Ile Gly Ile Pro Ile Asn Leu Leu
 85 90

<210> SEQ ID NO 75
<211> LENGTH: 67
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 75

Met Thr Lys Arg Val Lys Val Ile Thr Asp Pro Glu Val Ile Lys Val
 1 5 10 15
 Met Leu Glu Asp Thr Arg Arg Lys Ile Leu Gln Leu Leu Arg Asn Arg
 20 25 30

US 9,447,445 B2

177

-continued

Glu	Met	Thr	Ile	Ser	Gln	Leu	Ser	Glu	Ile	Leu	Gly	Lys	Met	Pro	Gln
35					40				45						

Thr	Ile	Tyr	His	His	Ile	Glu	Lys	Leu	Lys	Glu	Ala	Gly	Leu	Val	Glu
50					55				60						

Val	Lys	Arg													
65															

<210> SEQ ID NO 76

<211> LENGTH: 100

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 76

Met	Glu	Glu	Ile	Lys	Glu	Ile	Met	Lys	Ser	His	Thr	Leu	Gly	Asn	Pro
1					5			10			15				

Val	Arg	Leu	Gly	Ile	Met	Ile	Tyr	Leu	Phe	Pro	Arg	Arg	Arg	Ala	Pro
20					25						30				

Phe	Ser	His	Ile	Gln	Lys	Ala	Leu	Asp	Leu	Thr	Pro	Gly	Asn	Leu	Asp
35					40					45					

Ser	His	Ile	Lys	Val	Leu	Glu	Lys	His	Gly	Phe	Val	Arg	Thr	Tyr	Lys
50				55				60							

Val	Ile	Ala	Asp	Arg	Pro	Arg	Thr	Met	Val	Glu	Ile	Thr	Asp	Tyr	Gly
65					70				75			80			

Met	Glu	Glu	Thr	Arg	Lys	Phe	Leu	Ser	His	Leu	Lys	Thr	Val	Ile	Asp
85					90					95					

Ala	Ile	His	Phe												
		100													

<210> SEQ ID NO 77

<211> LENGTH: 99

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 77

Met	Gly	Glu	Glu	Leu	Asn	Arg	Leu	Leu	Asp	Val	Leu	Gly	Asn	Glu	Thr
1					5			10			15				

Arg	Arg	Arg	Ile	Leu	Phe	Leu	Leu	Thr	Lys	Arg	Pro	Tyr	Phe	Val	Ser
20				25					30						

Glu	Leu	Ser	Arg	Glu	Leu	Gly	Val	Gly	Gln	Lys	Ala	Val	Leu	Glu	His
35				40					45						

Leu	Arg	Ile	Leu	Glu	Glu	Ala	Gly	Leu	Ile	Glu	Ser	Arg	Val	Glu	Lys
50				55					60						

Ile	Pro	Arg	Gly	Arg	Pro	Arg	Lys	Tyr	Tyr	Met	Ile	Lys	Lys	Gly	Leu
65					70			75		80					

Arg	Leu	Glu	Ile	Leu	Leu	Thr	Pro	Thr	Leu	Phe	Gly	Ser	Glu	Met	Tyr
85				90					95						

Glu Ala Lys

<210> SEQ ID NO 78

<211> LENGTH: 61

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 78

Met	Arg	Arg	Met	Asp	Lys	Val	Asp	Leu	Gln	Leu	Ile	Lys	Ile	Leu	Ser
1				5				10			15				

Gln	Asn	Ser	Arg	Leu	Thr	Tyr	Arg	Glu	Leu	Ala	Glu	Met	Leu	Gly	Thr
20				25					30						

178

-continued

Thr Arg Gln Arg Val Ala Arg Lys Val Asp Lys Leu Lys Lys Leu Gly
 35 40 45

Ile Ile Arg Lys Phe Thr Ile Ile Pro Asn Leu Glu Lys
 50 55 60

<210> SEQ ID NO 79

<211> LENGTH: 82

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 79

Gly Arg Lys Val Arg Thr Gln Gln Asn Glu Ile Leu Asn Leu Leu Asn
 1 5 10 15

Glu Lys Glu Lys Ala Val Leu Arg Ala Ile Leu Glu His Gly Gly Glu
 20 25 30

Ile Lys Gln Glu Asp Leu Pro Glu Leu Val Gly Tyr Ser Arg Pro Thr
 35 40 45

Ile Ser Lys Val Ile Gln Glu Leu Glu Asn Lys Gly Leu Ile Lys Arg
 50 55 60

Glu Lys Ser Gly Lys Thr Phe Val Val Lys Ile Glu Arg Lys Ile Lys
 65 70 75 80

Leu Asp

<210> SEQ ID NO 80

<211> LENGTH: 59

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 80

Lys Ser Leu Gln Arg Phe Leu Arg Arg Asn Thr Thr Ser Ile Lys His
 1 5 10 15

Leu Ser Glu Ile Thr Gly Val Ala Arg Asn Arg Leu Ser Asp Ile Leu
 20 25 30

Asn Gly Lys Thr Gln Lys Ile Arg Gly Glu Thr Leu Arg Lys Ile Ala
 35 40 45

Lys Ala Phe Glu Lys Ser Asn Ile Leu Ser Phe
 50 55

<210> SEQ ID NO 81

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Thermotoga

<400> SEQUENCE: 81

Asp Val Ile Gln Arg Ile Lys Glu Lys Tyr Asp Glu Phe Thr Asn Ala
 1 5 10 15

Glu Lys Lys Ile Ala Asp Thr Ile Leu Ser Asp Pro Lys Gly Ile Ile
 20 25 30

Glu Ser Ser Ile Ser Asp Leu Ser Glu Lys Ala Gly Val Lys Ser Glu
 35 40 45

Ala Ser Val Val Lys Phe Tyr Lys Lys Leu Gly Leu Asn Ser Phe Gln
 50 55 60

Gln Phe Lys Val Leu Leu Ala Gln Ser Ile Ser Arg Ala Pro Leu Glu
 65 70 75 80

Ile Val Tyr Glu Asp Val Ser Ser Glu Asp Asp Thr Lys Thr Ile Thr
 85 90 95

Glu Lys Ile Phe Lys Ala Thr Val Arg Ala Ile

US 9,447,445 B2

181**182**

-continued

100

105

<210> SEQ ID NO 82
<211> LENGTH: 101
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 82

Lys	Ile	Arg	Asp	Lys	Ile	Leu	Asn	Val	Tyr	Thr	Gln	Phe	Ser	Pro	Ala
1					5			10						15	
Glu	Arg	Lys	Val	Ala	Asp	Tyr	Val	Leu	Glu	Arg	Pro	Asp	Asp	Val	Ile
			20				25						30		
His	Tyr	Ser	Ile	Thr	Glu	Phe	Ala	Lys	Ile	Val	Gly	Val	Ser	Glu	Thr
			35				40					45			
Thr	Ile	His	Arg	Met	Ile	Lys	Lys	Leu	Asp	Phe	Glu	Gly	Tyr	Gln	Ala
				50			55				60				
Phe	Lys	Ile	Ala	Leu	Ala	Arg	Glu	Leu	Ser	Gly	Leu	Glu	Glu	Thr	Ile
			65				70				75		80		
Glu	Arg	Arg	Asp	Phe	Ile	Asp	Glu	Ile	Asp	Ile	Leu	Arg	Arg	Leu	
				85			90				95				
Lys	Asp	Thr	Leu	Asp											
			100												

<210> SEQ ID NO 83
<211> LENGTH: 60
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 83

Lys	Arg	Arg	Pro	Thr	Ile	Asn	Asp	Val	Ala	Lys	Leu	Ala	Gly	Val	Ser
1					5			10				15			
Ile	Ser	Thr	Val	Ser	Arg	Tyr	Leu	Lys	Asp	Pro	Ser	Gln	Val	Ser	Glu
			20				25				30				
Lys	Leu	Gly	Glu	Arg	Ile	Arg	Glu	Ala	Ile	Lys	Lys	Leu	Gly	Tyr	Lys
			35				40				45				
Pro	Asn	Lys	Ile	Ala	Gln	Gly	Leu	Arg	Thr	Gly	Asp				
			50				55				60				

<210> SEQ ID NO 84
<211> LENGTH: 58
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 84

Met	Ala	Ser	Ile	Lys	Asp	Val	Ala	Lys	Leu	Ala	Gly	Val	Ser	Ile	Ala
1					5			10				15			
Thr	Val	Ser	Arg	Val	Ile	Asn	Gly	Tyr	Asn	Asn	Val	Ser	Glu	Glu	Thr
			20				25				30				
Arg	Lys	Lys	Val	Ile	Asp	Ala	Ile	Arg	Lys	Leu	Asn	Tyr	His	Pro	Val
			35				40				45				
Tyr	Ala	Val	Lys	Gly	Ala	Val	Leu	Lys	Arg						
			50				55								

<210> SEQ ID NO 85
<211> LENGTH: 61
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 85

-continued

Met Lys Lys Tyr Val Thr Ile Arg Asp Ile Ala Glu Lys Ala Gly
1 5 10 15

Val Ser Ile Asn Thr Val Ser Arg Ala Leu Asn Asn Lys Pro Asp Ile
20 25 30

Ser Glu Glu Thr Arg Arg Lys Ile Leu Lys Ile Ala Gln Glu Leu Gly
35 40 45

Tyr Val Lys Asn Ala Thr Ala Ser Ser Leu Arg Ser Lys
50 55 60

<210> SEQ ID NO 86

<211> LENGTH: 58

<212> TYPE: PRT

<213> ORGANISM: Thermotoga

<400> SEQUENCE: 86

Met Pro Thr Ile Glu Asp Val Ala Lys Leu Ala Gly Val Ser Ile Ala
1 5 10 15

Thr Val Ser Arg Val Ile Asn Gly Ser Gly Tyr Val Ser Glu Lys Thr
20 25 30

Arg Tyr Lys Val Trp Lys Ala Ile Glu Glu Leu Gly Tyr Lys Pro Glu
35 40 45

Ile Ser Ala Lys Leu Leu Ala Ser Lys Gly
50 55

<210> SEQ ID NO 87

<211> LENGTH: 61

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 87

Met Arg Ile Gly Glu Lys Leu Arg Lys Leu Arg Leu Ser Arg Gly Leu
1 5 10 15

Thr Gln Glu Glu Leu Ala Glu Arg Thr Asp Leu Ser Arg Ser Phe Ile
20 25 30

Ser Gln Leu Glu Ser Asp Lys Thr Ser Pro Ser Ile Asp Thr Leu Glu
35 40 45

Arg Ile Leu Glu Ala Leu Gly Thr Asp Leu Lys His Phe
50 55 60

<210> SEQ ID NO 88

<211> LENGTH: 67

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 88

Met His Met Lys Thr Val Arg Gln Glu Arg Leu Lys Ser Ile Val Arg
1 5 10 15

Ile Leu Glu Arg Ser Lys Glu Pro Val Ser Gly Ala Gln Leu Ala Glu
20 25 30

Glu Leu Ser Val Ser Arg Gln Val Ile Val Gln Asp Ile Ala Tyr Leu
35 40 45

Arg Ser Leu Gly Tyr Asn Ile Val Ala Thr Pro Arg Gly Tyr Val Leu
50 55 60

Ala Gly Gly
65

<210> SEQ ID NO 89

<211> LENGTH: 75

<212> TYPE: PRT

US 9,447,445 B2

185

-continued

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 89

Met	Asn	Thr	Leu	Lys	Lys	Ala	Phe	Glu	Ile	Leu	Asp	Phe	Ile	Val	Lys
1				5					10				15		
Asn	Pro	Gly	Asp	Val	Ser	Val	Ser	Glu	Ile	Ala	Glu	Lys	Phe	Asn	Met
	20					25							30		
Ser	Val	Ser	Asn	Ala	Tyr	Lys	Tyr	Met	Val	Val	Leu	Glu	Lys	Gly	
			35			40					45				
Phe	Val	Leu	Arg	Lys	Lys	Asp	Lys	Arg	Tyr	Val	Pro	Gly	Tyr	Lys	Leu
	50				55				60						
Ile	Glu	Tyr	Gly	Ser	Phe	Val	Leu	Arg	Arg	Phe					
	65				70				75						

<210> SEQ ID NO 90

<211> LENGTH: 81

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 90

Met	Lys	Ile	Ser	Lys	Lys	Arg	Arg	Gln	Glu	Leu	Ile	Arg	Lys	Ile	Ile
1						5		10			15				
His	Glu	Lys	Lys	Ile	Ser	Asn	Gln	Phe	Gln	Ile	Val	Glu	Glu	Leu	Lys
	20						25				30				
Lys	Tyr	Gly	Ile	Lys	Ala	Val	Gln	Pro	Thr	Val	Ala	Arg	Asp	Leu	Lys
	35					40				45					
Glu	Ile	Gly	Ala	Val	Lys	Ile	Met	Asp	Glu	Ser	Gly	Asn	Tyr	Val	Tyr
	50				55			60							
Lys	Leu	Leu	Asp	Glu	Thr	Pro	Val	Ile	Asp	Pro	Trp	Lys	Glu	Leu	Lys
	65				70			75				80			

Arg

<210> SEQ ID NO 91

<211> LENGTH: 82

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 91

Met	His	Lys	Lys	Leu	Asn	Pro	Lys	Ser	Met	Lys	Arg	Glu	Asn	Lys	Lys
1						5		10		15					
Met	Val	Leu	Arg	Tyr	Leu	Ile	Glu	Ser	Gly	Pro	His	Ser	Arg	Val	Glu
	20					25					30				
Ile	Ala	Arg	Lys	Thr	Gly	Leu	Ala	Gln	Ser	Ala	Ile	Trp	Arg	Ile	Ile
	35				40					45					
Glu	Glu	Leu	Val	Asn	Glu	Gly	Leu	Val	Glu	Glu	Lys	Gly	Thr	Ala	Thr
	50				55				60						
Gly	Arg	Arg	Arg	Lys	Ala	Val	Thr	Tyr	Gly	Pro	Thr	Arg	Ser	Phe	Ile
	65				70			75			80				

Thr Ser

<210> SEQ ID NO 92

<211> LENGTH: 79

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 92

Met	Pro	Ser	Pro	Leu	Leu	Arg	Arg	Glu	Asn	Lys	Ile	Lys	Ile	Leu	Arg
1						5		10		15					

186

-continued

Tyr Ile Leu Lys Asn Gly Lys Thr Thr Arg Asn Gln Leu Ala Ser Asn
 20 25 30

Leu Asn Leu Ala His Ser Thr Leu Ser Tyr Ile Ile Asp Glu Leu Leu
 35 40 45

Asp Glu Gly Phe Leu Val Phe Glu Ile Lys Lys Lys Arg Gly Arg
 50 55 60

Pro Tyr Gln Ile Leu Ser Val Asn Pro Glu Lys Phe Thr Ala Ile
 65 70 75

<210> SEQ ID NO 93
 <211> LENGTH: 79
 <212> TYPE: PRT
 <213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 93

Met Lys Glu Glu Arg Leu Lys Glu Ile Leu Asp Ile Val Asp Arg Asn
 1 5 10 15

Gly Phe Ile Ser Met Lys Asp Leu Gln Glu Gln Leu Gly Val Ser Met
 20 25 30

Ile Thr Val Arg Arg Asp Val Ala Glu Leu Val Lys Arg Asn Leu Val
 35 40 45

Lys Lys Val His Gly Gly Ile Arg Lys Val Asn Tyr Phe Glu Lys Glu
 50 55 60

Thr Asp Phe Met Lys Arg Leu Ser Ile Asn Arg Glu Ala Lys Glu
 65 70 75

<210> SEQ ID NO 94
 <211> LENGTH: 137
 <212> TYPE: PRT
 <213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 94

Met Phe Thr Met Arg Ser Glu Tyr Ala Leu Arg Leu Met Ile Val Met
 1 5 10 15

Ala Lys Glu Tyr Gly Asn Tyr Leu Ser Met Thr Glu Ile Leu Glu Lys
 20 25 30

Ala Lys Gln Ser Val Pro Arg Glu Phe Ala Glu Lys Ile Leu Tyr Thr
 35 40 45

Leu Lys Lys Ala Gly Leu Val Lys Thr Arg Arg Gly Lys Ser Gly Gly
 50 55 60

Tyr Met Leu Ser Arg Pro Pro Lys Glu Ile Lys Val Ser Glu Ile Val
 65 70 75 80

Phe Leu Leu Asp Arg Lys Ser Lys Val Phe Phe Asp Met Pro Gly Cys
 85 90 95

Pro Asp Glu Leu Asp Cys Val Ile Arg Ala Leu Trp Lys Arg Val Glu
 100 105 110

Asn Glu Ile Glu Lys Ile Leu Ser Gly Val Thr Leu Glu Asp Leu Val
 115 120 125

Arg Glu Gln Glu Glu Lys Met Lys Gln
 130 135

<210> SEQ ID NO 95
 <211> LENGTH: 95
 <212> TYPE: PRT
 <213> ORGANISM: Thermotoga naphthophila

<400> SEQUENCE: 95

US 9,447,445 B2

189**190**

-continued

Met	Arg	Asp	Thr	Lys	Gly	His	Leu	Lys	Phe	Leu	Val	Leu	His	Ile	Ile
1				5			10						15		

Ser	Gln	Gln	Pro	Ser	His	Gly	Tyr	Tyr	Ile	Met	Lys	Lys	Ile	Ser	Gln
				20			25				30				

Ile	Ile	Gly	Ala	Glu	Pro	Pro	Ser	Pro	Gly	Ala	Leu	Tyr	Pro	Ile	Leu
		35			40				45						

Ser	Ser	Leu	Arg	Lys	Gln	Lys	Tyr	Ile	Glu	Thr	Tyr	Asn	Glu	Gly	Lys
		50			55			60							

Arg	Lys	Val	Tyr	Arg	Leu	Thr	Asp	Lys	Gly	Arg	Lys	Tyr	Leu	Glu	Glu
	65			70			75			80					

His	Lys	Glu	Ile	Lys	Lys	Ala	Leu	Asp	Phe	Ala	Glu	Arg	Phe		
	85				90				95						

<210> SEQ_ID NO 96

<211> LENGTH: 118

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 96

Met	Arg	His	Arg	Gly	Gly	Arg	Gly	Phe	Arg	Gly	Trp	Trp	Leu	Ala	Ser
1				5			10			15					

Thr	Ile	Leu	Leu	Leu	Val	Ala	Glu	Lys	Pro	Ser	His	Gly	Tyr	Glu	Leu
		20			25			30							

Ala	Glu	Arg	Leu	Ala	Glu	Phe	Gly	Ile	Glu	Ile	Pro	Gly	Ile	Gly	His
	35				40			45							

Met	Gly	Asn	Ile	Tyr	Arg	Val	Leu	Ala	Asp	Leu	Glu	Glu	Ser	Gly	Phe
	50			55			60								

Leu	Ser	Thr	Glu	Trp	Asp	Thr	Thr	Val	Ser	Pro	Pro	Arg	Lys	Ile	Tyr
	65			70			75					80			

Arg	Ile	Thr	Pro	Gln	Gly	Lys	Leu	Tyr	Leu	Arg	Glu	Ile	Leu	Arg	Ser
	85			90			95								

Leu	Glu	Asp	Met	Lys	Arg	Arg	Ile	Glu	Thr	Leu	Glu	Glu	Arg	Ile	Lys
	100				105			110							

Arg	Val	Leu	Gln	Glu	Glu										
		115													

<210> SEQ_ID NO 97

<211> LENGTH: 70

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 97

Met	Leu	Ser	Lys	Arg	Asp	Ala	Ile	Leu	Lys	Ala	Ala	Val	Glu	Val	Phe
1				5			10		15						

Gly	Lys	Lys	Gly	Tyr	Asp	Arg	Ala	Thr	Thr	Asp	Glu	Ile	Ala	Glu	Lys
	20			25			30								

Ala	Gly	Val	Ala	Lys	Gly	Leu	Ile	Phe	His	Tyr	Phe	Lys	Asn	Lys	Glu
	35			40			45								

Glu	Leu	Tyr	Tyr	Gln	Ala	Tyr	Met	Ser	Val	Thr	Glu	Lys	Leu	Gln	Lys
	50			55			60								

Glu	Phe	Glu	Asn	Phe	Leu										
	65			70											

<210> SEQ_ID NO 98

<211> LENGTH: 291

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

US 9,447,445 B2

191

192

-continued

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 98

Met	Ser	Lys	Ser	Trp	Gly	Lys	Phe	Ile	Glu	Glu	Glu	Glu	Ala	Glu	Met
1				5				10					15		

Ala	Ser	Arg	Arg	Asn	Leu	Met	Ile	Val	Asp	Gly	Thr	Asn	Leu	Gly	Phe
		20					25				30				

Arg	Phe	Lys	His	Asn	Asn	Ser	Lys	Lys	Pro	Phe	Ala	Ser	Ser	Tyr	Val
35				40						45					

Ser	Thr	Ile	Gln	Ser	Leu	Ala	Lys	Ser	Tyr	Ser	Ala	Arg	Thr	Thr	Ile
50				55				60							

Val	Leu	Gly	Asp	Lys	Gly	Lys	Ser	Val	Phe	Arg	Leu	Glu	His	Leu	Pro
65				70				75		80					

Glu	Tyr	Lys	Gly	Asn	Arg	Asp	Glu	Lys	Tyr	Ala	Gln	Arg	Thr	Glu	Glu
85				90					95						

Glu	Lys	Ala	Leu	Asp	Glu	Gln	Phe	Phe	Glu	Tyr	Leu	Lys	Asp	Ala	Phe
100				105					110						

Glu	Leu	Cys	Lys	Thr	Thr	Phe	Pro	Thr	Phe	Thr	Ile	Arg	Gly	Val	Glu
115				120				125							

Ala	Asp	Asp	Met	Ala	Ala	Tyr	Ile	Val	Lys	Leu	Ile	Gly	His	Leu	Tyr
130				135				140							

Asp	His	Val	Trp	Leu	Ile	Ser	Thr	Asp	Gly	Asp	Trp	Asp	Thr	Leu	Leu
145				150				155			160				

Thr	Asp	Lys	Val	Ser	Arg	Phe	Ser	Phe	Thr	Thr	Arg	Arg	Glu	Tyr	His
165					170				175						

Leu	Arg	Asp	Met	Tyr	Glu	His	His	Asn	Val	Asp	Asp	Val	Glu	Gln	Phe
180					185				190						

Ile	Ser	Leu	Lys	Ala	Ile	Met	Gly	Asp	Leu	Gly	Asp	Asn	Ile	Arg	Gly
195					200				205						

Val	Glu	Ile	Gly	Ala	Lys	Arg	Gly	Tyr	Asn	Ile	Ile	Arg	Glu	Phe
210				215				220						

Gly	Asn	Val	Leu	Asp	Ile	Ile	Asp	Gln	Leu	Pro	Leu	Pro	Gly	Lys	Gln
225				230				235			240				

Lys	Tyr	Ile	Gln	Asn	Leu	Asn	Ala	Ser	Glu	Glu	Leu	Leu	Phe	Arg	Asn
245				250				255							

Leu	Ile	Leu	Val	Asp	Leu	Pro	Thr	Tyr	Cys	Val	Asp	Ala	Ile	Ala	Ala
260				265				270							

Val	Gly	Gln	Asp	Val	Leu	Asp	Lys	Phe	Thr	Lys	Asp	Ile	Leu	Glu	Ile
275				280				285							

Ala	Glu	Gln
290		

<210> SEQ ID NO 99

<211> LENGTH: 53

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (17)..(37)

<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 99

tttctagctc taaaacnnnn nnnnnnnnnnn nnnnnnnncgg tgtttcgtcc ttt

53

<210> SEQ ID NO 100

-continued

<211> LENGTH: 148
<212> TYPE: PRT
<213> ORGANISM: *Sulfolobus solfataricus*

<400> SEQUENCE: 100

```

Met Glu Glu Lys Val Gly Asn Leu Lys Pro Asn Met Glu Ser Val Asn
1           5           10          15

Val Thr Val Arg Val Leu Glu Ala Ser Glu Ala Arg Gln Ile Gln Thr
20          25          30

Lys Asn Gly Val Arg Thr Ile Ser Glu Ala Ile Val Gly Asp Glu Thr
35          40          45

Gly Arg Val Lys Leu Thr Leu Trp Gly Lys His Ala Gly Ser Ile Lys
50          55          60

Glu Gly Gln Val Val Lys Ile Glu Asn Ala Trp Thr Thr Ala Phe Lys
65          70          75          80

Gly Gln Val Gln Leu Asn Ala Gly Ser Lys Thr Lys Ile Ala Glu Ala
85          90          95

Ser Glu Asp Gly Phe Pro Glu Ser Ser Gln Ile Pro Glu Asn Thr Pro
100         105         110

Thr Ala Pro Gln Gln Met Arg Gly Gly Arg Gly Phe Arg Gly Gly
115         120         125

Gly Arg Arg Tyr Gly Arg Arg Gly Gly Arg Arg Gln Glu Asn Glu Glu
130         135         140

Gly Glu Glu Glu
145

```

<210> SEQ ID NO 101
<211> LENGTH: 673
<212> TYPE: PRT
<213> ORGANISM: *Thermus thermophilus*

<400> SEQUENCE: 101

```

Met Thr Leu Glu Glu Ala Arg Lys Arg Val Asn Glu Leu Arg Asp Leu
1           5           10          15

Ile Arg Tyr His Asn Tyr Arg Tyr Tyr Val Leu Ala Asp Pro Ile Ser
20          25          30

Asp Ala Glu Tyr Asp Arg Leu Leu Arg Glu Leu Lys Glu Leu Glu Glu
35          40          45

Arg Phe Pro Glu Leu Lys Ser Pro Asp Ser Pro Thr Leu Gln Val Gly
50          55          60

Ala Arg Pro Leu Glu Ala Thr Phe Arg Pro Val Arg His Pro Thr Arg
65          70          75          80

Met Tyr Ser Leu Asp Asn Ala Phe Asn Leu Asp Glu Leu Lys Ala Phe
85          90          95

Glu Glu Arg Ile Glu Arg Ala Leu Gly Arg Lys Gly Pro Phe Ala Tyr
100         105         110

Thr Val Glu His Lys Val Asp Gly Leu Ser Val Asn Leu Tyr Tyr Glu
115         120         125

Glu Gly Val Leu Val Tyr Gly Ala Thr Arg Gly Asp Gly Glu Val Gly
130         135         140

Glu Glu Val Thr Gln Asn Leu Leu Thr Ile Pro Thr Ile Pro Arg Arg
145         150         155         160

Leu Lys Gly Val Pro Glu Arg Leu Glu Val Arg Gly Glu Met Pro Ile
165         170         175

Glu Ala Phe Leu Arg Leu Asn Glu Glu Leu Glu Glu Arg Gly Glu Arg
180         185         190

```

US 9,447,445 B2

195**196**

-continued

Ile Phe Lys Asn Pro Arg Asn Ala Ala Ala Gly Ser Leu Arg Gln Lys
195 200 205

Asp Pro Arg Ile Thr Ala Lys Arg Gly Leu Arg Ala Thr Phe Tyr Ala
210 215 220

Leu Gly Leu Gly Leu Glu Glu Val Glu Arg Glu Gly Val Ala Thr Gln
225 230 235 240

Phe Ala Leu Leu His Trp Leu Lys Glu Lys Gly Phe Pro Val Glu His
245 250 255

Gly Tyr Ala Arg Ala Val Gly Ala Glu Gly Val Glu Ala Val Tyr Gln
260 265 270

Asp Trp Leu Lys Arg Arg Ala Leu Pro Phe Glu Ala Asp Gly Val
275 280 285

Val Val Lys Leu Asp Glu Leu Ala Leu Trp Arg Glu Leu Gly Tyr Thr
290 295 300

Ala Arg Ala Pro Arg Phe Ala Ile Ala Tyr Lys Phe Pro Ala Glu Glu
305 310 315 320

Lys Glu Thr Arg Leu Leu Asp Val Val Phe Gln Val Gly Arg Thr Gly
325 330 335

Arg Val Thr Pro Val Gly Ile Leu Glu Pro Val Phe Leu Glu Gly Ser
340 345 350

Glu Val Ser Arg Val Thr Leu His Asn Glu Ser Tyr Ile Glu Glu Leu
355 360 365

Asp Ile Arg Ile Gly Asp Trp Val Leu Val His Lys Ala Gly Gly Val
370 375 380

Ile Pro Glu Val Leu Arg Val Leu Lys Glu Arg Arg Thr Gly Glu Glu
385 390 395 400

Arg Pro Ile Arg Trp Pro Glu Thr Cys Pro Glu Cys Gly His Arg Leu
405 410 415

Leu Lys Glu Gly Lys Val His Arg Cys Pro Asn Pro Leu Cys Pro Ala
420 425 430

Lys Arg Phe Glu Ala Ile Arg His Phe Ala Ser Arg Lys Ala Met Asp
435 440 445

Ile Gln Gly Leu Gly Glu Lys Leu Ile Glu Arg Leu Leu Glu Lys Gly
450 455 460

Leu Val Lys Asp Val Ala Asp Leu Tyr Arg Leu Arg Lys Glu Asp Leu
465 470 475 480

Val Gly Leu Glu Arg Met Gly Glu Lys Ser Ala Gln Asn Leu Leu Arg
485 490 495

Gln Ile Glu Glu Ser Lys Lys Arg Gly Leu Glu Arg Leu Leu Tyr Ala
500 505 510

Leu Gly Leu Pro Gly Val Gly Glu Val Leu Ala Arg Asn Leu Ala Ala
515 520 525

Arg Phe Gly Asn Met Asp Arg Leu Leu Glu Ala Ser Leu Glu Glu Leu
530 535 540

Leu Glu Val Glu Glu Val Gly Glu Leu Thr Ala Arg Ala Ile Leu Glu
545 550 555 560

Thr Leu Lys Asp Pro Ala Phe Arg Asp Leu Val Arg Arg Leu Lys Glu
565 570 575

Ala Gly Val Glu Met Glu Ala Lys Glu Lys Gly Gly Glu Ala Leu Lys
580 585 590

Gly Leu Thr Phe Val Ile Thr Gly Glu Leu Ser Arg Pro Arg Glu Glu
595 600 605

-continued

Val Lys Ala Leu Leu Arg Arg Leu Gly Ala Lys Val Thr Asp Ser Val
610 615 620

Ser Arg Lys Thr Ser Tyr Leu Val Val Gly Glu Asn Pro Gly Ser Lys
625 630 635 640

Leu Glu Lys Ala Arg Ala Leu Gly Val Pro Thr Leu Thr Glu Glu Glu
645 650 655

Leu Tyr Arg Leu Leu Glu Ala Arg Thr Gly Lys Lys Ala Glu Glu Leu
660 665 670

Val

<210> SEQ ID NO 102

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 102

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg
20 25 30

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35 40 45

Asp Asp Val Lys Lys Ile Thr Ala Glu Arg His Gly Lys Val Val Arg
50 55 60

Val Val Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Asn Glu Glu Leu Lys Leu Leu Ala Phe Asp Ile Glu Thr
130 135 140

Leu Tyr His Glu Gly Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Val
165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys
180 185 190

Arg Phe Leu Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
210 215 220

Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Gly Ser Glu Pro Lys
225 230 235 240

Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu
275 280 285

Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly

US 9,447,445 B2

199**200**

-continued

290	295	300
Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr		
305	310	315
320		
Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu		
325	330	335
Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu		
340	345	350
Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala		
355	360	365
Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser		
370	375	380
Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Gly		
385	390	395
400		
Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr		
405	410	415
His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr		
420	425	430
Asp Val Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly		
435	440	445
Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Asp Glu Arg Gln Lys Ile		
450	455	460
Lys Arg Arg Met Lys Ala Ser Lys Asp Pro Ile Glu Arg Lys Leu Leu		
465	470	475
480		
Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly		
485	490	495
Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu		
500	505	510
Ser Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Leu Val Arg Arg Glu		
515	520	525
Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu		
530	535	540
Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg		
545	550	555
560		
Ala Leu Glu Phe Val Asn Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu		
565	570	575
Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys		
580	585	590
Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Ile Thr Arg Gly		
595	600	605
Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln		
610	615	620
Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala		
625	630	635
640		
Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Ile		
645	650	655
Pro Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn		
660	665	670
Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala		
675	680	685
Ala Arg Gly Ile Lys Val Arg Pro Gly Met Val Ile Gly Tyr Val Val		
690	695	700
Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ala Glu Glu		
705	710	715
720		

-continued

Phe Asp Pro Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
725 730 735

Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly Tyr Arg
740 745 750

Lys Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala
755 760 765

Trp Leu Lys Val Lys Lys Ser
770 775

<210> SEQ ID NO 103
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 103

ggccgcaacc 10

<210> SEQ ID NO 104
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 104

tataagcgcc gg 12

<210> SEQ ID NO 105
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 105

ggccgcattc at 12

<210> SEQ ID NO 106
<211> LENGTH: 148
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 106

cgttaacttga aagtatttcg atttcttggc tttatataatc ttgtggaaag gacgaaacac 60

cggcgaagaa cctcttccca agagtttag agctagaat agcaagttaa aataaggcta 120

gtccgttatac aacttgaaaa agtggcac 148

<210> SEQ ID NO 107

<400> SEQUENCE: 107

000

<210> SEQ ID NO 108
<211> LENGTH: 73
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

```

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (27)..(47)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 108

taaccttgcta tttcttagctc taaaacnnnn nnnnnnnnnn nnnnnnnncgg tgtttcgtcc      60
tttccacaag ata                                         73

```

What is claimed is:

1. A preparation, comprising:

a fusion protein comprising an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:3, wherein the fusion protein comprises:

- (i) an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:1; and
- (ii) an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:2.

2. The preparation according to claim 1, further comprising a 5'-3' exonuclease.

3. The preparation according to claim 2, wherein the 5'-3' exonuclease is T5 exonuclease.

4. The preparation according to claim 1, further comprising a single strand DNA binding protein.

5. The preparation according to claim 4, wherein the single strand DNA binding protein is ET SSB (Extreme Thermostable Single-Stranded DNA Binding Protein), *E. coli* recA, T7 gene 2.5 product, phage lambda RedB or Rac prophage RecT.

6. The preparation according to claim 1, further comprising a ligase.

7. The preparation of claim 1, wherein the preparation does not comprise a crowding agent and/or a non strand-displacing polymerase.

8. The preparation of claim 1, further comprising a potassium salt.

9. The preparation according to claim 1, further comprising a plurality of polynucleotides in a set wherein at least a polynucleotide in the set has a sequence that overlaps with another polynucleotide in the set; and wherein the polynucleotides are selected from: (i) double stranded polynucleotides; (ii) single stranded oligonucleotides; (iii) at least one double strand polynucleotide and at least one single strand oligonucleotide; and (iv) a subpopulation of polynucleotides that are otherwise identical to one another except for a sequence that varies between the members of the subpopulation.

10. The preparation according to claim 9, wherein the set of polynucleotides has at least 3 members or at least 4 members or at least 5 members.

11. A method for producing a synthon, comprising:
incubating a preparation according to claim 2 further optionally comprising a ligase and a single strand DNA binding protein, with a plurality of polynucleotides that form a set, wherein members of the set have sequences that overlap under suitable reaction conditions; and

joining at least two the polynucleotides to produce a synthon.

12. The method according to claim 11, wherein the set of polynucleotides contains at least 3 members or at least 4 members or at least 5 members.

13. The method according to claim 11, wherein the preparation further comprises a ligase.

14. The method according to claim 11, wherein the preparation further comprises a single strand DNA binding protein.

15. The method according to claim 11, wherein the polynucleotides are double stranded and the double strand polynucleotides are overlapping PCR products, overlapping restriction fragments or assembled from single stranded oligonucleotides.

16. The method according to claim 11, wherein the polynucleotides are single stranded oligonucleotides.

17. The method according to claim 11, wherein the set of polynucleotides comprises at least one double strand polynucleotide and at least one single strand oligonucleotide.

18. A kit for polynucleotide assembly, comprising:

(a) a preparation according to claim 1; and
(b) a 5'-3' exonuclease.

19. A kit according to claim 18, further comprising a single strand binding protein.

20. The kit according to claim 18, further comprising a ligase.

21. The kit according to claim 18, further comprising a buffering agent.

22. The kit according to claim 18, wherein the 5'-3' exonuclease is T5 exonuclease.

23. The kit according to claim 18, does not include a crowding agent.

24. The kit according to claim 18, wherein (a)-(b) are in the same vessel.

25. The preparation according to claim 1, wherein the fusion protein comprises an amino acid sequence that has at least 95% identity to SEQ ID NO:3, wherein the fusion protein comprises:

(i) an amino acid sequence that has at least 95% sequence identity to SEQ ID NO:1; and

(ii) an amino acid sequence that has at least 95% sequence identity to SEQ ID NO:2.

26. The preparation according to claim 1, wherein the fusion protein comprising the amino acid sequence of SEQ ID NO:3.

* * * * *